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ABSTRACT  
Background: Despite preventive guidelines, iatrogenic contrast-induced nephropathy (CIN) 
ranks third as a cause of hospital acquired acute kidney injury (AKI), and impacts significantly 
on morbidity and mortality and is associated with high hospital costs. In Sub-Saharan Africa, 
the rates and risk factors for CIN remain unexplored. Despite the positive association of 
genetic polymorphisms in the TNFα and IL10 genes with CIN in Asian populations, the CIN 
genetic susceptibility in other races is unknown. Serum creatinine is a sub-optimal biomarker 
for the early diagnosis of CIN resulting in delayed interventions.  This study investigated rates, 
risk factors and outcomes of CIN, the influence of genetic susceptibility to CIN in the black 
population and lastly, the accuracy of novel biomarkers in the early diagnosis of CIN and 
prognosticating patient outcomes. 
Methods: This was a prospective case-controlled study conducted at Charlotte Maxeke 
Johannesburg Academic Hospital, in South Africa from January 1, 2014 to December 30, 
2015.Hospitalized patients undergoing enhanced computed tomography and angiography were 
consecutively recruited to the study and followed up for development of CIN. CIN was 
defined as an increase in serum creatinine >25% or an absolute increase of >44 µmol/l from 
baseline at 48-72 hours after exposure to contrast media. In the second part of the study, a 
nested case-controlled cohort that included 30 CIN patients and 60 controls (those undergoing 
contrast administrations and not meeting CIN criteria) were ethnically matched for gender, 
and age in a case: control ratio of 1:2 at all-time intervals. Sera for neutrophil gelatinase-
associated lipocalin-2 (NGAL), cystatin C, beta-2 microglobulin (β2M), interleukin 18 (IL18), 
IL10, and tumor necrosis factor alpha (TNFα) were collected at four time points: baseline 
(pre-contrast), 24 hours, 48 hours and ≥5-7 days after contrast administration and their 
concentrations were determined using luminex assays and an enzyme linked immunosorbent 
assay for β2M as per manufacturer’s instructions. The areas under receiver operating 
characteristic curves (AUROC) were generated to determine accuracy of novel biomarkers to 
diagnose CIN and CIN mortality.   
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Genomic DNA was extracted from peripheral blood samples of 208 black South Africans 
using the Maxwell DNA purification kit (Promega AS1010, USA) and their genotypes for -
308(rs1800629) and -857(rs1799724) in the TNFα gene and -592(rs1800872), -
819(rs1800871), -1082 (rs1800896) and +1582(rs1554286) in the IL10 gene were determined 
by restriction fragment length polymorphism (RFLP).  
Results: We recruited 371 hospitalized patients (mean age 49.3±15.9); the rates of CIN 
were4.6% and 16.4% respectively, using an absolute or relative increase in serum creatinine 
from baseline. Anaemia was an independent predictor for the development of CIN (RR 1.71, 
95% 1.01-2.87; p=0.04). The median serum albumin was 34 g/l (IQR: 29-39.5) vs. 38 g/l 
(IQR: 31-42), p=0.01 in the CIN and control groups respectively.Mortality was significantly 
increased in the CIN group (22.4% vs. 6.8%; p<0.001), and CIN together with anaemia 
predicted mortality with a 2-fold (p=0.01) and a 3-fold (RR p=0.003) riskrespectively. The 
median cystatin C at 24 hours (p<0.001) and β2M(at all-time points)levels were significantly 
higher in the CIN group compared to controls. The median cystatin C at 24 hours and 
β2Mlevels at 48 hours were 856.59 ng/ml (IQR 620.75-1002.96) vs. 617.42 ng/ml (IQR 
533.11-805.20); p<0.001 and 5.3 µg/ml (IQR 3.8-6.9) vs. 3.3 µg/ml (IQR 2.7-4.5); p<0.001 
with AUROCs of 0.75 and 0.78 respectively for early CIN discrimination.Pre-contrast IL18 (p 
<0.001), β2M (p=0.04) and TNFα (p<0.001) levels were significantly higher in the non-
surviving group and their AUROC were 0.83, 0.82 and 0.94 for CIN+ mortality. Baseline 
NGAL was a better marker for excluding patients at higher risk of developing CIN with 
negative predictive and positive predictive values of 0.81 and 0.50 respectively. The frequency 
of TNFα -308 AA genotype was significantly increased in the CIN group compared to 
controls (13.3% vs.1.82%, p=0.016) and the presence of the TNFα-308 AA (high producer) 
vs. GA genotypes was associated with a 9-fold CIN risk (9.24, 95% CI, 1.88-45, p=0.006). 
The IL10-1082 AA-allele (low producer) was significantly higher in the non-surviving CIN+ 
patients compared to controls (p=0.01). 
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Conclusions:CIN occurred at a relatively high rate in our study and predicted poorer clinical 
outcomes. The presence of CIN and anaemia positively predicted mortality. Caution should be 
exercised in patients with anaemia and hypoalbuminaemia undergoing contrast studies. 
Serumcystatin C was the best novel biomarker for the early diagnosis of CIN and while 
baseline NGAL is superior as a biomarker for excluding patients at higher risk for CIN. IL18, 
β2M and TNFα are the best novel biomarkers for predicting the prognosis of patients with 
CIN. Increased frequency of the TNFα-308 AA genotype is a predisposing factor for CIN 
development. The low producer IL10-1082 AA genotype decreases survival in patient with 
CIN. 
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PREFACE  
CIN is linked with increased morbidity and mortality; however, in South Africa (including 
Sub-Saharan Africa) there is dearth of data on rates and patient outcomes due to CIN. Despite 
recent reporting on positive associations of genetic polymorphisms in TNFα and IL10 with 
contrast induced nephropathy (CIN) among Asian populations, its role in other populations 
remains unexplored. Treatment of CIN is non-specific and limited to supportive care only and 
early diagnosis and interventions are delayed due to the existing suboptimal traditional 
biomarkers (serum creatinine). 
It is for these reasons that this study was undertaken to identify prevalence of CIN and patient 
outcomes, the novel biomarkers for early diagnosis of CIN and prognostication and the genes 
associated with susceptibility to CIN in black South Africans. This will help in implementing 
targeted therapy among high risk populations with polymorphisms in these inflammatory 
cytokines genes (IL10 and TNFα genes). Identification of higher risk individuals to avoid 
exposure and earlier diagnosis of CIN using new biomarkers and identification of 
susceptibility genes will not only reduce morbidity and mortality but will also add knowledge 
to renal medicine. 
This PhD is presented in an integrative format consisting of 6 chapters: 
Chapters 1-2; literature review and the methods 
Chapter 3; Chapter 3; are the results on the prevalence and risk factors of CIN including 
patient outcomes (Chapter 3 was accepted for publication in the South African medical 
Journal on 20.2.2016). 
Chapter 4; are results on accuracy of novel biomarkers in predicting and prognosticating CIN 
Chapter 5; are the results on influence of genetic susceptibility in the TNF and IL10 genes to 
CIN 
Chapter 6 is summary of study findings, recommendations and limitations of the study.
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1. CHAPTER 1. LITERATURE REVIEW 
1.1 Introduction  
Despite preventive guidelines, iatrogenic contrast-induced nephropathy (CIN) ranks third as a 
cause of hospital acquired acute kidney injury (AKI) and impacts significantly on morbidity 
and mortality and is associated with longer duration of hospitalization and higher medical 
costs (1-4).Globally, the number of iodinated contrast media procedures exceeds 80 million 
per year and is administered for both diagnostic and therapeutic indications (5, 6). In 
developed countries, rates of computed tomography procedures using iodinated contrast media 
are almost 30 million per year (7) and rates of angiography performed in developed countries 
also exceeds 2 million per year (7).  Hence, CIN is a complication and an outcome of 
increased iodinated contrast media administration (8). 
1.2 Incidence and prevalence of CIN 
The rates of CIN vary, depending on study definitions employed and underlying risk factors, 
and ranges from 0.6% to 50% or higher among risk groups (9-13). Shema et al. reported a 
4.5% incidence of CIN among hospitalized Israeli patients; CIN was defined as an increase in 
serum creatinine of more than 44 umol/l five days post contrast media administration (1). 
Chang et al. found 10.3% prevalence of CIN in a prospective study of cardiac patients 
undergoing percutaneous coronary intervention (PCI) in Taiwan (14).In this study, CIN was 
defined as an increased serum creatinine ≥ 44 umol/l from baseline. In other studies, Mitchell 
et al. reported a 14% prevalence of CIN among patients with suspected pulmonary embolism 
in Northern Carolina, USA (3, 4). A recent randomized clinical trial (RCT), the harmonizing 
outcomes with revascularization in acute myocardial infarction (HORIZONS-AMI) study, 
reported a 16.1% rate of CIN among PCI patients (12).
.
 
1.3 Risk factors associated with CIN 
Patient factors that include age, comorbidities and contrast media related factors are associated 
with development of CIN in different settings (12, 15, 16) [Table 1.1].   
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Table 1.1 Risk factors for contrast induced nephropathy 
Fixed (non-modifiable) risk factors Modifiable risk factors 
Older age  Volume of contrast media 
Diabetes mellitus  Hypotension 
Pre-existing renal failure  Anaemia and blood loss 
Advanced CHF Dehydration  
Low LVEF Low serum albumin (<35g/l) 
Acute myocardial infarction  ACE inhibitors 
Cardiogenic shock Diuretics  
Renal transplant  Non-steroidal anti-inflammatory drugs 
 Nephrotoxic antibiotics 
 IABP 
ACE, angiotensin-converting enzyme; CHF, congestive heart failure; IABP, intra-aortic 
balloon pump; LVEF, left ventricular ejection fraction. Reproduced with permission from 
Mehran et al.2006 (16).  
1.3.1 Association of age and CIN 
In previous retrospective and observational studies, age independently predicted development 
of CIN (1, 17). Marenzi et al. in an observational studyof patients undergoing PCI, reported 
that age exceeding 75 years predicted a 5-fold risk for developing CIN (OR 5.28, 95% 1.98-
14.05, p<0.001) (17). In a prospective observational study of patients undergoing iodinated 
computed tomography in Greece, the rates of CIN were 38.5% vs. 0% (p=0.02) in patients 
aged ≥ 65 years and < 65 years respectively (18). Sherma et al. in a retrospective study found 
age a significant risk factor for CIN development; patients aged 64.4±17 years had a 
significant risk for CIN compared to those of a younger age (59±19 years, p=0.04) (1). 
Various factors are implicated in age causing CIN and these include decreasing glomerular 
filtration rate following structural changes due to fibrotic changes to the kidneys with 
advancing age, calcification and likely increased presence of comorbidities in elderly patients 
(17, 18). However, Diogo et al. found a non-significant association between ages> 65 years 
and risk for CIN (19).  
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1.3.2 Association between comorbidities and CIN 
The presence of comorbidities such as diabetes mellitus (DM), underlying renal and cardiac 
diseases are linked with high rates of CIN development (20). 
In several observational and retrospective studies, presence of underlying renal disease 
positively predicted CIN development (21, 22). In a retrospective analysis of 322 patients 
undergoing PCI in France, underlying renal disease was associated with a 9-fold odds of 
developing CIN (OR 8.8, 95% CI 2.61-9.74; p=0.002) (21).In this study, renal disease was 
defined as estimated glomerular filtration (eGFR) <60 ml/min per 1.73m
2
(21). Underlying 
renal disease defined by either decreased eGFR or increased serum creatinine are dominant 
risk factors for CIN in both retrospective and observational studies (10). An even smaller 
increase in serum creatinine 48 hours post contrast media administration was associated with a 
14% mortality increase (10). Serum creatinine exceeding 132.6 µmol/l was an independent 
predictor for CIN in a retrospective study of patients who underwent angiography (23). 
Diabetes mellitus is reportedly a significant risk factor for CIN with a rate as high as 30% 
(16). In an observational study of patients undergoing computed tomography with contrast in 
Brazil, Diogo et al. found a 2-fold odds of CIN in DM patients (OR 2.15; 1.13-4.06, p=0.02), 
while cardiac and underlying renal diseases were associated with a 2-fold and 3-fold odds for 
CIN risk  (19). Evola et al. also reported a 3-fold presence of CIN in DM patients compared to 
controls (2). The increased risk of CIN in DM patients is linked to two factors; exacerbated 
hypoxia following overproduction of mediators of vasoconstriction (endothelins and 
angiotensin levels) and overwhelming production of reactive oxygen species (ROS) due to 
multivessel disease (24, 25). In animal studies, medullary partial pressure of oxygen (pO2) 
was 36 mmHg vs. 50 mmHg in DM rats and controls respectively (25).  
Presence of cardiovascular diseases,that include congestive heart failure, myocardial infarction 
(MI) and cardiogenic shock, is associated with increased risk for CIN in both observational 
and RCT studies (22, 26).  In a prospective study of PCI patients, low ejection fraction was 
associated with a 0.94 odds for developing CIN (p=0.007) (22).   
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Rosenstocket al.in a RCT in New York, USA found almost 5-fold odds of developing CIN in 
patients with cardiac disease (defined as low ejection fraction <40%) (26), while Bouzas-
Mosqueraet al. in Spain reported a 5-fold odds for CIN in patients with cardiogenic shock (OR 
4.56, 95% CI 1.08-19.23, p=0.03) (23). In the majority of cases, haemodynamic compromise 
that characterizes cardiovascular diseases is the strong determining mechanism underlying 
CIN risk in these patients (26, 27). Presence of circulatory compromise positively activates 
renal vasoconstrictors that include sympathomimetics and angiotensin and thereby 
exacerbating medullary hypoxia occurring during contrast administration (26).  
Recently, Li et al.2016 demonstrated that hypotension following contrast media administration 
was a significant predictor for CIN (28). In this study,  a decrease >10 mmHg in systolic blood 
pressure (SBP) was associated with a 2-fold odds for CIN risk (2.37, 95% CI 1.04-5.38; 
p=0.04) (28). The mean decrease in SBP pressures were 16.2±19.1 vs. 5.9±18.9 mmHg, 
(p=0.001) in the CIN group compared to controls respectively (28).  
Despite limited studies looking at the impact of anaemia on CIN, anaemia is a significant risk 
factor for CIN (16). Anaemia worsens the existing renal medullary hypoxia post contrast 
media administration (29). Li et al. reported 2-fold odds for developing CIN in patients with 
anaemia post PCI (29). In this study, when eGFR was 30-59 ml/min per 1.73m2; the rates of 
CIN were 7.9% vs. 3.8% in anaemic patients compared to controls (29).  
1.3.3Impact of contrast media osmolality and administration 
Regarding contrast media, type, volume and mode of administration of contrast determine the 
development of CIN e.g. patients receiving a higher than maximal recommended dose of 
contrast media  were more likely to develop CIN or require renal replacement therapy (16, 
30). Contrast media utilized in computed tomography and angiography is derived from tri-
iodinated benzene (31). The iodine functions to provide radio opacity which is provided by the 
iodine component and therefore better visualization is associated with administration of higher 
volumes of iodinated contrast media (31).  
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Based on osmolality, three categories of contrast media are used; the high osmolar contrast 
media (HOCM), low osmolar contrast media (LOCM) and iso-osmolar contrast media 
(IOCM) (31). The HOCM has an osmolality above 1000 mOsmol/kg of water compared to 
plasma osmolality. The LOCM that include iopamidol and iohexol have an osmolality of 2-3 
times higher (32) than plasma while the IOCM osmolality are comparable or lower than 
plasma (31).  Despite the low osmolality, the IOCMs are extremely hyperviscous (31).  
Previous studies have linked contrast volume and osmolality to increased CIN risk. In patients 
undergoing PCI recently, Shams-Eddin Taher et al.found a 4-fold and a 1-fold odds of 
developing CIN in patients using HOCM and contrast volume exceeding ≥ 400mls 
respectively (33). In this study, the odds for CIN in using a HOCM and higher contrast media 
volumes were OR 4.08, 95% CI 1.1-15.1, p=0.03 and OR 1.1 95% CI 1.00-1.01, p=0.01 
respectively (33). In other studies of patients undergoing PCI, exceeding the maximum 
allowable dose was positively linked with a 2-fold odds (OR 2, 95% CI 1.67-2.40; p<0.001) 
for developing CIN and 6-fold odds (OR 6.41, 95% CI 3.3-12.1; p<0.001) for undergoing 
renal replacement therapy (30). 
In other studies, increased volumes above 200 mls of contrast media were associated with a 2-
fold odd of developing CIN (16). When the contrast media volume exceeded 600 ml, the odds 
ratio was almost 5-fold (adjusted OR 4.86, 95% CI 1.73-13.67) (16). Marenzi et al. found an 
almost 3-fold odds of developing CIN when contrast volume exceeded 300 mls (OR 2.80, 
95% CI 1.17-6.68, p=0.02) (17).  
1.4 Impact of CIN on early and late outcomes 
In several studies, development of CIN is positively associated with increased hospitalization 
and early and late adverse clinical outcomes (13, 16, 34, 35) [Table 1.2].  
Various mechanisms are implicated in causing increased mortality in patients with CIN (34). 
In animal studies with ischaemia-induced AKI, the vasoconstriction that characterizes the 
renal medulla is experienced in distant organs as well (34, 36).  
 
 
6 
 
 
In this study, the coronary vessels experienced severe narrowing and thereby severely 
affecting cardiac outcome post ischaemia (36). A similar mechanism might occur in patients 
with ischaemia-induced CIN and hence increasing mortality (34). However, other studies 
support the influence of comorbidities on outcomes following contrast media administration 
(34). However, after adjusting for these comorbidities, CIN still remained an independent 
predictor for mortality (34). 
1.4.1 Morbidity due to CIN 
Due to increased comorbidities, the rates of CIN are higher among hospitalized patients 
compared to ambulatory patients (17) and several studies have reported both renal and extra-
renal complications following contrast media administration (34).  
1.4.1.1 Extra renal complications due to CIN 
CIN is associated with significant complications that include increased duration of 
hospitalization, renal and extra-renal adverse outcomes (1, 2, 23). In a study cohort of chronic 
kidney disease (CKD) and non CKD patients undergoing PCI patients in USA, Neyra et al. 
observed a longer duration of hospitalization in patients with CIN (37). The length of 
hospitalization in the non CKD group with CIN was 8.3±13.3 days vs.4.1±5.6 days, p<0.001 
and CKD with CIN was 9±8.5 days vs. 6.1 ±12.6 days, p<0.001
.
in patients with CIN 
compared to controls (37).Shema et al. also reported increased duration of hospitalization 
among patients with CIN compared to controls (24 days vs.13 days, p<0.001) (1).  
The rate of cardiovascular events is also higher in patients with CIN (17). Marenzi et al. found 
increased rates of cardiogenic shock and atrial fibrillation in CIN patients compared to 
controls (17). The presence of respiratory compromise was also higher in the CIN group 
compared to controls in this study (17). CIN was associated with a 2-fold risk of developing 
late myocardial infarction (MI) compared to controls 24.0 % vs. 11.6%, p<0.005 (16). 
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In a prospective single center study, Wi et al. reported higher rates of major adverse 
cardiovascular and cerebral vascular events together with mortality in the CIN group 
compared to controls (38).  
In another retrospective study, Bouzas-Mosqueraet al. in Spain reported increased rates of 
respiratory compromise associated with ventilation, increased duration of hospitalization and 
cardiogenic shock and cardiac arrhythmias in CIN patients compared to controls (23). The 
rates of respiratory compromise, cardiogenic shock and duration of hospitalization were 0.7% 
vs. 13.9%, 3.6% vs. 36.1%, 1.8% vs. 11.4% and 6 days vs. 12 days respectively, (with a p 
<0.001) (23).  
1.4.1.2Intrinsic renal complications due to CIN 
The rates of dialysis requiring CIN are less than 1% (39); however in patients with underlying 
renal dysfunction, it occurs in up to 12% (when baseline serum creatinine exceeded 124 
µmol/l prior to contrast) and is associated with adverse clinical outcomes (39).  In a 
retrospective study of 161 patients with underlying renal dysfunction prior to radio contrast 
administration, almost 20% of the CIN patients underwent renal replacement therapy and 
progressed to CKD (40).  
1.4.2 Mortality due to CIN 
CIN is strongly linked with both early and late mortality in several observational and 
retrospective studies (34, 39) [Table 1.2]. In-hospital mortality due to CIN ranges from 7-22% 
or higher.McCullough et al. reported early mortality of 1.1% in controls, 7.1% in CIN 
patients, and 35% in CIN patients that required dialysis(34, 41). Sedeghi et al. in a multicentre 
study found that 30 day mortality was significantly higher among patients with CIN compared 
to controls (16.2 vs. 1.2; p <0.001) (42). 
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Shema et al. found ten times higher mortality in CIN patients in a Western Galilee Hospital in 
Israel (31.4% vs. 3%, p <0.001)(1) while Mitchell et al. in the USA, reported a one year 
mortality rate of 18% vs. 6% in CIN compared to controls, and a 3-fold risk for mortality (RR 
3.1, 95% CI; 1.7-5.4)(5).  
Neyra et al. reported increased early and late mortality in CKD and non CKD patients who 
developed CIN (37). In the non CKD group, CIN was associated with a 2-fold adjusted odds 
for mortality (2.2 95% CI; 1.2-4.1, p=0.02) and a 9-fold adjusted odds for mortality in the 
CKD group with CIN (8.95; 95% CI 1.9-34.5, p=0.005) compared to controls. In the RCT, 
CIN was an independent predictor for mortality (8% vs. 0.9%, p<0.0001) (12).  
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Table 1.2 Mortality rates associated with contrast-induced nephropathy 
Reference No. of Patients and 
Type of Contrast 
Procedures 
CIN Definition 
(Size of Increase 
in SCr from 
Baseline) 
In-Hospital Mortality 
Rates: CIN vs. No 
CIN 
Long-Term Mortality 
Rates: CIN vs. No 
CIN 
McCullough et al., 
(41). 
1826 in a derivation 
set, 2251 in a 
validation set; PCI 
>25% during 
first 5 days 
7.1% vs. 1.1%;35.7% 
for dialysis-dependent 
(P< 0.0000001) 
- 
Rihal et al.,  (43).  254 with CIN, 6890 
without CIN; PCI 
>0.5 mg/dl 
during first 48 
hours 
22.0% vs. 1.4%  
(P< 0.001) 
12.1% vs. 3.7% (P< 
0.0001) (1-yr hospital 
survivors);44.6% vs. 
14.5%  
(P< 0.0001) (5-yr 
hospital survivors) 
 
Gruberg et al.,  
(40). 
439 with CKD (SCr 
≥1.8 mg/dl) not 
dialysis-dependent; 
PCI 
≥25% during 
first 2 days or 
needing dialysis 
14.9% vs. 4.9%;22.6% 
for dialysis-dependent  
(P< 0.001) 
 
 
37.7% vs. 19.4% 
 (P = 0.001)  
(1-yr cumulative rate) 
Gruberg et al., 
(44) 
7741; PCI Requiring 
dialysis 
27.5% vs. 1.0%  
(P< 0.001) 
54.5% vs. 6.4%  
(P< 0.0001)  
(1-yr cumulative rate) 
Dangas et al., (45) 5250 CKD(+), 1980 
CKD(−); PCI 
≥25% or ≥0.5 
mg/dl during 
first 48 hours 
6.3% vs. 0.8% 
(CKD(+),  
P< 0.0001);2.5% vs. 
0.1% (CKD(−),  
P< 0.0001) 
22.6% vs. 6.9% 
(CKD(+);  
P< 0.0001) 
8.0% vs. 2.7% 
(CKD(−); 
P< 0.0001)  
(1-yr cumulative rate) 
 
Levy et al.,  (46) 183 with CIN, 183 
matched control 
subjects; various 
procedures (about 
half angiography) 
≥25% to ≥2 
mg/dl during 
first 2 days 
34% vs. 7%  
(P< 0.001) 
 
CIN, contrast induced nephropathy, CKD, chronic kidney disease, SCr, serum creatinine, PCI, 
percutaneous coronary intervention.  
Reproduced with permission from Rudnick et al.2008(34).  
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1.4.3. Correlation between CIN risk score with CIN and mortality 
The presence of multiple and additive risk factors are associated with a higher frequency for 
CIN and mortality risk (16, 47) [Figure 1.1]. Mehran et al. included eight CIN variables, and 
assigned a scoring system; a higher score predicted poor outcomes (47). In another study, 
Sgura et al. recruited 891 patients with segmental elevation myocardial infarction (STEMI) 
undergoing angiography and classified them into low to high risk groups based on the number 
of CIN risk factors present (48). The odds for CIN was 3.82 vs. 1.73, p<0.001, in the high 
score vs. low score respectively (48). Similarly, zero mortality was experienced in the low risk 
group compared with 10% mortality in the high risk group (48). In other studies, the frequency 
of CIN were 1.2%, 11.2% and >20% in patients with zero, one and >2 CIN risk factors 
respectively (49).  
Despite retrospective and observation studies including RCT studies from developed countries 
demonstrating increased morbidity and mortality associated with increased CIN, Sub-Saharan 
Africa has limited data on rates, risk factors and outcomes of CIN.  
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Figure 1.1 Association of CIN risk score with CIN and mortality 
Increase in number of risk factors (CIN risk score) is associated with direct increase in CIN 
and mortality. For determination of risk score, variables eGFR < 60 ml/min per 1.73m
2
, an 
urgent PCI, use of an intra-aortic pump device were scored 2 CIN risk points while presence 
of DM, cardiac disease, hypertension and peripheral vascular disease including iodinated 
contrast volumes exceeding 260 mls were scored 1 CIN risk point.  
 Reproduced with permission from Rudnick et al. 2008 (34).  
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1.5 Definition of CIN 
CIN is defined as an acute decline in renal function that occurs following the administration of 
contrast media (14, 50-52). The definition is based on three factors; increased serum creatinine 
from baseline, exposure to contrast media and exclusion of other confounders for renal 
disease.  Therefore in several studies, CIN is mostly defined as a rise in serum creatinine of 
>44 umol/l or a 25% increase from baseline assessed at 48-72 hours after a radiological 
procedure in accordance with the European Society of Urogenital Radiology (ESUR)(12, 16, 
35, 50, 53).  Additionally the above definition positively predicted adverse cardiovascular 
events and early and late mortality (12, 16, 50). The updated Canadian Association of 
Radiologists (CAR) guidelines also defines CIN as >44 µmol/l serum creatinine increase over 
a 72 hour period (54). Classically CIN occurs within 1-3 days,  peaking at 3-5 days after 
contrast administration (53, 54). In comparison between using an absolute (>44 µmol/l) or 
relative increase (>25%) in serum creatinine, the Contrast Induced Nephropathy Consensus 
Working Panel approved the later definition (55). However the Kidney Disease Improving 
Global Outcomes (KDIGO)  defines CIN as ―an increase in serum creatinine by 50% within 7 
days or increase in serum creatinine >26.5µmol/l from baseline and occuring within 48 hours 
or presence of oliguria‖ (56, 57).   
1.6 Pathogenesis of CIN 
In spite of an unclear understanding of the mechanisms underlying CIN, tubular toxicity and 
endothelial vasoconstriction, together with reactive oxygen species (ROS), are implicated in 
the pathogenesis of CIN (11, 13, 58-62) [Figure 1.2]. 
1.6.1 Contrast induced tubular toxicity 
Iodinated contrast media directly injures the renal tubular epithelium by producing ROS 
radicals that cause intra-renal vasoconstriction leading to ischaemia and death of tubular cells 
(3, 13). Contrast media is characterized by high osmolality and increased viscosity (thickness) 
(32), even the iso-osmolar contrast media is extremely hyperviscous compared to plasma (31). 
Following glomerular filtration, contrast media is localized to the tubules due to impaired 
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absorption (31). With increased water reabsorption in the proximal tubules, intratubular 
viscosity and pressure are increased and consequently, cause injury to the surrounding 
interstitium and descending vasa recta (31). Increased hyperviscosity and osmolality cause 
direct damage to renal tubules and with increased intratubular pressure consequently lead to 
compromised renal blood flow and decreased glomerular filtration rate. (31). Previous studies 
have reported a positive association between contrast media administration and tubular cell 
vacuolation. (4, 59). 
 
Figure 1.2 Pathophysiology of CIN. 
An interaction of vasoconstriction and contrast media leads to oxidative stress and ischaemia. 
Reproduced with permission from Azzalini et al. 2016(61). 
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1.6.2 Endothelial dysfunction in CIN 
An imbalance of vasoconstrictors and vasodilators plays a critical role in mediating CIN 
[Figure 1.3]. Contrast media suppresses intra-renal vasodilators i.e. nitric oxide (NO) and 
prostaglandin E2 (PGE2) and increases intra-renal vasoconstrictors that decrease blood flow to 
the renal medulla leading to hypoxic ischaemia, production of ROS and death of tubular cells 
(59-61, 63). Vasoconstriction in CIN is mediated by adenosine and endothelins acting on A1 
and E1 receptors respectively (58-60, 62, 63). Endothelin receptor stimulation is associated 
with decreased GFR (64). Microcirculation in the renal medulla is provided by the descending 
vasa recta whose diameter ranges from 12-18 µm (65) compared to 7.5 µm for red blood cells 
(66). After radio contrast administration, the diameter of the descending vasa recta is 
decreased by almost 50% due to vasoconstriction and loss of NO(65). The vasoconstricted 
descending vasa recta diameter which approximates the red blood cell diameter after contrast 
media further impedes circulation in the renal medulla (65). 
1.6.3 Medullary hypoxia and CIN 
In CIN, the presence of hypoxia in the outer medulla of the kidney is essential in the 
pathogenesis of CIN (27, 65). For several reasons, the renal outer medulla is susceptible to 
hypoxia following CIN; firstly only 10% of renal blood flow is directed to the medulla and 
secondly the medulla is normally characterized by low oxygen pressures ranging from 30-40 
mmHg (65). Lastly the medulla is actively involved in adenosine triphosphate (ATP) mediated 
transportation of salt in the medullary thick ascending limb (mTAL) of the loop of henle and 
therefore exhibits high metabolic activity (31, 65). Following contrast administration, the outer 
medullary renal blood flow exhibits two phases; a brief period characterized by increased flow 
that is later followed by an almost 25% sustained decrease in renal blood flow that ultimately 
impacts poorly on oxygen delivery to the medulla (65).  
The partial pressure of oxygen decreases to as low as 10-15 mmHg post contrast 
administration (25, 31, 65).       
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Figure 1.3Vasoconstrictors mediating CIN 
Presence of contrast media down regulates action of vasodilating NO synthase and also 
mitochondrial enzyme activities and the later leads to increased ATP hydrolysis production of 
adenosine. The contrast media also increases interstitial and intratubular pressures and sodium 
uptake. This increases oxygen consumption and production of damaging ROS. Endothelins 
together with adenosine leads to CIN (ATN). Reproduced with permission from Wong et al. 
2012 (58). 
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1.7 Cytokine induced inflammation in CIN  
In recent studies, evidence strongly implicates inflammation in the mechanism of CIN and 
other forms of ischaemic AKI (63, 67-69). Cytokine induced inflammation plays a significant 
role as predictive biomarkers of disease and prognosis (67). Increased levels of cytokines are 
associated with adverse outcomes in patients with AKI (68). Polymorphisms in these 
inflammatory cytokines genes are also strongly implicated in renal disease including CIN and 
studies have shown individual variation in genetic regulation of cytokine levels in plasma 
following insults (14, 67).Therefore, knowledge of the key roles played by inflammatory 
cytokines in CIN is critical in laying down workable interventions for CIN. 
Cytokines exist as soluble molecules produced locally and exert their actions at the injury and 
distant sites(67). In the circulation and tissues, cytokines generally remain in insignificant 
amounts and are sometimes beyond detection limit in tissues (67). Due to their damaging 
effects, various systems exist to regulate and neutralize pro-inflammatory cytokinese.g. TNFα 
release is linked with production of IL10 by similar stimulating agents (67). 
Iodinated contrast induced vasoconstriction leading to ischaemia is a central mechanism for 
CIN due to decreased renal blood flow (13, 69). Like other forms of ischaemia induced-AKI, 
studies have found a strong interaction of inflammation, tubular and endothelial injury as 
mediators in the pathogenesis of ischaemic-induced AKI including CIN (14, 63, 68, 70) 
[Figure 1.4]. Impairment of renal blood flow and ischaemia to the outer medulla is linked with 
injury to the endothelium and renal tubules and this leads to structural and pathological 
changes in these cells (68). Renal ischaemia to the medulla is associated with increased 
metabolism and depletion of adenosine triphosphate (ATP) and production of adenosine (67). 
The latter is a potent vasoconstrictor implicated in pathogenesis of CIN (63). ATP depletion is 
associated with increased renal tubular injury and endothelial injuryand this leads to 
cytoskeletal structural deformities and functional derangements of these cells (67, 69).  
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Figure 1.4 Renal ischaemia and AKI 
In ischaemic AKI, an interaction of endothelial injury, epithelial injury and inflammation 
occurs and leads to ATP depletion and cell death. Inflammation leads to upregulation of cell 
adhesion molecules and secretion of cytokines. Resulting vasoconstriction and inflammation 
cause decreased filtration (ischaemic-AKI). Reproduced with permission from Sharfuddin et 
al. 2011 (69). 
The injured endothelial and renal tubular cells following ischaemia respond by initiating an 
inflammatory cascade and the microvascular injury remains critical in initiating this event (68, 
71). The endothelial and tubular injury performs two important functions that initiate 
inflammation; the endothelium in close proximity to the insult is characterized by increased 
permeability and upregulationof intracellular cell adhesion molecule 1 (ICAM-1), vascular 
cell adhesion molecule (VCAM-1) and P and E-selectins and together with injured renal 
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tubules, function in recruiting inflammatory cells (67, 68, 71). The recruited inflammatory 
cells include neutrophils, macrophages and lymphocytes(68, 69). Post recruitment, the 
inflammatory cells and injured endothelial and epithelial cells secrete various cytokines and 
chemokines that mediate renal injury (68, 69) [Figure 1.5]. Cytokines of significance 
includingtumor necrosis factor alpha (TNFα), interleukin 6 (IL6), IL10, IL18 and interferon-1 
beta (IL-1β) are upregulated by injured epithelial and endothelial cellsand also infiltrating 
neutrophils and microphages (67, 68, 70, 71). The presence of cytokines and hypoxia leads to 
cytokine induced inflammation in AKI (67).  
 
 
Figure 1.5 Inflammatory cytokines in pathogenesis of AKI  
Ischaemia induced AKI leads to upregulation of inflammatory cytokine including IL18, IL6, 
and TNFα that serve as AKI biomarkers. Infiltrating neutrophils and macrophages secrete 
adhesion molecules and produce oxygen free radicals. Reproduced from Akcay et al. 2009 
(68) under the Creative Common Attribution License. 
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1.7.1 The influence of TNFαon CIN  
TNFα positively mediates inflammation in the kidneys by recruiting other pro-inflammatory 
cytokines such as IL6 and IL8 and also increases expression of cell adhesion molecules (63, 
72).  Excessive production of TNFα is linked to the development of several inflammatory 
diseases, including CIN (3, 63, 72, 73). 
In previous animal and human studies, TNFα and Interleukin 6 (IL6) were upregulated 
following contrast media administration and potentiated CIN (14, 70, 74). Recently Deng et 
al. reported almost 2-fold increased levels in the TNFα and IL6 cytokines in diabetic rats with 
CIN compared to controls (48.6±5.2 vs. 27.1± 2.3 pg/ml, p<0.01) and (15.1±1.2 vs. 7.6±0.7 
pg/ml) respectively (63). Hudzik etal.found increased levels of IL6 in the CIN group 
compared to controls (8.3 vs. 2.7 pg/ml, p < 0.001) among patients undergoing PCI (70). 
Chang et al. also reported increased expression of TNFα in the patients with CIN (70). In 
other studies, serum and urine levels of TNFα correlated with severityof renal disease (72).  
TNFα functions as a mediator of inflammation and it initially occurs as a large membrane 
bound molecule; however, it is split into its functional and soluble 17 kDa protein. The tumor 
necrosis factor receptors TNFR1 and TNFR2 both mediate function of TNFα with varying 
affinities (72).  
The TNFα cytokine is undetectable in normal kidney tissue; however post renal injury, the 
injured endothelium and renal tubules together with infiltrating inflammatory cells secrete 
significant amounts of it (69, 72). Despite the absence of TNFR2 in uninjured kidneys, it is 
over expressed in renal tubules, endothelium and interstitium post renal injury (72).  
1.7.2Association of TNFα gene polymorphisms with CIN 
The central positioning of the TNFα gene on class III of the major histocompatibility complex 
makes it a highly polymorphic gene and polymorphisms of the gene are associated with 
disease risk and poorer outcomes (72, 73).  
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Within the promoter region, TNFα has several single nucleotide polymorphisms (SNPs) that 
include -308G/A and -857C/T; however, the former is the commonest genotype linked with 
disease susceptibility (72).   
The TNFα -308 genotype exists in two forms; the predominant guanine (G-allele) and lesser 
adenine (A-allele) (75); in previous studies, the A allele was positively associatedwith a 6-fold 
higher transcription rate (72, 75). The A allele also predicted poor clinical outcomes in post-
transplant kidney patients (72).  
Among the Han Chinese populations with CIN, Chang et al. found a 2-fold increase in 
frequency of the A-allele (rs1800629) compared to controls (OR 2.01, 95% CI 1.13-3.35, 
p=0.02) (14). 
1.7.3Influence of Interleukin 10 on CIN 
A decreased level of IL10 positively predicts development of AKI (14, 76, 77).  Chang et al. 
reported reduced baseline IL10 levels in CIN patients compared to controls (1.02±1.14 vs. 
2.78±4.73 pg/ml, p=0.008) (14).  
The IL10 cytokine is involved in suppression of many inflammatory cytokines and therefore 
protects the kidney following insult and hastens renal recovery (76, 78). IL10 occurring as a 
37 kDa homodimer molecule (78) is located on chromosome 1(14, 78). IL10 is mostly 
produced by inflammatory cells, however, the mesangial and endothelial cells in presence of 
renal injury produce IL10 (72, 76, 78).IL10 performs various functions through its linked IL10 
receptors 1 and 2 that include down regulation of cytokines TNFα andIL12 and also inhibition 
of T helper cells (77).  
1.7.4 Association of IL10 gene polymorphism with CIN 
IL10 contains several SNP in its promoter region that include -1082 G/A, -819 C/T, -592C/A 
(78), and these influence the production of IL10 levels (77). In previous studies, SNPs in the 
IL10 gene were positively associated with CIN risk (14).   
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Recently, Chang et al. reported a positive association between individuals with genetic 
polymorphisms in rs1800896 in the IL10 gene with CIN (14).In this study, increased 
frequency in the –IL10 -1082 G-allele (rs1800896) was associated with an almost 3-fold 
increase in development of CIN (14).  
In summary, CIN is characterised by an imbalance of inflammatory cytokines namely TNFα 
and IL10 whose genetic polymorphisms are known to influence disease. TNFα as a 
proinflammatory cytokine accelerates disease such as CIN and therefore poorer clinical 
outcomes, while IL10 accelerates recovery. Identification of protective cytokine genetic 
polymorphisms is critical in implementing targeted modalities that will lessen the impact of 
CIN among patients with decreased IL10 and high TNFα levels.  
1.8 Accuracy of biomarkers in predicting and prognosticating CIN 
1.8.1 Diagnostic limitation of serum creatinine  
Treatment of CIN including AKI in general remains supportive,non-specific and diagnosis is 
based on serum creatinine based definitions(9). Earlier diagnosis of CIN is paramount in 
offering timely interventions. However, early intervention is limited because serum 
creatinine,the golden diagnostic marker, is suboptimal in the early diagnosis of AKI (79-84). 
Previous studies have shown that almost 80% of CIN would be identified within 24 hours post 
contrast administration, however delayed detection of AKI due to shortcomings in serum 
creatinine lead to poorer outcomes in patients with CIN (82, 85).  
For several reasons, serum creatinine is limited in the early detection of AKI; it is affected by 
extra renal factors that include an individual mass and extracellular volume irrespectiveof the 
level of glomerular filtration rate; it does not increase immediately post kidney injury and 
occasionally exhibits a downward trend post kidney injury(67-72 (86, 87). Increase in 
serumcreatinine is also noticed at least 72 hours after injury to the kidney and sometimes delay 
of up to 5 days occurs after an insult (56, 82).   
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Additionally, a significant loss of renal injury is accompanied by normal serum creatinine 
levels (88). Due to increased morbidity and mortality associated with AKI, the Acute Dialysis 
Quality Initiative (ADQI) recognized the development of early biomarkers of AKI(89).  
There is the need of identifying biomarkers that will identify early AKI and also stage the 
severity of kidney disease in line with the available risk, injury failure loss and end stage 
(RIFLE) and also according to the Acute Kidney Injury Network (AKIN) severity grading 
systems for renal injury(89, 90)[Figure 1.6].  
Increased serum creatinine to post RIFLE-I or AKIN-2 is associated with worse outcomes (89, 
91) and hence the need of early biomarker that will identify subclinical AKI. Studies confirm 
that even small variations in levels of serum creatinine were associated with morbidity and 
mortality (48, 92, 93). AKI is classified into three stages as; increased serum creatinine ≥ 1.5, 
≥ 2 and ≥ 3 as stages one, two and three respectively (57). 
 
Figure 1.6Roles of novel biomarkers in RIFLE and AKIN criteria 
The interaction of novel biomarkers with the current RIFLE and AKIN criteria will improve 
the diagnosis of AKI. Reproduced with permission from Charlton et al. 2014 (90). 
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1.8.2 Definition of a biomarker 
A biomarker is defined as a―measurable characteristic that is indicative of normal biological 
processes, including pathological and pharmacological processes‖ (93). An ideal biomarker of 
AKI should be non-invasive by utilizing blood and urine and should demonstrate diagnostic 
accuracy for early risk, prediction and good functionality in recognizing stable disease and 
prognosis (93, 94). 
Biomarkers (either single or multiple) are needed at several stages of renal disease or risk 
identification for the management of renal disease. Several major questions on biomarkers of 
AKI remain unexplored especially in heterogeneous populations (95);which biomarkers 
identify earlier risk, best timing, threshold to use for identification, which biomarkers 
prognosticate outcome and whether multiple biomarkers perform better compared to one 
[Figure 1.7].  Lastly, in a few studies that explored accuracy of AKI biomarkers in 
heterogeneous populations that are characterized by varying renal insults, the area under the 
receiver operating curves (AUC-ROC) results were conflicting (85, 89, 95). 
 
Figure 1.7 Clinical uses of biomarkers in AKI.  
Reproduced with permission from Murray et al. 2014(89).  
 
 
24 
 
 
1.8.3 Classification of novel biomarkers 
Sources of novel biomarkers are variable (96) and include renal and non-renal tissues (90) and 
are classified as those molecules reflecting glomerular function (cystatin C and β2M) and 
those that are upregulated in both plasma and urine (IL18, NGAL) and reflect renal injury, 
damage (tubular and endothelial) or repair (85, 89, 90, 96). AKI including CIN is 
characterized by impaired glomerular filtration and tubular dysfunction (85). The resultant 
kidney dysfunction leads to accumulation of these biomarkers in both plasma and urine (85, 
96). Cystatin C and β2M including serum creatinine are considered as filtration biomarkers 
(85, 89). Extra renal production of biomarkers due to systemic inflammation leads to increased 
accumulation of these biomarkers in circulation and impairment in glomerular filtration or 
absorption worsens clinical picture (85).   
1.8.4 Functions of novel biomarkers  
In normal kidneys, novel biomarkers for AKI are barely detectable in blood or urine; however 
they are upregulated following injury such as contrast administration (97, 98). A good 
biomarker should potentially identify the risk and severity of acute renal injury and it should 
prognosticate AKI; that is recovery, renal replacement therapy in form of dialysis and patient 
outcomes such as  mortality (92, 93, 99) [Figure 1.8]. However, as shown in Figure 1.8, serum 
creatinine is a traditional biomarker of significance in late stages of renal disease. 
Additionally, levels of the biomarker should reflect the degree of injury intrinsic to the AKI 
(94). The ideal AKI biomarker should be able to monitor progression of renal disease (94).  
Either urine or plasma/serum is utilized for AKI biomarkers with significant variation in 
biomarker results (100). A recent observational study showed superiority of plasma/serum in 
biomarker assessment compared to urine (100). Schley et al.in a recent comparative study of 
novel biomarker performance in patients undergoing cardiopulmonary surgery in Germany 
reported that the plasma biomarkers demonstrated superior diagnostic accuracy for AKI (100).  
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There are several advantages of plasma/serum in biomarker assessment; unlike urine, serum is 
unaffected by bacterial contamination and can be collected despite presence of anuria in 
patients (100). Zhou et al. 2016 in a meta-analysis demonstrated similar diagnostic accuracy in 
plasma and urine (101). 
 
Figure 1.8 Timing of novel biomarkers in AKI progression 
Injury to the kidney occurs prior to decreasing GFR or increasing serum creatinine and novel 
biomarkers identify early acute kidney injury and are useful in prognostication. Reproduced 
with with permission from Bellomo et al. (99).  
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1.8.5 Neutrophil gelatinase-associated lipocalin-2 (NGAL) 
NGAL occurs as a 25 kDa glycoprotein and is composed of 198 amino acids belongs to the 
lipocalin super family (94). Unique to all lipocalins is the presence of eight beta strands that 
are folded together through hydrogen bonds and creates a site binding ligand (102, 103).  
The NGAL gene called LCN2 is localized to chromosome 9q34.11 (103). Three forms of 
NGAL are described: a 25 kDa monomer, 45 kDa homodimer and 135 kDa heterodimer (94); 
however, the 25 kDa remains the most important. Homodimeric NGAL is processed by 
neutrophils from their myeloperoxidase (MPO) granules while in the kidney predominantly 
monomeric NGAL and to a limited extent heterodimer NGAL are expressed (94). The sources 
of NGAL in the kidneys are the proximal tubules and collecting ducts (93).  
Normally NGAL is expressed at very low levels in many tissues including the kidneys (94). In 
the circulation and in the urine, the levels of NGAL are kept low, averaging 20 ng/ml(90). 
NGAL is filtered by the glomerulus andundergoesabsolute megalin mediated endocytosis in 
the proximal tubules (90) [Figure 1.9]. The main NGAL receptors are megalin located in the 
proximal tubular cells of the kidneys (102). Following internalization, NGAL is degraded in 
lysozymes into a 14 kDa product (90).  
However, post-acute kidney injury NGAL is up regulated within 2-6hours(79, 81, 104, 105). 
The main stimulant to NGAL production is ischaemia-induced hypoxia to the kidneys (93) 
such as contrast induced hypoxia. In previous studies, the levels of serum NGAL were also 
increased in the presence of inflammation and in some malignancies (93). During injury, IL-
1β positively activates nuclear factor kappaB (NF-kB) that leads to translocation of the latter 
into the nucleus and ultimately leads to increased transcription of NGAL promoters (93).  
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Figure 1.9 Metabolism of NGAL in the kidney 
NGAL, predominantly produced by neutrophils and to a smaller extent by the liver and 
kidneys, undergoes filtration and megalin mediated endocytosis. After injury, NGAL increases 
in blood and urine. Reproduced with permission from Charlton et al. 2014 (90). 
1.8.5.1 Functions of NGAL and lipocalin  
Lipocalins are involved in immunological (bacteriostatic) function and transportation of 
smaller molecules that include retinol binding proteins and siderophores(90, 94). In humans, 
ferritin, transferrin and lactoferin serve as major iron binding molecules; however compared to 
siderophores in microorganisms, the latter has increased affinity for iron (103). NGAL serves 
an important immunological role by depriving microorganisms of iron and thereby inhibiting 
their proliferation (102, 103).   
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Microorganisms rely on the presence of siderophores for multiplication; however, once 
complexed to siderophores (iron binding molecules in microorganisms), iron is internalized by 
NGAL (102, 103).  
1.8.5.2 NGAL as a biomarker of AKI 
Studies support NGAL as an early marker for predicting AKI and its outcomes (106). In 
patients undergoing enhanced computed tomography, Filiopoulos et al. demonstrated a 10-
fold increase in plasma NGAL in the CIN group compared to controls at six hours after 
contrast administration (106). Despite insignificant differences in NGAL values at baseline in 
the two groups, at 6 hours the levels of plasma NGAL were 779.25 ng/ml ±361.5 vs. 82.3 
ng/ml ±40.6, p <0.001 in CIN group and controls respectively (106). In this study, the reported 
sensitivity and specificity at 6 hours after radio contrast was 100% with an area under the 
receiver operating characteristic curve (AUROC) of 1.00 when the cut-off value for NGAL of 
200 ng/ml (106). 
In hospitalised patients admitted to an intensive care unit, Cruz et al. demonstrated 
significantly high levels of plasma NGAL in the entire study cohort compared to a healthy 
population irrespective of the development of AKI (104). The median plasma NGAL in this 
study cohort was 117.0 ng/ml (68.2-213.8), P<0.001. Increased levels of plasma NGAL were 
observed in AKI patients compared to controls (185 ng/ml vs. 82 ng/ml, p<0.0001)(104). 
Vijayasimha et al. in India reported maximum rise in NGAL levels within 4 hours of contrast 
administration and the AUC was 0.96 (97). After 48 hours post contrast administration, 
plasma NGAL levels in the CIN group were not significantly raised (97).  
Despite variations in cut-off values for NGAL in discriminating AKI (including CIN), a recent 
meta-analysis supported the accuracy of NGAL in the early  diagnosis of CIN (83); however 
several studies on NGAL are predominantly limited to surgical and ICU based homogenous 
populations studies and few to CIN or heterogeneous populations (83, 101). 
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 Tong et al. in a recent meta-analysis of ten studies that included patients undergoing contrast 
media administration, reported the overall diagnostic odds ratio (DOR) for NGAL to predict 
CIN of 20.56, 95% CI 9.67-43.74 with AUROC of 0.87, 95% CI 0.84-0.96) (83). NGAL 
sensitivity and specificity in this meta-analysis were 0.80, 95% CI 0.74-0.90 and 0.83, 95% CI 
0.73-0.90 respectively and cut-off levels ranged from 52.4 ng/ml to 115 ng/ml (83). NGAL at 
2-6 hours provided the best discrimination for CIN compared to 24 hours after contrast media 
(83). Despite being the only meta-analysis with ten studies that associated NGAL and CIN; 
only five studies from this meta-analysis were limited to AKI (with four looking at patients 
undergoing PCI and one in critical patients) (83). 
Another meta-analysis found that the overall DOR for AKI was 18.6, 95% CI 9-38.1 and the 
AUROC; 0.81, 95% CI 0.73-0.89 across all settings using NGAL cut-off values of 190.2 
ng/ml (122.8-257.2) (107). In this meta-analysis, the DOR for CIN was 92, 95% CI 10.7-794.1 
and the AUROC was 0.83-0.95 using a NGAL cut-off of 100 ng/ml (80-100ng/ml) despite 
extreme wide confidence intervals (107). Using high cut-off values of 212 ng/ml (121-
506.7ng/ml), the overall DOR in predicting mortality was 8.8, 95% CI 1.9-40.8 with an 
AUROC of 0.71, 95% CI 0.53-0.75(107). The mortality sensitivity and specificity were 65, 
95% CI 51.2-80.8 and 82.6, 95% CI 51.8-95.5 respectively (107). 
In a recent meta-analysis that included 46 studies of cardiac surgery associated-AKI, Zhou et 
al. observed significant variations in the predictive accuracy of NGAL for AKI post-surgery 
(101). The overall serum NGAL DOR of 13.05, 95% CI 7.85-21.70 was lower in this meta-
analysis compared to the previous ones and so were the sensitivity (0.68, 95% CI; 0.65-0.70) 
and specificity (0.79, 95% CI 0.77-0.80 (101). This meta-analysis also showed similar 
diagnostic accuracy in using both serum/plasma and urine (101). The DOR for NGAL in urine 
was 13.09 with AUROC of 0.85 while in plasma/serum the DOR was 13.20 and AUROC was 
0.88 (101). Only 2 studies from this meta-analysis showed superiority in using urine NGAL 
compared to plasma/serum (101). 
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The limitation of the NGAL meta-analysis is that the study populations were predominantly 
homogenous, included CKD patients, uncontrolled for sex and age and few of these studies 
included patients exposed to contrast media in which the insults to the kidneys may be 
heterogeneous.  
1.8.6 Cystatin C and AKI 
Cystatin C belonging to the cystatin superfamily is a non-glycosylated protein with a 
molecular weight of 13 kDa and 120 amino acids (108, 109).  
The CST3 gene for cystatin is mapped on chromosome 20 (109). Intracellularly, cystatin C is 
in an inactive form and is localized to the endoplasmic reticulum of cells as well as the Golgi 
apparatus, but prior to secretion, it is activated to an active monomer (109). Cystatin C 
occurring as monomers is linearly secreted and has wide distributed in body fluids and tissues 
(109).  
Cystatin C, produced by all nucleated cells is freely filtered by the glomerulus and is 
completely reabsorbed by the tubules and therefore barely detectable in the urine (87, 98, 
110). Up to 99% of the metabolism of cystatin C is via the kidney (109) [Figure 1.10]. 
Following reabsorption, cystatin C is complexed to proteases and internalized within lysozyme 
organelles where it functions to inhibit cystatin peptidases (109). In studies, cystatin C has 
been shown to down regulate chemotaxis by neutrophils and production of ROS (109).  
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Figure 1.10 Metabolism of cystatin C in the kidney 
As a filtration biomarker, cystatin undergoes freely filtration and reabsorption in the proximal 
tubules. In acute kidney injury due to decreased glomerular filtration or impaired proximal 
tubular absorption (b), cystatin C accumulates in circulation and urine. However the presence 
of albuminuria also increases urine cystatin C levels. Reproduced with permission from 
Charlton et al.2014 (90). 
Levels of cystatin C in blood range from 0.8-1.2 mg/dl; however, this is increased in 
conditions of decreased glomerular filtration or reabsorption (109). Levels of cystatin C in 
blood or urine correlate directly with the development of AKI; however, cystatin C is 
negatively affected by proteolytic enzymes in the urine (109).   
Cystatin C positively predicts AKI and poorer early and late clinical outcomes in patients with 
AKI (111, 112).   
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In previous studies, cystatin C predicted AKI earlier compared to serum creatinine; however 
the results were variable (111, 113). Ishibashi et al. reported significantly high baseline 
cystatin C levels in CIN patients compared to controls (1.08±0.42 vs.0 0.77±0.15 mg/l)(111). 
The sensitivity and specificity of cystatin C in the diagnosis of CIN were 81.8%, 95% CI 0.81-
1.06 and 91%, 95% CI 0.81-1.06 respectively with a cut-off value above 1.18 mg/l (111).  
In a prospective study of 374 post cardiopulmonary bypass patients under 18 years of age, 
cystatin C levels at 12 and 24 hours positively predicted AKI and patient outcomes (113). At 
baseline, Krawczeski et al. observed insignificant differences in cystatin levels at baseline 
between the two groups; however after 2 hours, cystatin C increased significantly until 
24hours and independently predicted AKI (113). The AUROC at 12 hours was 0.81; 95% CI 
0.74-0.88; p<0.001 and 24 hours was 0.84; 95% CI 0.78-0.91; p<0.001 (113). In CKD patients 
undergoing coronary angiography, the pre-contrast and 24 hours post contrast serum creatinine 
were not significantly different between the CIN group and controls until 48 hours (114). 
However, serum cystatin C increased significantly at 24 hours after contrast administration 
and the AUROC for  serum cystatin C discrimination for CIN at 24 hours was 0.80 (114).  
Evidence from meta-analysis strongly supports cystatin C as an early biomarker of AKI (115). 
In a meta-analysis that included 19 studies, Zhang et al found an overall DOR for cystatin C in 
predicting AKI of 23.5, 95% CI 14.2-38.9 (115). Cystatin C measured within 24 hours 
demonstrated good AUROC ranging from 0.86-0.88 (115). The studies included in this meta-
analysis were uncontrolled, the majority looked a homogenous populations and only one study 
addressed patients with CIN (115). This is due to limited studies exploring the role of cystatin 
C and other biomarkers in patients undergoing contrast media administration. 
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1.8.7 Beta-2Microglobulin and AKI 
Beta-2Microglobulin (β2M) with a molecular weight of 11.8 kDa occurs as a non-glycosylated 
functional polypeptide expressed on all nucleated cells (116-118). β2M is a component of the 
major histocompatibility complex (MHC) class 1 molecules and is linked non-covalently to 
the α-1 chain (116, 118).  
Insignificant levels of β2M are seen in the circulation averaging less than 2 mg/l and less than 
400 μl is reflected in urine per 24 hours (116, 117). When released into the circulation, β2M 
undergoes almost 95-100% metabolism in the kidneys; it is filtered by the kidneys and 
completely absorbed via megalin mediated proximal tubular endocytosis (116, 117, 119). 
Increased serum levels of β2M are seen in patients with impaired renal function; either due to 
reduced glomerular filtration rate or decreased absorption by the proximal tubules (116). 
However, inflammatory conditions including malignancies and rheumatoid arthritis have been 
linked with increased levels of β2M (116).  
Beta-2 microglobulin predicts AKI earlier compared to serum creatinine (119). Nozue et al. 
reported higher serum β2M levels among patients with CIN compared to controls and its 
sensitivity was 75% and specificity 80% at a cut off value of 2.8 mg/l (112). Studies have 
demonstrated positive association between β2M with cardiovascular changes and patient 
outcomes (116). In a case controlled study of CKD patients, Sedighi et al. found increased 
serum β2M in renal patients compared to controls 7.6 ±3.7 vs. 2.1mg/l ± 1.7 mg/l, p <0.001 
(116). In previous studies, increased levels of β2M are also positively associated with 
increased mortality (116). 
Despite previous studies demonstrating positive association of high β2M in patients with 
impaired filtration (118) and also association with mortality (116), there are lack of studies 
that have looked at β2M as a biomarker for CIN and prognostication.  
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1.8.8 Interleukin 18 and AKI 
IL18 is an inflammatory cytokine produced by both inflammatory and non-inflammatory cells 
(120). The primary inflammatory cells producing IL18 are the macrophages, neutrophils and 
lymphocytes while in the kidneys, it is produced by the proximal tubular cells, mesangial cells 
and podocytes (120) [Figure 1.11]. IL18, belonging to the IL1 family of cytokines, is initially 
produced as an inactive pro-IL18 consisting of a 24 kDa molecule of 192 amino acids, but is 
later cleaved into an active 18 kDa molecule with 157 amino acids by caspase-1 (90, 120). 
IL18 performs its functions through two receptors; IL18 receptor alpha (IL18Rα) and IL18 
receptor beta (IL18Rβ) (121). The β chain is linked to an accessory molecule. The α-chain is 
the binding ligand for IL18 while the β chain is involved in signaling pathways (90, 121). IL18 
performs various functions linked to inflammation, increases transcription rate for 
chemokines, adhesion molecules and inflammatory cytokines, and also induces nitric oxide 
and NF-kB (120). 
An insult to the kidney is associated with significant secretion of IL18 by the proximal tubular 
cells and endothelial cells (90). Sirota et al. reported increased IL18 in the urine in AKI 
patients compared to controls (884.0 vs.0 ng/ml, p=0.004) with an AUC of 0.75 in patients 
that underwent liver transplant (122). In other studies, IL18 was associated with almost 4-fold 
and 5-fold odds for AKI and mortality respectively (123). In this study, AUC-ROC for IL18 in 
discriminating AKI was 0.73 within 24 hours (123).  
Few studies have explored the association of IL18 and other inflammatory cytokines including 
TNFα and IL10 as biomarkers of CIN. In a meta-analysis of IL18 (and limited to urine) that 
included 11 studies, Lin et al. observed significant heterogeneity in the included studies and 
the overall diagnostic odds of urine IL18 for AKI was lower than NGAL with a sensitivity and 
specificity of 0.51 and 0.79 respectively (124) compared to other biomarkers such as cystatin 
C or NGAL. In this meta-analysis, the diagnostic performance of urine IL18 in adults was 
suboptimal compared to paediatric populations (124).  
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Figure 1.11Metabolism of interleukin 18 in acute kidney injury  
An insult to the kidney leads to cleavage of the pro-IL18 to IL18 by Caspase 1 and secretion 
into blood and urine. The sources of IL18 are both inflammatory cells and injured renal tissue. 
Reproduced with permission from reference (90). 
1.9 Correlation of novel biomarkers with morbidity and mortality 
CIN biomarkers have been shown to predict short and long term outcomes in various studies, 
even in the presence of normal baseline serum creatinine values (114).Ishibashi et al. reported 
high short term mortality with increased cystatin C levels (OR 0.31; 95% CI 0.058-0.0538; 
P=0.03) (111). Patients with cystatin C levels exceeding ≥ 1.29 mg/dl had increased 
cardiovascular deaths, MI and strokes (111). 
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Among patients undergoing contrast studies for acute pulmonary embolism, increased baseline 
NGAL and cystatin C plasma levels positively predicted thirty day mortality (125).  
In other studies, cystatin C predicted the development of heart failure and prognosis better 
than serum creatinine (126).Recently, Tong et al. reported NGAL cut-off values of 91 ng/ml 
as a predictor of major cardiovascular events (83).
 
1.10 Association of HIV withnovel biomarkers of AKI 
The levels of serum creatinine shows variation in human immune deficiency virus (HIV) 
infected patientsdue to underlying reduced body mass and medications e.g. septrin, a 
recommended primary and secondary prophylactic treatment for pneumocystis Carinii 
pneumonia (PCP) in HIV patients, increases serum creatinine (127). 
Studies have shown variable levels of new biomarkers among HIV infected patients (128). 
Cross sectional studies of 1008 HIV infected and 290 uninfected patients found significantly 
raised levels of cystatin C in the HIV infected subgroup (0.90± 0.22 mg/dl) compared to the 
uninfected group (0.76± 0.15) (127, 128). There were no differences in creatinine levels in the 
two groups. Presence of HIV infection was associated with an at least 10-fold increase in 
cystatin C after adjusting for other parameters and cystatin C predicted worse renal kidney 
dysfunction in the HIV subgroup (128).  
In other studies, the levels of NGAL were low in highly active antiretroviral therapy 
(HAART) naïve patients and increased after commencement of HAART (110, 128, 129). 
Landro et al. in a 24 month follow up of HIV infected patients, demonstrated decreased levels 
of NGAL prior to HAART; however after commencement of HAART, the levels of NGAL 
were comparable to healthy controls. In this study, decreased NGAL levels in the presence of 
impaired immunity were probably a reflection of decreased neutrophils or impaired neutrophil 
chemotaxis (129). However, the association of novel biomarkers with HIV remains 
unexplored.  
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In summary, novel biomarkers produced from various sources are upregulated in blood or 
urine leading to their role in early AKI diagnosis and prognostication(53) [Table 1.3] 
Table 1.3 Novel biomarkers proposed in AKI   
Novel Biomarker Use   Measured in Sources  
Filtration 
biomarkers           
Cystatin C 
Early 
diagnosis 
severity 
(prognosis) 
 
Serum, 
Plasma and 
urine 
 
Belongs to a family of cysteine 
proteinase inhibitors, filtered and 
reabsorbed (53) 
     
  
Β2-microglobulin  
Severity 
(prognosis)  
Serum, 
plasma and 
urine  
Present on all nucleated cells. 
Glomerular or tubular dysfunction 
leads to increased levels in blood 
and urine(53).  
      
              
Renal tubular 
injury/damage           
Neutrophil 
gelatinase-
associated 
lipocalin-2   
Early 
diagnosis 
and severity 
(prognosis) 
 
Serum, 
plasma and 
urine  
 
Plasma NGAL is freely filtered 
and reabsorbed in the proximal 
tubules(53). 
 
  
    
  
Interleukin 18   
Early 
diagnosis 
and severity  
 
Serum, 
plasma and 
urine  
 
A proinflammatory cytokine 
secreted by injured renal 
cells(53). 
Tumor 
necrosis 
factor alpha 
and 
interleukin 10   
Severity(14, 
76)   
Plasma, 
serum and 
urine   
Inflammatory cytokines 
upregulated after injured renal 
cells (72, 76) 
 
The table on all biomarkers (excluding IL10 and TNFα) is reproduced from Chalikias et 
al.2016(53) with permission. Information on IL10 and TNFα from is from Chang et al. 
(14)and Jaber et al.(76)  
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1.11 Summary of the study and the research gaps 
In developed countries, CIN ranks third as a cause of hospital acquired AKI impacting highly 
on morbidity and mortality (Chang, 2013). In sub-Saharan Africa, information on prevalence 
and risk factors for CIN including patient outcomes remains unexplored. 
The diagnosis of CIN utilizes serum creatinine (a traditional biomarker) that peaks at 3-5 days 
(53) after an insult and therefore delays diagnosis by almost 48 hours post contrast media 
when compared to the new biomarkers (125).  
Additionally, despite identification of the traditional risk factors for CIN and its pathogenesis 
from studies in developed countries, information on susceptibility genes contributing to 
development of CIN and its severity in Africans and other populations, and the influence of 
new biomarkers of CIN on patient outcomes is lacking. Treatment for CIN is limited to 
supportive care only (9).  
There has been no study that has investigated the susceptibility genes for CIN in black 
populations including other races (except Han Chinese). Additionally, the roles of novel 
biomarkers in the diagnosis of CIN or prognostication remains unexplored among South 
Africans. Identification of higher risk and genetically susceptible individuals to avoid 
exposure and earlier diagnosis of CIN using new biomarkers and identification of 
susceptibility genes will not only reduce morbidity and mortality but will also add knowledge 
to renal medicine. 
It is for these reasons that the study was undertaken to identify the rates of CIN, important 
novel biomarkers for diagnosis and prognostication and the genes associated with 
susceptibility to CIN.  
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1.11.1 Research hypotheses  
Our research hypotheses were as follows; 
1 The proportion of CIN is significantly higher in hospitalized South Africans compared to 
developed countries. 
2 Novel biomarkers are more accurate in diagnosing and prognosticating CIN compared to 
serum creatinine 
3. The TNFα and IL10 cytokine genotype single nucleotide polymorphisms (SNPs) are 
positively associated with CIN in black South African populations. 
 
 
  
 
 
40 
 
 
1.12 AIMS 
The aim of this study was to determine the diagnostic and prognostic utility of biomarkers for 
CIN and genetic susceptibility for AKI in patients receiving contrast media  
1.12.1 Specific objectives  
1 To determine the prevalence of CIN and associated risk factors at Charlotte Maxeke 
Johannesburg Academic Hospital. 
2 To determine the accuracy of biomarkers in identifying post contrast AKI 
3 To evaluate the accuracy of non-traditional biomarkers in predicting morbidity and mortality 
in patients with post contrast AKI. 
4 To determine the influence of genetic susceptibility in contrast induced AKI patients. 
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CHAPTER 2 MATERIALS AND METHODS  
2.1 Study design, setting and population  
A prospective case-controlled study was conducted at the Charlotte Maxeke Johannesburg 
Academic Hospital in South Africa from July 1, 2014 to July 30, 2015. Ethical approval was 
obtained from the human research ethics committee (HREC) of the University of the 
Witwatersrand (Appendix A) and informed written consent was obtained from all patients 
(Appendix C). In-patients undergoing computerized tomography and angiography from the 
Divisions of Radiology and Cardiology were recruited consecutively and followed-up for 
developing of AKI [Figure 2.1].  
2.1.1 Inclusion criteria 
Inclusion criteria were patients aged 18 years and above, written informed consent, 
undergoing computed tomography contrast media administration or angiography and stable 
chronic kidney disease (CKD). All included patients received contrast media administration. 
2.1.2 Exclusion criteria  
The following patients were excluded: participants below 18 years, evidence of pre-existing 
AKI (clinical or laboratory), end stage renal disease (ESRD) on renal replacement therapy 
(RRT), prior contrast media administration in the preceding 7 days, pregnancy and non-
consenting participants. 
2.1.3 Study outcomes 
The primary end point was the occurrence of CIN, defined as a serum creatinine increase 
>25% from baseline or at least 44 umol/l assessed within 48-72 hours post contrast media 
administration. Patients included in the study but not meeting the CIN definition criteria where 
designated as controls. The secondary endpoints were death and duration of hospitalization 
obtained from discharge summaries. 
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Figure 2.1 Participants and specimen flow chart 
  
 Assessed for eligibility (n=431) 
Post contrast patients (n=371) 
Blood Urea, blood creatinine, urine and blood B2M, NGAL, 
TNFα genes, IL10 genes, Cystatin C, KIM1, TNFα, IL10, IL18, 
imaging (CT , echo), urine dipstick 
 
 Blood Urea, blood creatinine, urine and blood B2M, 
NGAL, Cystatin C, IL18 (24hrs, 48hrs &day 5) 
 
CIN patients (n=61) No CIN/control group (n=310) 
Recovered 
AKI  
Mortality 
(n=20) 
 
Mortality 
(n=13) 
Genetic analysis: TNF-α, IL10 genotypes 
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2.2 Study procedures 
2.2.1 Clinical procedures  
The study physician reviewed participants’ medical records and examined the participants in 
order to determine pre-existing risk factors for CIN.Using a data collection sheet, demographic 
data was obtained in addition to information on factors associated with CIN i.e. hypertension, 
DM, heart failure, current medications and hypotension. Co-morbidities, presence of 
peripheral edema, HIV status, anaemia, and current medications and information on type and 
dose of contrast media were also recorded. The medical records were reviewed to determine 
patient duration of hospitalization, dialysis requirements and mortality.  
2.2.2 Blood and urine sample preparation 
Study phlebotomists’ collected blood and urine samples prior to and post contrast media 
administration. Whole blood (5 mls) was collected into ethylenediaminetetraacetic (EDTA) 
tubes and stored at -20
o
C for genomic DNA extraction. For biomarker studies, 5 mls whole 
blood collected in serum separating tubes (SST) prior to CT contrast administration and at 24 
hours, 48 hours and 5 to 7 days post contrast media administration were left at room 
temperature over 10 minutes to clot and later centrifuged at 5000 rpm at 4
o
C for 10 minutes 
(U-32012 Centrifuge, Boeco, Germany). Post centrifuge, 500 μl of obtained serum was 
aliquoted into 1500 ul microcentrifuge tubes and stored at -80
o
C. Pre contrast urine was 
collected for determination of proteinuria and microalbuminuria. 
2.3 DNA extraction and genotyping  
2.3 1 DNA extraction 
Genomic DNA was extracted using the Maxwell DNA purification kit (Promega AS1010, 
USA) as per manufacturer’s protocol. DNA concentrations were determined by the 
NanoDrop
TM
 2000 spectrophotometer (Thermo Scientific, USA) with A260/280 ratios. 
Samples that had suboptimal DNA concentrations <10 ng/ul were re-extracted using a 
standard salting out method.     
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For the salting out method, buffy coats of nucleated cells obtained via anti-coagulated blood 
(EDTA) were re-suspended in 15 mls polypropylene centrifugation tubes with 3 mls of nucleic 
lysis buffer (1% SDS; 2 mM EDTA) containing 2 mg/ml proteinase K.  
The cell lysate was left for digestion overnight in a 37
0
C water bath and post digestion; 
sodium chloride was added to each tube, mixed vigorously and incubated on ice for 5 minutes 
and thereafter centrifuged at 2300 rpm. In order to remove the salt used to precipitate DNA, 
the pellets were washed with ice cold 70% ethanol and centrifuged at 8000 rpm for 20 minutes 
at 4
0
C. The DNA pellets were air dried at room temperature and later dissolved in 500 ul 1X 
TE (10 mM Tris-Cl; 2 mM EDTA, pH 8.0) buffer before undergoing quantification. The DNA 
samples were then stored at -80
0
C until final genotyping analysis.  
2.3.2 PCR reaction set up and amplification 
PCR reactions consisted of water, 1 x master mix (KAPA2G Robust Hot Start Ready-Mix 
PCR kit, Kapa Bio systems, USA), 1.25 ul DNA primers [Table 1] and 100 ng DNA (diluted 
to 25 ng/ul). The reactions were amplified on the MJ Mini
TM
 Thermal cycler (Bio-Rad, USA) 
with initial denaturation at 95
o
C for 3 minutes followed by a 40 cycles with denaturation at 
95
o
C for 15 seconds, annealing at 60
0
C for 15 seconds and final extension at 72
0
C for 20 
seconds.  
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Table 2.1 Primers and restricting enzymes  
 
Gene  Primer  Alleles (bp) Enzyme 
 
Annealing 
temperature 
TNFα  -308 F: 5’-GAG GCA ATA GGT 
TTT GAG GGC CAT-3’ 
R: 5’-GGG ACA CAC 
AAG CAT CAA G-3’ 
 
 GG: 126bp, 21bp, GA: 
147bp, 126bp, 21bp and 
AA: 147bp 
NcoI  
(5’-C/CATGG-3’) 
60
o
C 
TNFα  -857 F: 5’-AAG TCG AGT ATG 
GGG ACC CCC CGT 
TAA-3’ 
R: 5’-CCC CAG TGT GTG 
GCC ATA TCT TCT T-3’ 
CC: 106bp, CT: 131bp, 
106bp, 25bp and TT: 
131bp 
HincII  
(5’-GTY/RAC-3’) 
60
o
C 
IL10   -592 F: 5’-GGT GAG CAC TAC 
CTG ACT AGC-3’ 
R: 5’-CCT AGG TCA CAG 
TGA CGT GG-3’ 
 
CC:  412 bp, CA:  412 bp, 
236 bp and 176 bp, AA:  
176pb 
RsaI  
(5’-GT/AC-3’) 
60
o
C 
IL10  -819 F: 5’-TGT ACC CTT GTA 
CAG GTG ATG TGA-3’ 
R: 5’-ACC CCG ATT TCA 
TTA GGA TTC T-3 
 
TT: 190bp, 25bp, TC: 
215bp, 190bp, 25bp and 
CC: 219bp 
EcorRV  
(5’-GAT/ATC-3’) 
60
o
C 
IL10  -1082 F: 5’- CCC TTA CCT TCT 
ACA CAC ACA C-3’ 
 
R: 5’- TCC TCT TAC CTA 
TCC CTA CTT CC-3 
MnlI (5’-CCTC(N7)/- AA: 
106bp, 11bp; 
AG:106bp,83bp,23bp,11b
p and GG: 
83bp,23bp,11bp. 
MnlI  
(5’-CCTC(N7)/-3’ 
 60
o
C 
IL10  -
1582F 
F: 5’-CTG TGT AAG TAG 
CAG ATC AGA T-3 
R: 5’-TGC CAG TCT GTG 
TCT TTG-3’ 
TT: 112bp, TC: 112bp, 
91bp, 21bp and CC: 91bp, 
21bp. 
BglII  
(5’-A/GATCT-3’) 
60
o
C 
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2.3.3 TNFα and IL10 restriction fragment length polymorphism 
Genotypes for -308 (rs1800629) and -857 (rs1799724) in TNFα, and -592 (rs1800872), -819 
(rs1800871), -1082 (rs1800896), and +1582 (rs1554286) in IL10 were determined by 
restriction fragment length polymorphism (RFLP) that consisted of water, 1 x buffer, enzymes 
and PCR products see Table 2.1. To prevent evaporation, 15 ul of sigma mineral oil was added 
to the mixture and incubated over night at 37
0
C. Next day, a two colour gel dye was added to 
each sample and mixed.  
2.3.4 Gel electrophoresis  
Restricted products were resolved on either 10% polyacrylamide or 1.5% agarose gels by 
pipetting 10ul of restricted PCR products to the gel. Polyacrylamide gel electrophoresis were 
performed for TNFα (SNPs -308 and -857), and IL10 (SNPs 819, -1082, 1592) genotypes and 
agarose gel for IL10 (-592) genotype. A 10% polyacrylamide gel was constituted with water, 
10X tris-borate EDTA (TBE) buffer, 30% acrylamide solution, ammonium per sulfate (APS) 
solution and tetramethylethylenediamine solution while the 1.5% agarose gel consisted of 
water, agarose, 10XTBE buffer and ethidium bromide (EtBr).  
2.3.5 Gel imaging  
Visualization of the restricted PCR products representing TNFα and IL10 genotypes 
performed using Gel Doc
TM
 EZ imager (Bio-Rad systems, USA).  
2.4 Determination of serum IL10, IL18, TNFα, NGAL, cystatin C, and B2M 
Concentrations of IL10; IL18; TNFα; NGAL and cystatin C were determined using Magnetic 
Luminex® Screening Assays (#LXSAHM-3, R&D Systems, Inc. Minneapolis, USA, in 
accordance with the manufacturer’s instructions.  
Serum was initially thawed and vortexed for 30 seconds. For Lipocalin-2/NGAL, KIM1 and 
cystatin C, sera were diluted 20-fold i.e. 10 ul sera: 190 ul Calibrator Diluent RD6-52 
(supplied), and 2-fold i.e. 75 ul sera: 75 ul Calibrator Diluent (supplied) for IL18, TNFα and 
IL10 as per kit protocol. A set of 7 standards were prepared by addition of 100 ul of each 
cocktail to standard 1 and after mixing, a similar volume was removed and added to the next 
standard with an exception of the blank, see [Tables 2.2] and [Table 2.3].  
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Table 2.2 Standards preparation for NGAL and cystatin C 
Standard  Volume of RD-52 diluent  Volume of standard  
1 900 ul 100 ul Standard Cocktail J 
2 200 ul 100 ul Standard 1 
3 200 ul 100 ul Standard 2 
4 200 ul 100 ul Standard 3 
5 200 ul 100 ul Standard 4 
6 200 ul 100 ul Standard 5 
7 200 ul 100 ul Standard 6 
Blank  200 ul 0 
 
Table 2.3 Standard preparation for TNFα, IL10 and IL18 
Standard  Volume of RD-52 diluent  Volume of standard  
1 800 ul 100 ul Cocktail A and 100 ul Cocktail 
C 
2 200 ul 100 ul Standard 1 
3 200 ul 100 ul Standard 2 
4 200 ul 100 ul Standard 3 
5 200 ul 100 ul Standard 4 
6 200 ul 100 ul Standard 5 
7 200 ul 100 ul Standard 6 
Blank  200 ul 0 
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The microparticle, biotinylated antibody and Streptavidin-Phycoerythrin (SA-PE) solutions 
were mixed in 15 ml aluminum foil covered tubes and vortexed for 30 seconds with additional 
15 seconds ultra-sonication for microparticle cocktail.  
Fifty microliters of microparticle cocktail solution and 50 ul standard/diluted samples were 
added to each microplate well, secured with a foil cover and left on a shaker for 2 hours. The 
plates were washed three times, followed by the addition of 50 ul of diluent Biotin Antibody 
Cocktail. After an hour duration on a shaker and another three washes, a 50 ul Streptavidin-PE 
was added to each well followed by 30 minutes on a shaker. 
2.4.1 Biomarker concentration determination  
The mean fluorescent intensities for TNFα, IL10, NGAL, KIM1, cystatin C, and IL18 were 
determined using BioPlex
TM
 200 system (Bio-Rad, Texas, USA) in bead regions 12; 22; 53; 
57; 75; and 78 respectively IL10, IL18, TNFα, NGAL, cystatin C were read in bead regions of 
12, 22 and 78 respectively. Bio-Plex manager software, version 5 was used to generate a 
standard curve for concentrations determination.  
2.4.2β-2-Microglobulin determination  
Serum concentrations of β-2-microglobulin (β2M) were determined by enzyme linked 
immunosorbent assay (ELISA) (R&D systems, Inc.). Briefly, 20 ul of undiluted sera or 
standard were added to each well, followed by the application of 100 ul conjugate and 100 ul 
primary antibody. The plate was sealed and left to incubate on a shaker for 1 hour at room 
temperature. The wells were washed 6 times, followed by incubation with 100 ul substrate 
solution for 7 mins, and the reaction was stopped by the addition of 100 ul 0.5 M H2SO4. 
Optical density at 450 nm was measured on an ELx800 microplate reader (BioTek, Winooski, 
VT, USA). Protein concentrations were calculated using the 5 parameter logistic curve on 
MyAssays software (http://myassays.cloudapp.net/).  
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2.5 Determination of serum creatinine 
Blood samples for serum creatinine were collected before and after contrast media. Serum 
creatinine was analyzed using the Jaffe method(130) (Siemens ADVIA 1200 chemistry 
system) and estimated glomerular filtration rate (eGFR) was calculated using the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI)(131). The CKD-EPI equation 
belowhas demonstrated superiority to other equations (131). 
GFR=141 X min (SCr/κ, 1)α X max (SCr/κ,1)-1.209 X 0.99 Age X 1.018[ if female] X1.159 [if 
black] 
κ = 0.7 if female and 0.0 if male 
α=-0.329 if female and -0.411 if male 
Min = ―The minimum of SCr/κ or 1 and max= the maximum of SCR/κ or 1‖ 
2.6 Determination of the Microalbuminuria  
 Microalbuminuria was determined using the Chemistrip
R
 Micral 30 immune assay test 
(ROCHE 11544039172).  
2.7 Determination of serum albumin  
Determination of serum albumin was based on the principle of Doumns and Biggs in which 
serum albumin binds to bromocresol green solution (BCG) forming albumin-BCG compound. 
The latter is then measured at 596/694nm absorbance.  
2.8Procedure for contrast media 
Iopamidol (Jopamiron 370, Axim Pharmaceuticals in Italy); a low osmolar contrast agent was 
used in all contrastprocedures as intravenous or intra arteriolar in this study. 
2.9 Statistical analysis 
The statistics used are described in the respective chapters. 
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CHAPTER 3  
3. RISK FACTORS AND OUTCOMES OF CONTRAST INDUCED 
NEPHROPATHY IN HOSPITALIZED SOUTH AFRICANS 
Abstract 
Background: Despite ranking third as a cause of hospital acquired acute kidney injury (AKI), 
iatrogenic contrast-induced nephropathy (CIN) impacts significantly on morbidity and 
mortality and is associated with high hospital costs. In Sub-Saharan Africa, the rates and risk 
factors for CIN and patient outcomes remain unexplored. 
Methods: We conducted a prospective observational study at the Charlotte Maxeke 
Johannesburg Academic Hospital, in South Africa from July 1, 2014 to July 30, 2015. 
Hospitalized patients undergoing computed tomography scan contrast media administration 
and angiography were consecutively recruited to the study and followed up for development 
of AKI. CIN was defined as an increase in serum creatinine >25% or an absolute increase of 
>44 µmol/l from baseline at 48-72 hours post exposure to contrast media. Outcome variables 
were the occurrence of CIN, length of hospitalization and in-hospital mortality.  
Results: We recruited 371 hospitalized patients with a mean age of 49.3±15.9. The rates of 
CIN assessed using an absolute or relative increase in serum creatinine from baseline was4.6% 
and 16.4% respectively. Anaemia was an independent predictor for the development of CIN 
(RR 1.71, 95% 1.01-2.87; p=0.04). The median serum albumin was 34 g/l (IQR: 29-39.5) and 
38 g/l (IQR: 31-42) in the CIN and control groups respectively (p=0.01) and showed a 
significant trend for CIN development (RR 1.68 95% CI 0.96-2.92; p=0.06).  Mortality was 
significantly increased in the CIN group (22.4% vs. 6.8%; p<0.001), and CIN together with 
anaemia increased mortality 2-fold (RR 2.39, 95% CI 1.20-4.75; p=0.01) and a 3-fold (RR 
3.32, 95% CI 1.48-7.43; p=0.003) respectively.  
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Conclusion: CIN has a relatively high incidence in Sub-Saharan Africa and predicts poorer 
clinical outcomes. Presence of CIN and anaemia positively predicted mortality. Caution 
should be exercised in patients with hypoalbuminaemia and anaemia undergoing contrast 
media administration.  
3.1 Introduction  
Despite preventative guidelines, iatrogenic contrast-induced nephropathy (CIN) ranks third as 
a cause of hospital-acquired AKI and impacts significantly on morbidity and mortality and is 
associated with longer stays in hospitals with higher medical costs (1, 2, 5, 132). 
The rates of CIN vary, depending on the study definitions employed and underlying risk 
factors, and ranges from 0.6% to 30%, or higher, among risk groups(9-11, 13). CIN is also 
associated with increased duration of hospitalization and early and late mortality. In-hospital 
mortality due to CIN ranges from 7-22% (41).McCullough et al.(41) reported early mortality 
of 1.1% in controls, 7.1% in CIN patients, and 35% in CIN patients that required dialysis. Due 
to increased comorbidities, hospitalized patients have increased risk for developing CIN 
compared to ambulatory patients(51).
 
Inflammation and endothelial dysfunction, together with reactive oxygen species (ROS), are 
implicated in the pathogenesis of CIN (13). Iodinated contrast media directly injures the renal 
tubular epithelium by producing ROS radicals that cause intra-renal vasoconstriction leading 
to ischaemia and death of tubular cells (3, 13, 51).Serum albumin is an important anti-oxidant 
that reduces the formation of oxygen free radicals and is important in expanding intravascular 
volume (133, 134).However, the role of serum albumin in reducing the incidence of CIN 
remains unexplored. 
Sub-Saharan Africa has a dearth of data on rates of CIN. This study investigated the rates of 
CIN together with the influence of serum albumin, albuminuria, age, haemoglobin, and 
glomerular filtration (GFR) levels on CIN and patient outcomes.   
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3.2 Materials and methods  
The procedures are described in chapter 2. 
Statistical analysis 
Statistical analyses were performed using Stata version 13 software (STATA, Inc, Texas).  
Using conservative estimates for the prevalence of CIN, a minimum sample size of n=323 was 
required to sufficiently power this study. However based on the frequency of the rarest 
haplotypes for either the TNFα or IL-10 genes (at 5.2%) the samples size was be increased to 
371. Continuous variables are presented as means and standard deviations when normally 
distributed, and as medians and interquartile ranges when non-normally distributed.  
Categorical variables are presented as counts and frequencies.  Comparisons between CIN-
positive (CIN+) and CIN-negative (CIN-) groups were assessed using a t-test for normally-
distributed continuous variables, a Wilcoxon rank sum test for non-normally distributed 
continuous variables and a Pearson chi-squared test for categorical variables.  P-values of less 
than 0.05 were considered significant.  Multivariate analyses examined the associations of 
CIN and mortality with various risk factors and a generalized linear regression model built to 
adjust for confounding effects. 
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3.3 Results 
3.3.1Baseline characteristics  
After excluding 60 non-eligible patients [Figure 1], 371 participants remained in the study; 
74.9% were black, 18.9% caucasian, 3.8% indian and 2.4% mixed race. Participants’ baseline 
characteristics are reported in Table 1. Ages ranged from 18 to 92 years (mean 49.3±15.9). 
The rate of CIN was 16.4% (61 of 371) when based on 25% increase from baseline in serum 
creatinine and 4.6% when based on an absolute increase >44 umol/l. Baseline serum creatinine 
and GFR were not significantly different between the CIN and control groups; almost 97% 
had baseline GFR ≥ 60 ml/min/1.73m2 while the remaining 3% had baseline GFR ranging 
from 42-59 ml/min/1.73m
2
. Compared to the CIN-free group, CIN patients had significantly 
lower levels of baseline serum albumin and haemoglobin.  
3.3.2 Independent predictors of CIN 
After adjusting for all possible confounders, anaemia was found to be a predictor for CIN and 
additionally, low serum albumin showed a positive association for CIN development [Table 
2]. 
3.3.3 CIN and mortality 
Both duration of hospitalization and mortality were higher in the CIN group but only mortality 
was significantly increased; p <0.001(Figure 2). None of the patients who developed CIN 
required dialysis. Non-significant variables that included cardiac disease, malignancy, contrast 
volume and baseline eGFR and albumin were excluded in the final model. In multivariable 
analysis CIN and anaemia (but not comorbidities) were positive predictors for mortality (Table 
3) and not comorbidities. Among the 13 deaths in the CIN group, 7 had malignancy and 
among the 20 deaths in the controls, 14 had malignancy. However, after adjusting for all 
confounders and comorbidities, malignancy was insignificantly associated with mortality  
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Assessed for eligibility n=431 
Study participants n=371 
Excluded n= 60 
Not meeting inclusion 
criteria  n=38 
Missing lab data n=22 
 
 
 
 
CIN negative 
n=310 
CIN positive 
n=61 
 
   Within 48-72 hours 
Recovered AKI 
n=36 
 
 
In-hospital 
mortality 
 n=20 
 
CKD   
n=5 
Survived 
n=48 
 Lost to follow up n=7 
4= Not reachable 
2 =Declined  
1= Died  
 
 
      At 3 months 
 
 
 
 
In-hospital 
mortality  
n=13 
 
 
Figure 3.1 Results flow chart 
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Table 3.1 Baseline characteristics for study participants  
Characteristic ALL 
(n=  371) 
CIN- 
(n=  310) 
CIN+ 
(n=  310) 
P 
Age (years) 49.3±15.9 48.7±16.3 52.1 ±14.1 0.11 
Gender, n (male, %) 210 (43.4) 174 (56.1) 36 (59.0) 0.86 
Diabetes mellitus, n (%) 48 (13.2) 42 (13.8) 6 (10.3) 0.48 
HTN, n (%) 93 (25.8) 78 (25.7) 15 (25.9 0.98 
Malignancy (%) 159 (42.9) 136 (43.9) 23 (37.8) 0.34 
Cardiac disease, n (%) 56 (15.1) 45 (14.5) 11 (18.0) 0.48 
Stable CKD, n (%) 13 (3.6) 9 (2.9) 4 (6.9) 0.13 
Systolic BP (mmHg) 119 (109-130) 119 (109.5-130 120 (106-132 0.43 
Diastolic BP (mmHg) 73 (66-83) 73 (65-82.5) 74 (68-84) 0.18 
Duration of hospitalization, n (%)  11 (6-20) 11 (5-18) 15(8-23) 0.52 
Mortality, n (%) 33 (9.3) 20 (6.8) 13 (22.4) <0.001 
Pre-hydration, n (%) 38 (17.7) 28 (15.8) 10 (26.3) 0.12 
 N acetyl cysteine, n (%) 3 (0.8) 3 (1.0) 0 (0.0) 0.45 
 ACEI/ARBS, n (%) 69 (19.2) 59 (19.5) 10 (17.5) 0.73 
 Statins, n (%) 67 (18.6) 55 (18.2) 12 (20.7) 0.66 
 Diuretics, n (%) 70 (19.5) 55 (18.3) 15 (25.9) 0.18 
Serum creatinine (µmol/l) 68 (53-85) 68.5 (54-84) 61 (52-89) 0.49 
eGFR  (ml/min per 1.73m2 110.8 (89.5-134) 113.4 (89.9-134) 107 (89.5-133) 0.84 
eGFR <60m//min/1.73m2 , n (%) 13(3.5) 10 (76.9) 3 (23.1) 0.43 
Urea (mmol/l) 4.8 (3.6-6.3) 4.9 (3.5-6.3) 4.7 (4-6.7) 0.08 
Microalbuminuria, n (%) 58 (38.1) 46 (36.8) 12 (44.4) 0.46 
Serum albumin g/l 37 (30-41) 38 (31-42) 34 (29-39.5) 0.01 
Serum albumin <35g/l, n (%) 113 (41.0) 82 (37.4) 31 (55.4) 0.02 
Haemoglobin (g/dl) 12.3 (9.8-14.3) 12.5 (10.1-14.4) 11 (9.3-13.4) 0.01 
Anaemia, n (%) HB <11g/dl 117 (34.5) 89 (32.1) 28(50.9) 0.01 
White cell count  8.1 (6.3 -11.7) 7.9 (6.3-11.7) 8.6 (5.9-13.9) 0.70 
CRP (mg/L) 25.5 (10-70) 25.5 (10-70) 55 (12-115) 0.15 
HIV positive status, n (%) 74(36.8) 61 (37.2) 13 (35.1) 0.58 
Sodium (mmol/l) 139 (135-141) 139 (136-141) 138 (135-140) 0.17 
Bicarbonate (mmol/l) 25 (22-27) 25 (22-27) 24 (20-26) 0.45 
Phosphate (mmol/l) 1.1 (0.90-1.2) 1.10 (0.90-1.24) 1.00 (0.81-1.20) 0.10 
Contrast volume (mls) 103.8 ±39.9 103.7 ±37.3 104.2 ±351.8 0.95 
Contrast dose /CrCL ratio 0.88(0.72-1.16) 0.87 (0.72-1.17) 0.94 (0.71-1.1) 0.31 
Ejection fraction % 63.1±14.0 63.1±14.0 59.1±13.3 0.31 
CIN-, CIN absent; CIN+, CIN present; HTN, hypertension; ACEI/ARBs, angiotensin converting enzyme 
inhibitors/angiotensin receptor blockers, CRP, C-reactive protein; BP, Blood pressure; CKD, chronic kidney 
disease; Anaemia is defined as haemoglobin <11g/dL * Continuous variables expressed as mean ± SD when 
normally distributed and as medians (IQR) otherwise.   
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Table 3.2 Independent predictors forCIN  
  Unadjusted      Adjusted  
 
  RR 95%CI P value RR 95%CI P value 
 
Age 1.01 0.99-1.02 0.14 1.00 0.99-1.03 0.89 
 
Gender 
 
1.04   
 
0.66-1.66 0.86 1.37 0.82-2.29 0.22 
Albumin level 
(<35g/dl) 
 
1.60 1.00-2.56 0.05  1.68  0.96-2.92 0.06 
Anaemia   0.89 
 
0.81-0.98 0.025 1.71 1.01-2.87 0.04 
Baseline  
eGFR 
 
 0.99 0.98-1.00  0.70    
 *variables included in the final model were age, gender, anaemia, and albumin  
 
Table 3.3 Independent predictors for mortality  
  Unadjusted      Adjusted  
 
  RR 95% CI P value RR 95%CI  
P value 
CIN 3.27 1.72-6.18 <0.0001 2.39 1.20-4.75 0.01* 
 
Age 1.00 0.96-1.02 0.98 0.99 0.98-1.01 0.91 
 
Anaemia 3.61 1.75-7.45 0.001 3.32 1.48-7.43 0.003* 
CM dose 0.99 0.98-0.99 0.02 0.99 0.99-1.00 0.55 
 
Gender  
 
 
 1.06  0.55-2.05  0.18 0.96 0.49-1.89 0.91 
*Included in final model were age, gender, anaemia, contrast media volume and CIN 
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Figure 3.2 Contrast induced nephropathy and mortality 
 
 
 
 
 
 
 
 
P<0.001 
 
 
58 
 
 
3.4 Discussion  
The present study demonstrated a relatively high rate of CIN in hospitalized patients.   
Furthermore, the development of CIN resulted in increased mortality and highlighted the 
association of CIN with poorer clinical outcomes. 
Our study showed a 16.4% rate of CIN, which was slightly higher than that reported in most 
recent studies. Overall, the reported incidence of CIN is variable, depending on the study 
definitions employed and underlying risk factors, and ranges from 5-30%(9-11, 13, 20, 37). 
Recent observational studies have reported low rates of CIN among hospitalized patients (33, 
135). Shams-Edin Taher (33) observed a 11.5% rate of CIN in patients undergoing 
percutaneous intervention (PCI) while Salistre et al.(135)reported a 14% incidence of CIN in 
patients undergoing contrast CT administration in Brazil. A randomized controlled trial (RCT) 
in the USA found a 16.1% incidence of CIN in patients’ undergoing PCI(35). The 
heterogeneous study population, variable comorbidities and non-standardized preventative 
prescriptions used by clinicians may explain the high rate of CIN in our study. 
In this study, CIN patients had significantly lower levels of pre-contrast serum albumin 
compared to controls and showed a significant positive trend towards the development of CIN 
with serum albumin levels. Serum albumin is an important renoprotective, anti-inflammatory 
and anti-oxidant agent acting via several mechanisms; serum albumin binds non-
ceruloplasmin copper and iron which are important in the formation of ROS and maintains 
renal perfusion by dilating renal vessels via its binding to nitrogen oxide forming S-nitro-
albumin(29, 133, 136-138)However, during inflammation, albumin synthesis is reduced and 
activated neutrophils increase the levels of hypochlorous acid which inactivates albumin (133, 
134, 136).Low serum albumin is probably a biomarker reflecting baseline susceptibility to 
acute or chronic inflammation or under nutrition. In two previous studies, Murat et al. and 
Song et al. found a positive association between low serum albumin and an increased risk for 
the development of CIN(136, 137).
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A meta-analysis showed a positive association between decreased serum albumin and 
development of AKI as well as increased morbidity and mortality(139). The odds of 
developing AKI doubled with reduced serum albumin (29). Lee et al. reported 2-fold odds of 
developing post-operative AKI with decreased serum albumin
.
(140). 
Of interest in our study was the impact of baseline anaemia on patient outcomes. The rate of 
baseline anaemia was relatively high in our study population compared to controls and was 
associated with development of CIN and a 3-fold mortality risk. Limited studies have explored 
the association of anaemia with CIN and patient outcomes. Li et al. and Chong et al. in 
observational studies reported positive association between baseline anaemia and CIN (29, 
141). In these studies the presence of anaemia was associated with an almost 2-fold risk of 
developing CIN (29, 141). In patients undergoing PCI, Mckechnie etal.similarly reported 
baseline anaemia as an independent predictor for mortality (142). The increased risk of CIN in 
patients with anaemia and poorer clinical outcomes is multifactorial in aetiology; in presence 
of anaemia, CIN induced renal ischaemia and hypoxia is significantly worsened in the outer 
renal medulla amidst already prevailing low oxygen tension and oxygen affinity and demand 
is increased (29, 143, 144).Additionally, anaemia also signifies underlying comorbidities and 
therefore it is a biomarker for severity of disease at time of contrast media administration and 
therefore increased mortality risk(29, 142). 
Age, baseline renal function (determined by estimated glomerular filtration rate) and pre-
hydration were not associated with the risk of CIN in our study.  The positive association 
between CIN and age has been shown in the age group above 62 years (3).A RCT, found age 
above 75 years together with diabetes mellitus as independent predictors for CIN (35).In 
younger type two diabetic patients undergoing PCI, Zaki et al. reported age above 57 years to 
be a positive predictor for CIN (138). Our study population was relatively young, and fewer of 
our patients had multivessel diseases compared to previous studies. Baseline eGFR level was 
insignificantly associated with CIN in our study cohort. Previous studies have shown 
decreased risk of developing CIN with eGFR >60 ml/min per 1.73m
2
(135).  
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In an observational study, Weisbord et al. found <1% incidence of CIN in patients with eGFR 
>45-60 ml/min per 1.73m2 after contrast administration (145)In support of our study, Chong 
et al. found insignificant association between normal renal status and CIN development (141).  
In a cohort study of 80% study participants with eGFR >60 mls/min per 1.73m
2
, Salistre et al. 
also reported no association between baseline eGFR and risk for CIN (135). 
In our study cohort, 97% of study participants had normal baseline renal function based on 
eGFR with the remaining having eGFR ranging from 42-59 ml/min per 1.73m
2
with 
nosignificant association with CIN.  
Pre-hydration therapy was used in only 18% of patients in our study cohort compared to 70% 
seen in developed countries (146), and pre-hydration showed no impact on reducing the 
incidence of CIN. It is possible that only the patients at highest risk for CIN received pre-
hydration and this possibly obscured any beneficial effects of pre-hydration. In previous 
studies, Salistre et al.observed no association between fluid administration and CIN 
occurrence (135).Diogo et al. reported a low rate of pre-hydration therapy in Brazil (19).
 
Similar to previous findings, our study demonstrated a higher mortality in the CIN group 
compared to controls and CIN together with anaemia were independent predictors of mortality 
(34).Rihal et al., in a retrospective registry review at the Mayo Clinic reported in-hospital 
mortality rates of 22.0% and 1.4% in the CIN and controls groups respectively and CIN was 
positively associated with a 10-fold increased odd of death(43). Furthermore, cardiac disease 
was associated with a 2-fold increased odd for death. Sadeghi et al. in a multicentre study 
found that 30 day mortality was significantly higher among patients with CIN compared to 
controls (16.2% vs. 1.2%; p <0.001) (34, 42).In-hospital mortality due to CIN in the National 
Cardiovascular Registry in USA was reported to be 9.1% (147). 
Development of CIN also reflects underlying disease comorbidities at the time of contrast 
media administration. Despite increased mortality in the CIN group compared to controls, 
Sadeghi et al. found underlying cardiac disease as a positive predictor for mortality(42).  
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In other studies; age, cardiac disease and the requirement of dialysis were predictors for 
mortality in CIN participants (34). In our study, among the 13 deaths in the CIN group, 7 had 
a diagnosis of malignancy, however after adjusting for possible cofounders, only CIN and 
anaemia and not malignancy were predictors of mortality.  
The strength of our study is that it was a prospective cohort with a large sample size. 
However, it is limited by being a single centre,non-interventional study conducted at a tertiary 
hospital.  The study consisted of a heterogeneous population and prevention guidelines for 
CIN were not standardized or uniformly implemented. 
3.5 Conclusion  
Our study highlights the high rates of CIN and associated poorer clinical outcomes. Caution 
should be used when administering iodinated contrast media to hypoalbuminaemia and 
anaemic patients. To our knowledge, this is the first prospective study examining the risk and 
outcomes of CIN in Sub-Saharan Africa. This study advocates that preventative treatment 
guidelines for CIN should be standardized and uniformly implemented across various hospital 
departments. 
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CHAPTER 4 
4. ACCURACY OF BIOMARKERS IN PREDICTING AND 
PROGNOSTICATING CONTRAST INDUCED NEPHROPATHY 
Abstract  
Background: Serum creatinine is suboptimal as a biomarker in the early diagnosis of contrast 
induced nephropathy (CIN) resulting in delayed interventions and leading to an increase in 
adverse clinical outcomes. This study investigated a panel of novel biomarkers in the early 
diagnosis of CIN and in predicting patient outcomes. 
Methods: This was a single centre nested prospective case-controlled study that included 30 
patients with CIN and 60 controls (those undergoing radio contrast studies) and were matched 
for race, gender and age in a case:control 1:2 ratio at all-time points. Sera for neutrophil 
gelatinase-associated lipocalin-2 (NGAL), cystatin C, beta-2 microglobulin (β2M), interleukin 
18 (IL18), IL10, and tumor necrosis factor alpha (TNFα) were collected at four time points: 
baseline (pre-contrast), 24 hours, 48 hours and ≥5-7 days after contrast administration and 
their concentrations were determined using luminex assays and an enzyme linked 
immunosorbent assay for β2Mas per manufacturer’s instructions. Novel biomarkers were 
compared to CIN and CIN mortality by generating the area under the receiver operating 
characteristics (AUROC) curves. 
Results:The median cystatin C at 24 hour (p<0.001) and 48 hour (p=0.01) and β2M levels at 
all-time points were significantly higher in the CIN group compared to controls. The median 
24 hour cystatin C and 48 hour β2M levels were 856.60 ng/ml (IQR 620.75-1002.96) vs. 
617.42 ng/ml (IQR 533.11-805.20); p<0.001 and 5.3 µg/ml (IQR 3.8-6.9) vs. 3.3 µg/ml (IQR 
2.7-4.5); p<0.001 with AUROC of 0.75 and 0.78 respectively for early diagnosis of CIN. 
Baseline IL18 (p <=0.001), β2M (p=0.04) and TNFα (p=0.00) levels were significantly higher 
in the non-surviving group and their AUROC were 0.83, 0.82 and 0.94 for CIN+ mortality 
respectively.   
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Baseline NGAL was a better marker at excluding patients at risk for CIN with positive 
predictive value (PPV) and negative predictive value (NPV) of 0.50 and 0.81 respectively. 
Cystatin C (P=0.003) and β2M (p=0.03) at 24 hours independently predicted CIN risk. β2M at 
baseline and 24 hours were associated with a 1.4-fold and 1.5-fold mortality odds respectively. 
Conclusion: Serumcystatin C showed the best diagnostic discrimination for CIN while IL18, 
β2M and TNFα showed the best discrimination performance for CIN mortality. NGAL is a 
dependable biomarker for excluding patients at higher risk for CIN. 
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4.1 Introduction  
Despite increased morbidity and mortality linked with iodinated contrast media-induced 
nephropathy (CIN)(1, 2, 4),early interventions are delayed due to the suboptimal sensitivity 
and specificity of serum creatinine in the early diagnosis of CIN(79, 82-84, 86, 148). Almost 
80% of subclinical kidney injury caused by contrast media should be identified within 24 
hours using early diagnostic criteria(82). 
Previous studies have demonstrated that neutrophil gelatinase lipocalin-2 (NGAL), cystatin C, 
interleukin 18 (L18) and beta-2 microglobulin (β2M) are more sensitive as earlier biomarkers 
of acute kidney injury (AKI) compared with serum creatinine(100, 115, 116, 122, 123, 
148)and predicted adverse clinical outcomes (111, 125, 126). Biomarkers are needed in early 
identification of subclinical AKI characterised by small increases in levels of serum creatinine 
(148). In previous studies, even a small increase in serum creatinine exceeding 44.3 µmol/l 
was linked with a 7-fold mortality risk (148, 149). 
Cystatin C and β2M, with molecular weights of 13 kDa and 11.8 kDa respectively, are non-
glycosylated molecules that are increased in the circulation due to impaired glomerular 
filtration (85, 89). Cystatin C produced by all nucleated cells functions as an intracellular 
inhibitor of cysteine peptidase (88, 98) while β2M is found on major histocompatibility 
complex class-1 nucleated cells (117). NGAL, a 25 kDa glycoprotein is up regulated in 2-4 
hours in patients undergoing radio contrast administration (79, 81, 83).  In a multi-centre 
study, 24 hour serum cystatin C was a better predictor of CIN with an area under receiver-
operative curve (AUROC) of 0.86 (115). Inflammatory cytokines (including IL18, TNFα and 
IL10) are upregulated in renal injury or damage (14, 90, 96) and released into plasma and 
urine (96); however, limited studies have explored their roles in AKI particularly CIN. Liu et 
al. in a recent meta-analysis of 23 studies, urine IL18 showed suboptimal sensitivity and 
specificity of 0.58 and 75% respectively (150). 
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Previous studies on novel biomarkers looked at homogenous populations characterised by 
non-heterogeneous AKI insults (surgery and non-mixed intensive care units), and a few were 
based on radio-contrast administration. Additionally, these studies were uncontrolled and 
evaluated only NGAL and cystatin C and none looked at other novel biomarkers.  
Compared to urine, biomarker measurements using plasma/sera are unaffected by bacterial 
contamination and is also readily available, even in anuric patients (100). In a recent 
comparative observational study in Germany, Schley et al. demonstrated that plasma 
biomarkers had superior diagnostic accuracy for AKI after cardiopulmonary bypass (100). Our 
study investigated the diagnostic accuracy of serum NGAL, IL18, cystatin C, β2M, IL10, and 
TNFα in predicting CIN and their role in prognosticating patient outcomes. 
4.2Materials and methods  
This was a nested prospective case-controlled study that included 30 patients with CIN and 60 
controls (not meeting the contrast induced kidney injury criteria) that were consecutively 
selected from patients undergoing contrast administration. The controls were matched for race, 
gender and age in a case: control ratio of 1:2 at each time interval. Sera were collected at 4 
time point measurements:  baseline (pre-contrast), 24 hours, 48 hours, and 5-7 days after 
contrast administration.  
4.3.1 Study outcomes 
The study outcomes were discrimination performance of the novel biomarkers for CIN at 
different time intervals (defined according to the European Society of Urogenital Radiology 
(ESUR) and in-hospital CIN associated mortality (50). 
4.3.2 Statistical analysis  
Biomarkers characteristics are described as medians and interquartile ranges (IQR) as values 
were not normally distributed.  Comparisons of biomarkers with CIN and mortality were 
determined using the Wilcoxon-Mann-Whitney test.  
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To determine discrimination performance of biomarkers for CIN from non CIN and mortality 
(overall and CIN+ mortality), areas under receiver-operating curves (AUROC) were 
constructed. Sensitivity and specificity were calculated for each point on the curve and the 
optimal cut-point calculated by finding the point with the maximum Youden Index (Youden 
Index = sensitivity + specificity-1).  Positive predictive values (PPVs) were calculated for the 
optimal cut-point using the formula: PPV=(number of true positives)/(number of true positives 
+ number of false positives).  Similarly, the negative predictive values (NPVs) were calculated 
for the optimal cut-point using the formula: NPV=(number of true negatives)/(number of true 
negatives + number of false negatives).  Multivariable regression analysis of biomarkers, 
adjusted for age and gender, were performed to determine predictors of CIN and mortality. 
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4.3 Results  
4.3.1 Biomarker characteristics in CIN patients 
This nested case-controlled study included 30 CIN+ participants matched with 60 controls in a 
ratio of 1:2 and biomarker measurements were determined at four time points: baseline (pre-
contrast), 24 hours, 48 hours and ≥5-7 days after radio contrast media administration. Overall 
mortality occurred in 15 individuals with 7 deaths restricted to the CIN+ patients. The 
biomarker characteristics are described in in Table 4.1.  Compared to controls, the CIN+ group 
had increased median (IQR) levels of β2M at baseline (p=0.04) and 24 hours (p=0.01); and 
cystatin C at 24 hours (p<0.001). Pre-contrast medians (IQR) levels of IL18 (p<0.001), β2M 
(p=0.04), TNFα (p<0.001) including TNFα at 24 hours (p<0.001) were significantly higher in 
the group that demised [Table 4.3]. A non-significant association was also observed between 
rates of CIN in HIV infected individuals compared to controls and the characteristics of novel 
biomarkers in HIV infected patients compared to uninfected is described in Table 4.7.  
4.3.2 Diagnostic accuracy ofbiomarkers in predicting CIN 
The areas under the receiver operating curves (AUROC) were generated for determination of 
early CIN diagnosis and CIN mortality and only biomarkers that showed significance were 
considered. Table 4.1 and Figure 4.1 show biomarkers measurements in the CIN group vs. 
controls and their corresponding AUROC.  Cystatin C at 24 hours and β2M at 48 hours 
demonstrated good early discrimination for CIN with AUROC of 0.75 and 0.78 respectively 
and together predicted CIN development after adjusting for priori-selected age and gender 
[Table 4.4].   
Baseline β2M including the 48 hours independently predicted mortality [Table 4.2]. Table 4.2 
describes the optimal cut-off values for bio-markers in predicting CIN. Serum NGAL (Table 
4.2) at baseline and β2M showed superiority in excluding patients at risk of developing CIN.  
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The positive predictive values (PPV) and negative predictive values (NPV) for serum NGAL 
and β2M at baseline were 0.50 and 0.81, and 0.48 and 0.87, respectively. Cystatin C at 24 
hours showed the best PPV and NPV of 0.75 and 0.77 respectively. 
4.3.3 Diagnostic accuracy of biomarkers in prognosticating mortality  
Table 4.2 and Figure 4.2 describe biomarker characteristics in the surviving and non-surviving 
groups after contrast administration.  For prognosticating mortality, baseline pre-contrast 
measurements of IL18, β2Mand TNFα showed the best AUROCs of 0.83, 0.82 and 0.94 
respectively. After adjusting for age, gender, as well as IL18 and TNFα, baseline β2M 
(including the 24 hours β2M) independently predicted mortality.  
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Table 4.1 Biomarker characteristics in CIN+ and CIN- participants  
  CIN+ (n=30) CIN- (n=60) p-value 
variable median (IQR) median (IQR)   
NGAL_p (ng/ml) 100.31 (64.28-142.01) 74.33(43.97-127.99) 0.34 
NGAL _24 (ng/ml) 99..61(72.26-135.98) 78.42 (51.12-107.00) 0.07 
NGAL _48 (ng/ml) 83.81 (57.90-109.05) 60.91 (37.36-100.71) 0.13 
NGAL _5 (ng/ml) 96.20 (74.48-156.66) 65.77 (51.94-72.44) 0.06 
        
Cystatin C_ p (ng/ml) 711.45 (550.08-934.10) 687.41 (566.61-769.76) 0.25 
Cystatin C_24 (ng/ml) 856.59 (620.75-1002.96) 617.42 (533.11-805.20) <0.001 
Cystatin C_48 (ng/ml) 764.32 (560.28-1010.71) 572.13 (461.67-708.11) 0.01 
Cystatin C_5 (ng/ml) 811.52 (708.54-986.12) 596.14 (534.56-684.38) 0.01 
        
ILl18_p (pg/ml) 170.41 (105.19-327.4) 123.73 (65.87-178.2) 0.13 
IL18_24 (pg/ml) 152.32 (92.905-279.62) 122.36 (82.45-256.6) 0.40 
IL18_48 (pg/ml) 137.62 (100.965-285.14) 95.75 (73-165.59) 0.06 
IL18_5 (pg/ml) 133.385 (122.36-395.75) 131.93 (70.82-294.91) 0.64 
        
B2M_p (µg/ml) 4.4 (3.8-7.8) 3.8 (3.2-4.9) 0.04 
B2M _24(µg/ml) 4.55 (3.9-7.55) 3.7 (2.9-4.8) 0.01 
B2M _48 (µg/ml) 5.1 (3.8-6.9) 3.3 (2.7-4.5) <0.001 
B2M _5(µg/ml) 12.1 (4.4-16.4) 3.7 (3.1-4.9) 0.01 
        
TNFα_p (pg/ml) 4.87 (4.15-9.12) 4.6 (2.65-5.95) 0.12 
TNFα_24 (pg/ml) 5.3 (4.15-6.7) 5.23 (3.43-7.39) 0.94 
TNFα _48 (pg/ml) 5.9 (4.6-6.7) 4.29 (2.6-7.04) 0.06 
TNFα _5 (pg/ml) 4.3 (3.43-5.23) 6.315 (4.26-8.26) 0.22 
        
IL10_p (pg/ml) 4.94 (4.5-11.3) 4.1 (2.59-5.4) 0.19 
IL10_24 (pg/ml) 4 (3.4-5.5) 3.9 (2.6-5) 0.45 
IL10_48 (pg/ml) 4.6 (3.7-9.2) 3.4 (2-4.5) 0.10 
IL10_5 (pg/ml) 9.5 (9.5-9.5) 4.2 (3.24-19.4) 0.51 
Base creatinine 
(µmol/l) 
69 (53-96) 67 (52-84.5) 0.69 
Post creatinine (µmol/l) 104 (85-156) 63.5 (46.5-76.5) <0.001 
CIN-, CIN absent; CIN+, CIN present; NGAL, neutrophil gelatinase-associated lipocalin; cystatin C;IL, 
Interleukin; B2M, Beta 2 microglobulin; TNFα, Tumor necrosis factor alpha; p, pre-contrast baseline; 24, 24 
hours; 48, 48 hours; 5,  after 5 days after contrast studies.   
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Figure 4.1 Diagnostic accuracy of biomarkers in predicting CIN. 
Receiver operating characteristic curves (AUROC) demonstrating discrimination performance forCIN 
(at baseline, 24hours, 48 hours and ≥5-7 days after radio contrast administration).    
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Table 4.2 Positive and negative predictive values of biomarkers for patients with CIN 
 
 Cut point Sensitivity  Specificity  PPV NPV 
      
NGAL_p (ng/ml) 63.15 0.84 0.45 0.50 0.81 
NGAL_24 (ng/ml) 80.81 0.74 0.52 0.47 0.78 
NGAL_48 (ng/ml) 72.95 0.70 0.62 0.50 0.79 
      
Cystatin C_p (ng/ml) 893.43 0.37 0.96 0.88 0.70 
Cystatin C_24 (ng/ml) 856.59 0.52 0.90 0.75 0.77 
Cystatin C_48 (ng/ml) 764.32 0.52 0.86 0.67 0.78 
      
β2M_p (µg/ml) 3.6 0.88 0.45 0.48 0.87 
β2M_24 (µg/ml) 4.3 0.71 0.61 0.51 0.78 
β2M_48 (µg/ml) 5.1 0.57 0.88 0.67 0.80 
      
IL18_p (pg/ml) 182.0 0.48 0.80 0.60 0.71 
IL18_24 (pg/ml) 161.2 0.50 0.67 0.48 0.68 
IL18_48 (pg/ml) 116.6 0.75 0.60 0.50 0.81 
      
 
NGAL, neutrophil gelatinase-associated lipocalin;  IL18, Interleukin 18; B2M, Beta 2 microglobulin;; p, pre 
contrast baseline; 24, 24 hours post contrast administration; 48, 48 hourspost contrast administration; PPV, 
positive predictive value; NPV, negative predictive value 
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Table 4.3Biomarkers characteristics in surviving and non-surviving participants 
  Death (n=15) Survivors (n=75) p-value 
variable median (IQR) median (IQR)   
        
NGAL_p (ng/ml) 78.15 (37.01-105.11) 79.45 (57.28-131.51) 0.37 
NGAL_24 (ng/ml) 71.38 (32.80-108.82) 82.72(58.28-119.27) 0.24 
NGAL_48 (ng/ml) 88.99 (51.30-115.88 67.31 (41.00-100.71) 0.46 
NGAl_5 (ng/ml) 116.37 (74.48-143.87) 66.11(43.57-96.20) 0.09 
        
Cystatin C_p (ng/ml) 767.38 (633.02-893.43) 670.40 (548.52-789.58) 0.20 
Cystatin C_24 (ng/ml) 723.70 (358.95-811.31) 694.25 (569.08-870.31) 0.34 
Cystatin C_48 (ng/ml) 764.32 (240.03-843.25) 603.76 (505.55-760.62) 0.45 
Cystatin C_5 (ng/ml) 740.40 (706.22-816.65) 668.11 (550.32-724.65) 0.15 
        
IL18_p (pg/ml) 301.54 (211.10-461.28) 109.00 (64.47-165.50) <0.001 
IL18_24 (pg/ml) 203.30 (118.80-409.94) 125.18 (77.47-224.09) 0.09 
IL18_48 (pg/ml) 181.67 (86.40-331.40) 110.20 (77.00-156.90) 0.19 
IL18_5 (pg/ml) 356.50 (294.91-395.75) 122.36 (65.00-133.85) <0.001 
        
B2M_p(µg/ml) 7.8 (3.7-9.7) 4.0 (3.2-5.4) 0.04 
B2M_24(µg/ml) 4.6 (3.8-7.4) 4.1 (3.3-5.2) 0.21 
B2M_48(µg/ml) 4.6 (3.0-6.7) 3.7 (2.8-5.0) 0.09 
B2M_5(µg/ml) 8.0 (5.5-16.4) 4.1 (3.1-5.0) 0.03 
        
TNFα_p (pg/ml) 8.26 (6.00-79.60) 4.15 (2.60-5.30) <0.001 
TNFα _24 (pg/ml) 7.40 (5.45-14.69) 4.87 (3.23-5.60) <0.001 
TNFα _48 (pg/ml) 6.31 (3.08-11.37) 4.56 (2.70-6.70) 0.11 
TNFα _5 (pg/ml) 8.98 (4.87-10.86) 4.60 (2.70-7.04) 0.02 
        
IL10_p (pg/ml) 4.9 (3.6-17.8) 4.5 (3.0-5.5) 0.47 
IL10_24 (pg/ml) 15.2 (4.2-33.4) 3.9 (2.9-5.0) 0.08 
IL10_48 (pg/ml) 3.9 (3.0-14.8) 3.6 (2.5-5.0) 0.43 
IL10_5 (pg/ml) 11.3 (3.2-19.4) 4.6 (3.9-9.5) 1.00 
        
Base creatinine (µmol/l) 72 (44-96) 68 (55-85) 0.93 
Post creatinine  (µmol/l) 93 (45-126) 69 (54-91) 0.52 
NGAL, neutrophil gelatinase-associated lipocalin; IL18, Interleukin 18;β2M, Beta 2 microglobulin; TNFα,Tumor  
necrosis factor alpha; IL10, interleukin 10; p, pre contrast; 24, 24 hours; 48, 48 hours; 5,  after 5 days.   
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Figure 4.2 Diagnostic accuracy of biomarkers in predicting mortality. Receiver operating characteristic curves 
(AUROC) demonstrating discrimination for CIN diagnosis (at baseline, 24hours, 48 hours and ≥5-7 days pots 
radio contrast administration).  CIN+ indicated by solid line and dashed line for CIN-. 
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Table 4.4 Biomarkers predicting CIN 
  Unadjusted Adjusted 
  Odds Ratio 95% Confidence 
interval 
p-
value 
Odds Ratio 95% Confidence 
interval 
p-value 
Age 1.02 (0.99-1.06) 0.129 1.01 (0.97-1.06) 0.538 
Gender (Female) 0.87 (0.36-2.12) 0.766 0.55 (0.15-1.98) 0.357 
Cystatin C _24 
hours 
1.00 (1.00-1.00) 0.000 1.00 (1.00-1.00) 0.003 
B2M _24 hours  1.46 (1.14-1.87) 0.003 1.26 (1.02-1.56) 0.029 
              
Included in the model were age, gender B2M, Beta 2 microglobulin, and Cystatin C at 24 hours 
Table 4.5 Pre-contrast biomarkers predicting mortality 
  Unadjusted Adjusted 
  Odds Ratio 95% Confidence interval p-
value 
Odds Ratio 95% Confidence 
interval 
p-value 
age 1.01 (0.97-1.05) 0.611 1.02 (0.98-1.07) 0.331 
Gender 
(Female)  
0.54 (0.17-1.75) 0.305 1.25 (0.29-5.40) 0.763 
B2M_p 1.49 (1.12-1.99) 0.006 1.41 (1.09-1.84) 0.010 
IL18p 1.01 (1.00-1.01) 0.017 1.00 (1.00-1.01) 0.582 
              
Included in the model were age, gender, B2M, Beta 2 microglobulin and IL18, interleukin 18 at baseline; p, 
baseline  
Table 4.6 Biomarkers predicting mortality at 24 hours post radio contrast administration 
  Unadjusted Adjusted 
  Odds Ratio 95% Confidence interval p-value Odds Ratio 95% Confidence interval p-value 
              
age 1.01 (0.97-1.05) 0.611 1.01 (0.97-1.06) 0.588 
Female gender  0.54 (0.17-1.75) 0.305 0.90 (0.27-3.05) 0.868 
b2m_24 
(µg/ml) 
1.19 (0.98-1.45) 0.085 1.51 (1.15-1.98) 0.003 
tnfa_24 pg/ml  1.23 (1.03-1.47) 0.020 0.96 (0.89-1.02) 0.196 
              
Included in the model were age, gender, B2M, Beta 2 microglobulin; TNFα, Tumor necrosis factor alpha at 24 
hours after contrast administration 
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Table 4.7Comparison of levels biomarkers in HIV infected patients 
Characteristic HIV+ (n=22) HIV- (n=37) p-value 
        
NGAL-Pre (ng/ml) 78.67 (37.86-160.97) 78.15 (43.92-115.46) 0.811 
NGAL-48 hours (ng/ml) 54.41(36.57-121.13) 88.85 (60.31-115.88) 0.115 
Cystatin C Pre (ng/ml) 616.90 (547.71-872.31) 705.73 (566.61-769.76) 0.727 
Cystatin C 48 hours 
(ng/ml) 
564.53(382.54-761.88) 693.16 (483.97-764.32) 0.391 
IL-18 Pre (pg/ml) 109.00 (87.47-165.50) 126.80 (61.73-217.60) 0.797 
IL-18 48 hours (pg/ml) 128.31 (85.30-417.51) 101.73 (61.00-173.63) 0.166 
TNFα Pre (pg/ml) 4.60 (3.43-5.59) 5.09 (3.10-7.40) 0.745 
TNFα 48 hours (pg/ml) 5.65 (3.43-7.93) 4.62 (2.53-6.31) 0.175 
IL-10 Pre (pg/ml) 3.9 (3.1-4.5) 4.7 (3.6-8.3) 0.522 
IL-10 48 hours (pg/ml) 3.6 (1.9-5.0) 2.6 (1.8-3.7) 0.263 
Base creatinine µmol/l 61 (54-89) 71 (58-90) 0.551 
Post creatinine µmol/ 63 (46-91) 75 (57-95) 0.221 
Microalbuminuria (+) 5 (45.5%) 9 (47.37%) 0.919 
Proteinuria (+) 1 (10%) 3 (15.8%) 0.667 
B2M-Pre µg/ml 4.0 (3.2-4.9) 4.0 (3.4-7.8) 0.410 
B2M 48 hours µg/ml 3.5 (2.8-4.6) 4.4 (2.8-5.5) 0.566 
        
CIN-, CIN absent; CIN+, CIN present; NGAL, neutrophil gelatinase-associated lipocalin; IL10, Interleukin 10; 
IL18, Interleukin 18; B2M, Beta 2 microglobulin; p, pre contrast baseline; 24, 24 hours post contrast 
administration; 48, 48 hourspost contrast administration.   
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4.4 Discussion  
This prospective case-controlled study confirmed that increased levels of novel 
biomarkersdemonstrated better early diagnostic accuracy for CIN compared to serum 
creatinine and they are dependable in excluding patients at risk of developing CIN. 
Additionally the increased levels of novel biomarkers demonstrated prognostic significance 
compared to serum creatinine. To our knowledge, this the first prospective and case-controlled 
study that compared and associated a panel of novel structural, filtration and inflammatory 
biomarkers in diagnosis and prognostication in patients undergoing contrast studies.  
Our study showed that cystatin C at 24 hours after contrast administration showed best 
discrimination for CIN, which is consistent with previous observational and meta-analysis 
studies (100, 115, 151, 152). In a recent study of patients undergoing cardiopulmonary bypass 
surgery with cystatin C measurement at 2, 4, 24 and 72 hours after surgery, serum cystatin C 
levels significantly peaked at 24 hours in the acute kidney injury (AKI) group compared to 
controls (100). The cystatin C AUROC at 24 hours in discriminating presence of AKI after 
surgery in patients with normal baseline renal function was 0.75, a finding very similar to our 
study (100).  
In another study limited to chronic kidney disease (CKD) patients undergoing angiography, 
Briguori et al. observed a non-significant differences between levels of cystatin C in the CIN 
group compared to controls at baseline; however at 24 hours after contrast media 
administration, cystatin C was significantly higher in the CIN group (151). In this study, the 
AUROC at 24 hours was 0.92 and higher, compared to our study (151). This study cohort was 
composed of patients with CKD (151)whereas our study patients had almost normal baseline 
renal function. Previous studies have shown high AUROC in CKD patients compared to 
patients with normal renal function (100). 
In a meta-analysis that included 19 studies, Zhang et al. reported best discrimination for AKI 
with cystatin C measured within 24 hours in patients with homogenous insults to the kidney 
and after 24 hours in patients with non-homogenous insult to the kidney (115).  
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In this meta-analysis, the best AUROC for AKI were 0.81 at 12 hours after cardiac surgery 
and 0.92 after contrast media administration (115); however this meta-analysis  majorly  
comprised studies of patients with homogenous insults to the kidney and only one study on 
CIN in CKD patients was included in this study (115). 
There are several reasons why cystatin C demonstrates superiority over serum creatinine in 
detecting early AKI, including CIN (152). Cystatin C belonging to the cystatin is a small 
molecule of 13 kDa that intracellularly inhibits cystatin peptidases (109). Secretion of cystatin 
C into the circulation is linear (109, 152) and unaffected by muscle mass and volume as 
compared to serum creatinine.(152).  
In our study cohort, increased levels of beta 2 microglobulin (β2M) demonstrated early 
prediction for CIN and mortality. Several studies on β2M and outcomes have looked at 
populations with underlying chronic kidney disease (116). In a study limited to a paediatric 
population, El-Frargy et al. found significantly increased levels of baseline β2M in AKI 
patients compared to controls; however the levels of serum creatinine remained unchanged 
(153). After 72 hours, β2M demonstrated superiority in detection of AKI with sensitivity and 
specificity of 98% and 80% vs. 46% and 53% for serum creatinine (153). In another paediatric 
study (154), Herrero-Morrin et al. also demonstrated higher levels of β2M in the AKI group 
compared to controls despite insignificant differences in levels of serum creatinine (154). β2M 
also demonstrated superiority early detection of AKI with AUROC of 0.80 vs.0.63 for serum 
creatinine (154). This study defined renal disease as glomerular filtration rate (eGFR) <80 
mls/min per 1.73m
2
(154).   
Increased serum β2M levels were linked with mortality in our study, a finding previously 
reported (155, 156), In the CKD patients who died, increased β2M was an independent 
predictor of mortality (155). Two reasons could explain the association between increased 
levels of β2M and mortality in our study cohort. The underlying comorbidity of our study 
cohort was predominantly malignancy and in previous studies, malignancy together with 
micro inflammation is associated with increased secretion for β2M(156). In the presence of 
renal disease including CIN, the impact of high β2M is heightened (156).  
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Compared to serum creatinine, β2M performed superiorly in the diagnosis of CIN, similar to a 
few limited studies. β2M is a filtration biomarker produced by nucleated cells (116) and 
undergoes almost complete metabolism in the kidney and is completely absorbed by megalin 
mediated endocytosis (116, 117) and is also least affected by extra renal factors (157).  
In our study, NGAL showed dependable accuracy in excluding patients at risk of development 
of CIN. This finding is supported by two recent studies limited to CIN; one conducted in Italy 
among patients with underlying renal disease who underwent angiography (158) and another 
in Iran that was conducted in patients with normal renal function (159). In the Italian study, 
Quintaville et al. reported a NGAL positive predictive value (PPV) and negative predictive 
value (NPV) of 20% and 93% respectively (158), thus demonstrating superiority of NGAL in 
excluding patients at risk for CIN and suboptimal accuracy for diagnosing CIN. In patients 
with normal renal function undergoing angiography, Khatami et al. reported NGAL positive 
and negative predictive values of 9.4% and 97.1 % respectively, with suboptimal area under 
the receiver operative curves (159). Several studies correlating NGAL in the diagnosis of AKI 
were limited to patients with homogenous insults to the kidney such as surgical patients (101, 
107). In these studies, early NGAL discrimination for AKI was observed within 2-4 hours 
after an insult (100, 101). In non CKD population, Schley et al. recently reported a high AUC-
ROC of 0.85 in the non CKD group at 4 hours after surgery (100). However, in patients with 
CIN, the efficacy of NGAL in discriminating performance was conflicting. A recent meta-
analysis of 10 studies and limited to NGAL discriminating for CIN showed variable AUROC 
(83). In this meta-analysis, 4 studies looked at patients with CKD (83).  
Patients undergoing contrast administration are characterised by various heterogeneous insults 
to the kidney (160) compared to cardiac surgery and additionally the underlying comorbidities 
influence NGAL productions including baseline kidney function.The low diagnostic accuracy 
for NGAL in CIN could be due to the presence of underlying heterogeneity in kidney function 
at baseline in these patients and the influence of varying comorbidities (158).   
In our study serum IL18 together with TNFα demonstrated a prognostic significance with 
CIN+ mortality despite the poor the discrimination performance for CIN.  
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In a recent meta-analysis correlating urine IL18 with AKI, the discrimination performance of 
IL18 was modest with an AUROC of 0.66 in adults (161) and was lower compared to other 
serum biomarkers. Increased IL18 levels are shown with acute tubular necrosis, urine tract 
infections, pre-renal failure and therefore may not purely reflect an injury to the kidney (161). 
Therefore our study was limited to serum IL18.  
Similar to previous studies (123, 162), our study showed increased levels of serum IL18 in the 
non-surviving group of our study cohort. In previous study, an increase from 25-500 pg/ml in 
urine IL18 at baseline predicted an up to 5-fold mortality risk (123). Increased levels of serum 
IL18 are linked with dysfunction of cardiac myocytes, vascular injury and apoptosis (163). 
Our study found no association between HIV status and CIN or HIV positivity with levels of 
novel biomarkers. In previous studies, Landro et al.(129) reported decreased levels of plasma 
NGAL in HIV infected patients compared to controls. However after initiation of 
antiretroviral therapy, levels of NGAL increased. The insignificant difference in levels of 
biomarkers is a reflection of good immune competence of patients in this cohort and the 
increased accessibility to anti-retroviral therapy. 
The strength of this investigation was that it was a prospective case-controlled study and 
evaluated and compared several biomarkers in discriminating CIN and patient outcomes. Our 
study population was characterised as heterogeneous unlike previous studies. Despite this, our 
study was a single centre conducted at a tertiary hospital and the study analysed only serum 
measurements. 
4.5 Conclusions 
Compared to serum creatinine novel biomarkers have better diagnostic discrimination for CIN 
and prognosticating patient outcomes in patients with heterogeneous insults to the kidney. 
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CHAPTER 5 
5.0 Influence of Genetic Polymorphisms of TNFα and IL10 on Contrast 
Induced Nephropathy and Outcomes in Black South Africans 
Abstract  
Despite positive associations of genetic polymorphisms in TNFα and IL10 with contrast 
induced nephropathy (CIN) among Chinese populations, its role in other populations remains 
unexplored.  
Methods  
In this prospective observational study, 208 black Africans patients undergoing contrast 
administration were genotyped for TNFα and IL10 genes cytokine polymorphisms. Genomic 
DNA was extracted from peripheral blood samples using the Maxwell DNA purification kit 
(Promega AS1010, USA). The TNFα genotypes -308 (rs1800629) and -857(rs1799724), and 
IL10 genotypes -592(rs1800872), -819(rs1800871), -1082 (rs1800896) and +1582(rs1554286) 
were determined by restriction fragment length polymorphism (RFLP). The study outcomes 
measures were genetic susceptibility to development of CIN (defined as serum creatinine > 
25% from baseline) and mortality risk in patients with CIN. 
Results  
This study showed significant increase in the frequency of the TNFα -308 AA genotype in 
CIN patients compared to controls (13.3% vs.1.82%, p=0.016), In addition, the presence of the 
TNFα-308 AA (high producer) vs. GG+GA genotypes was associated with a 9-fold CIN risk 
(9.24, 95% CI, 1.88-45, p=0.006). The IL10-1082 AA genotype (low producer) was 
significantly high in the non-surviving CIN+ patients compared to controls (p=0.011) and also 
showed a significant trend in the non-surviving patients without CIN (p=0.05).  
  
 
 
81 
 
 
Conclusion 
The presence of the TNFα-308 AA genotype is a predisposing factor for CIN development 
while the IL10-1082 AA (the low producer) genotype decreases survival in CIN patients. 
5.1 Introduction 
In recent studies, inflammatory cytokines including tumor necrosis factor alpha (TNFα) and 
interleukin (IL10) are implicated in the pathogenesis of ischaemic acute kidney injury (AKI) 
including contrast induced nephropathy (CIN) (14, 67-69). Treatment of CIN remains 
supportive (9) and knowledge of existing risk factors and methods for CIN identification are 
suboptimal in diagnosis, determining CIN risk and patient outcomes. Therefore, inflammatory 
cytokine genetic susceptibility to CIN is an important marker in CIN identification and in 
guiding directed therapy.  
Genetic polymorphisms in TNFα and IL10 influence upregulation of inflammatory cytokines 
and consequently increase susceptibility to inflammatory diseases (75) including CIN (14) and 
result in poor clinical patient outcomes (76). Among the Han Chinese populations with CIN, 
Chang et al. found a 2-fold  increased frequency in the A-allele (rs1800629) compared to 
controls (OR 2.01, 95% 1.13-3.35, p=0.02) (14). The TNFα gene has several single nucleotide 
polymorphism (SNP) within its promoter region, however TNFα-308 remains the mostly 
associated with disease (75). The presence of the lesser adenine (A-allele) at position -308 of 
the TNFα gene is positively associated with a 6-fold increased transcription rate (75).  IL10 a 
35 kDa anti-inflammatory cytokine localised to chromosome 10 has several SNPs in its 
promoter region including the IL10 -1082 genotype (14) and almost 75% secretion of the IL10 
cytokine is genetically determined (76). Recently, Chang et al. reported positive association 
between the IL10-1082 G-allele and CIN risk (14). There are limited studies and only three 
meta-analyses (164-166) that have explored susceptibility genes (including inflammatory 
cytokines genes) linked with AKI and these studies demonstrated conflicting results.  
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Only one study examined the association of genetic polymorphisms in inflammatory cytokine 
genes with CIN and reported positive association (14) thereby providing potential targets for 
future anti-inflammatory therapies.  
TNFα is an inflammatory cytokine that accelerated acute kidney injury while IL10 accelerates 
recovery (14). Identification of protective genetic polymorphisms in these inflammatory 
cytokines will help in the implementation of targeted modalities that will lessen the impact of 
CIN. Our study investigated the impact of TNFα and IL10 SNPs on CIN and patient outcomes 
in black Africans.  
5.2 Materials and methods  
Study methods are described in chapter 2.This prospective observational study included 208 
black South Africans undergoing contrast media administration at Charlotte Maxeke 
Johannesburg Academic Hospital and was approved by Human Research Ethics Committee of 
the University of the Witwatersrand. All study participants gave a written informed consent. 
Statistical analysis  
Categorical data are presented as frequencies and percentages.  A Fisher’s exact test was 
employed to analyze differences between genotype frequencies among the CIN group and 
controls and also among the surviving and non- surviving group. Genotype susceptibility to 
CIN was determined by calculating odd ratios (ORs) and 95% CI with p values <0.05 regarded 
as significant. 
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5.3 Results  
In this prospective cohort study, 208 black Africans South Africans were genotyped for TNFα 
and IL10 genes. Among these genotyped participants, 32 (15%) developed CIN. Controls 
were those not meeting CIN diagnostic criteria. The overall mortality in this study cohort was 
21 with 12 occurring in the CIN+ black South Africans.  
5.1 Associations of TNFα and IL10 polymorphism with CIN 
The comparison of the frequency allele distribution between the CIN group and controls is 
described in Table 5.1. TNFα -308 AA (high producer) was significantly higher in the CIN 
group compared to controls (p=0.016) and was associated with a 9-fold CIN risk. The other 
TNFα and IL10 genotypes showed non-significant frequency differences between the CIN 
group and CIN negatives. 
5.2 Associations of TNFα and IL10 polymorphisms with overall mortality  
Table 5.2 describes an association of the genotypes with cause mortality. The IL10-1082 low 
producer (AA-allele) showed a trend for significance between the surviving groups and non-
surviving group (p=0.05). When mortality was restricted to the patients who developed CIN, 
there was increased frequency of the IL10-1082 AA-allele in the CIN+ patients who died vs. 
surviving CIN+ patients (p=0.011). The other genotypes showed a non-significant association 
with overall mortality as well as mortality restricted to the CIN+ groups only. 
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Table5.1 Associations of TNFα and IL10 polymorphism with CIN 
SNP ID Genotype CIN+ 
(n=32) 
CIN- (n=176) p 
value 
OR 95% CI p value 
         
 
TNFα 308 
      Low producer  
GG 15 (50%) 104(63.0%)  0.02  1(Ref)  
      High producer GA 11 (36.7%) 58 (35.2%)  1.31(0.56-3.05)  0.52 
      High producer AA 4 (13.3%) 3 (1.8%)  9.24(1.88-45.4)  0.006* 
         
TNFα-857 CC 5 (18.5%) 38 (24.7%) 0.77 1 (Ref)   
  CT 20 (74.1%) 106 (68.8%)  1.43(0.50-4.08)  0.50 
  TT 2 (7.4%) 10 (6.5%)  1.52 (0.26-9.02)  0.65 
         
IL10-592 CC 14 (46.7%) 76 (43.9%) 0.32 1 (Ref)   
  CA 13 (43.3%) 89 (51.5%)  0.79 (0.35-1.79)  0.57 
  AA 3 (10.3%) 8 (4.6%)  2.03(0.48-8.63)  0.35 
         
IL10-819 TT 3 (9.4%) 11 (6.3%) 0.75 1 (Ref)   
  TC 15 (46.9%) 88 (50.0%)     
  CC 14 (43.7%) 77 (43.8%)  0.67(0.16-2.69)  0.57 
         
IL10-1082 
  Low producer 
AA 3 (9.1%) 10 (5.6%) 0.60 1 (Ref)  
  Intermediate AG 25 (78.1%) 143 (82.7%)  0.58 (0.14-2.25)  0.43 
  High producer GG 4 (12.1%) 21 (11.7%)  0.63(0.11-3.39)  0.59 
         
IL10+1582 TT 6 (19.4%) 22 (14.4%) 0.77 0.72 (0.26-1.97) 0.52 
  TC 23 (74.2%) 117 (76.8%)     
  CC  2 (6.5%)  14 (9.2%)    0.52(0.09-2.96)  0.46 
 
*OR for TNFα -308 (rs1800896) AA vs. AG+GG 
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Table5.2 Associations of TNFα and IL10 polymorphisms with overall mortality  
SNP ID Genotype Mortality + 
(n=21) 
Mortality – 
(n=187) 
p value OR 95% CI p value 
         
 
TNFα 308 
      Low producer  
GG 12 (70.6%) 102 (60%)  0.79  Ref (1)   
      High producer GA 5 (29.4%) 61 (35.9%)  0.52 (0.23-2.07)  0.51 
      High producer AA 0 (0.0%) 7 (4%)     
         
TNFα-857 CC 6 (35.3%) 35 (22.3%) 0.19 1 (Ref)   
  CT 9 (52.9%) 113 (71.9%)  0.46(0.15-1.39)  0.17 
  TT 2 (11.8%) 9 (5.7%)  1.29 (0.22-7.5)  0.77 
         
IL10-592 CC 11 (52.4%) 73 (41.9%) 0.29 1 (Ref)   
  CA 8 (38.0%) 92 (52.9%)  0.57(0.22-1.50) 0.26  
  AA 2(9.5%) 9 (5.2%)  1.47(0.28-7.74) 0.65 
         
IL10-819 TT 2 (9.5%) 12 (6.7%) 0.75 1 (Ref)   
  TC 9(42.9%) 92 (51.4%)  0.58(011-3.04)  0.52 
  CC 10 (47.6%) 75 (41.9%)  0.80 (0.15-4.10)  0.79 
         
IL10-1082 
  Low producer 
AA 4(18.2%) 9 (4.9%) 0.05 1(Ref)  
  Intermediate AG 14 (66.1%) 153 (83.6%)  0.22(0.14-2.25)  0.02* 
  High producer GG 3 (13.6%) 21 (11.5%)  0.32(0.05-1.73)  0.19 
         
IL10+1582 TT 2 (12.5%) 25 (15.5%) 0.77 1 (ref)   
  TC 13 (81.3%) 122 (75.8%)  1.33(0.28-6.27)  0.72 
  CC  1(6.3%)  14 (8.7%)   0.89(0.07-10.7)  0.92 
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5.4 Discussion 
This prospective observational study and the first in Africans confirmed the positive 
association of inflammatory TNFα and IL10 genes polymorphisms with CIN including CIN 
mortality. In our study, the presence of the TNFα high producer AA genotype was associated 
with an almost 10-fold CIN risk and presence of IL10 AA (low producer) genotype was 
significantly high in the non-surviving CIN+ patients.  
In this study, the presence of TNFα-308 high producer allele increased the risk for developing 
CIN. Our finding is similar to a previous study conducted among the Han Chinese population 
(14). In this study Chang et al. demonstrated positive association between high producer 
TNFα 308 alleles and development of CIN. In patients with autoimmune disease, Ivanova et 
al. also reported a 3.4-fold increase risk for systemic lupus erythromatosis in patients carrying 
the TNFα -308 A-alleles(167). In a recent study in the USA, Susantitaphong et al. observed 
increased frequency of the TNFα-308 AA-alleles in patients with high peak serum creatinine 
and high levels of novel biomarkers (168).  
Inflammatory cytokines including TNFα play significant roles in the pathogenesis of CIN as 
well as in other forms of AKI (14, 63) and genetics determines individual variation in 
secretion of TNFα and other cytokines (167). Jaber et al observed increased levels of TNFα 
and IL10 cytokines in patients carrying the TNFα -308 and IL10-1082 high producer alleles 
(76). TNFα, mapped to chromosome 6, is upregulated during renal injury (14, 63) and 
performs the following functions; recruitment of inflammatory cells and other inflammatory 
cytokines; increases upregulation of various adhesion molecules (ICAM, VCAM ) (72). Upon 
activation, TNFα binds to its receptors (TNFR1 and TNFR2) and this leads to activation of the 
TNF receptor associated factor-2 and NF-kβ, ultimately leading to inflammation and cell death 
(72).  
Few studies have investigated genetic susceptibility of inflammatory cytokines with AKI, and 
including CIN (164). Additionally these limited studies (including the only three meta-
analyses) have demonstrated conflicting results (164, 166, 169).  
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In a meta-analysis that included 11 studies, the presence of the high producer TNFα was 
associated with a decrease in patient survival (169). However, only one study in these meta-
analyses was limited to inflammatory cytokine genes. Other observational studies showed 
non-significant association between the TNFα-308 and other genotypes with AKI or patient 
outcomes (164).  
In a recent prospective and observational study of patients hospitalised to an intensive care 
unit (ICU) in Spain, Cardinal-Fernandez et al. reported non-significant differences in the 
frequency of the TNFα -308 A-allele between the AKI group and controls (169).  
Our study showed increased frequency in the IL10-1082 low producer allele in the CIN+ non-
surviving patients. Additionally, there was a trend for increased frequency in the IL10-1082 
low producer genotypein patients without CIN who died. In a prospective nested control ICU 
based study in Brazil, the IL10 -1082 low producer allele in combination with TNFα 
positively predicted mortality (170). In this study, the IL10 -1082 genotype showed a non-
significant frequency increase between the AKI and controls groups (170), a similar finding in 
our study. However, Jaber et al. reported decreased AKI mortality in patients with IL10 
intermediate or high producer genotypes (76).  
There are several reasons for increased CIN mortality in patients with the IL10-1082 low 
producer allele. The IL10 gene mapped to chromosome 1, is an important inflammatory 
cytokine that inhibits transcription of pro-inflammatory cytokines (TNF, IL-1 and IL6) and 
also down regulated production of nitric oxide (171)(78). In animal studies, IL10 is also 
important in induction of heme oxygenase, an enzyme that metabolizes heme to carbon 
monoxide, biliverdin and iron. Heme oxide functions as an oxidative stress responding 
molecule in various inflammatory states (171). The metabolites of heme functions as anti-
oxidants and also inhibits inflammatory cytokines (171).  
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Similar to other previous findings in AKI (172), the IL10 gene polymorphisms were not 
associated with CIN in our study. In a paediatric cohort study, Treszl et al. observed 
insignificant differences in the frequency of the IL10 genotypes (including TNFα -308) 
between the AKI groups and controls (172). However few studies have explored the 
association of IL10 gene polymorphisms with AKI 
The strength of this study is that it was a prospective observational study and the first to 
explore association of cytokine genetic susceptibility with CIN. 
Our study also confirms Chang et al. findings which demonstrated a positive association of 
these genes in the Han Chinese population. However due to conflicting results on the 
association of ischaemic AKI and cytokine genes, there is need to replicate the studies in large 
populations and other races. 
5.5 Conclusion 
The TNFα 308 AA (high producer) genotypeincreases susceptibility to development of CIN 
while the IL10 -1082 AA (low producer) decreases survival in CIN patients. 
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CHAPTER 6 
6. DISCUSSION 
The hypothesis tested in  this study were three-fold; that the rates of CIN were higher among 
hospitalised South Africans compared to developed countries, that the cytokine gene 
polymorphisms (TNFα and IL10 genes) were positively linked with CIN development and 
patient outcomes and lastly that novel biomarkers were accurate in the early prediction of CIN 
and prognosticating. 
6.1 Summary of study findings 
This study revealed the following;  
1.6.1 There is an increased rate of CIN in hospitalised South Africans compared to 
developed countries with anaemia acting as an independent risk factor.  
1.6.2 The novel biomarker cystatin C showed the best discrimination for early 
diagnosis of CIN at 24 hours and together with together with β2M at 48 hours after 
contrast media administration. Baseline NGAL (pre-contrast) demonstrated early 
accuracy for excluding patients at risk of developing CIN. 
1.6.3 The novel biomarkers at baseline (IL18, β2M and TNFα) demonstrated best 
prognostic significance for CIN mortality while IL18 and TNFα at baseline showed 
prognostic significance for overall mortality. 
1.6.4 Genetic polymorphisms in the cytokine genes (TNFα and IL10) showed positive 
association with CIN development including CIN mortality. The TNFα -308 AA-allele 
(high producer) showed increased frequency in the CIN group compared to controls 
and was associated with an almost 10-fold CIN risk. The IL10-1082 (low producer) 
showed increased frequency with CIN mortality risk.  Table 6.1 summarizes the study 
findings 
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Table 6.1 A summary of the study findings   
 Objective  Chapter  Findings 
 
1 Determination of rates of CIN  3 The rates of CIN were 16.4% and 
relatively high compared to 
developed countries. CIN was 
defined using the ESUR criteria: an 
increase in serum creatinine > of 
25% or >44 µmol/l from baseline. 
The >25% relative increase 
criterion is also supported by the 
Contrast Induced Nephropathy 
Consensus Working Group.  
2 Risk factors for CIN 3 In an adjusted model, presence of 
anaemia was associated with a 2-
fold odds for developing CIN 
(p=0.04). Levels of albumin were 
significantly lower in the CIN 
group (p=0.01) in our study, and 
showed a significant trend for CIN 
risk in adjusted model (p=0.06) 
3 Outcomes of CIN 3 The rates of in-hospital mortality 
was significantly high in CIN 
group, 22.4% vs.6.8%, p<0.001 
4 Predictors of mortality   CIN together with anaemia were 
associated with 2-fold (p=0.01) and 
3-fold (p=0.03) mortality risks. Of 
the 13 deaths in the CIN group, 7 
had malignancy. After adjusting for 
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comorbidities, CIN remained an 
independent predictors 
 
5  
Accuracy of biomarkers in 
predicting CIN 
4  
Cystatin C at 24 hours and B2M at 
48 hours showed best 
discrimination for CIN with 
AUROC of 0.75 (p<0.001) and 
0.78 (p<0.01) respectively. 
Baseline NGAL demonstrated 
accuracy in excluding patients at 
risk of developing CIN  
6 Accuracy of biomarkers in 
prognosticating CIN patient 
outcomes  
4 Baseline IL18, β2M and TNFα 
showed best discrimination for 
CIN+ mortality. The AUROC were 
0.83 (p<0.001), 0.82(p<0.04) and 
0.94 (p<0.001) respectively. In the 
controls, IL18 and TNFα showed 
best discrimination of mortality 
with AUROC of 0.91 and 0.84. 
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7 Influence of genetic (TNFα and 
IL10 genes) susceptibility to 
CIN 
5 The CIN group showed a 
significant increased frequency in 
the TNF-308 A-allele (high 
producer) compared to G-allele 
(p=0.016).  Presence of the A-allele 
was associated with a 10-fold CIN 
risk (p=0.006) 
8  
 
Influence of genetic (TNFα and 
IL10 genes) susceptibility to 
CIN mortality  
 
 
5 
 
The IL10-1082 AA genotype 
showed a significant frequent 
increase in the non-surviving 
participants in the study cohort 
(p=0.046). When restricted to 
CIN+ group, the IL10 low 
producer was higher in the non-
surviving group (p=0.011) 
 
 
6.2 Rates and risk factors for CIN 
In South Africa including Sub-Saharan Africa, this is the first prospective study that has 
examined the risk and outcomes of CIN among hospitalised patients. The rate of CIN in our 
study was 16.4% (defined according to the updated guidelines of European Society of 
urogenital Radiation (ESUR) (50, 53).  
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The rate of CIN in this study was relatively high compared to previous findings in developed 
countries. Sherma et al. in Israel (1), Chang et al. in Taiwan (14) and Mitchel et al. in USA 
(132) reported 4.5%, 10% and 14% rates of CIN respectively.   
In a recent observational study and randomized controlled trial, Shams-Eddin Taher et al.(33) 
and Narula et al. (35) reported rates of CIN of 11.5% and 16.1% rates of CIN respectively. 
The relatively high rates of CIN in this study could be explained by two reasons; the non-
standardised prescription practices by clinicians, including pre-hydration, and the 
heterogeneous comorbidities of our study population at the time of contrast administration. 
The presence of anaemia at baseline was associated with almost 2-fold and 3-fold increased 
rates of CIN and mortality risks respectively. In previous studies, anaemia was positively 
associated with CIN development (53); however; there are limited studies on the association 
of anaemia with CIN mortality. In an observational study, Lin et al. (29) observed a 2-fold 
CIN risk in patients with underlying anaemia while McKechnie et al. reported positive 
association of baseline anaemia with mortality (142). There are several reasons why baseline 
anaemia is associated with CIN risk including mortality. Firstly only 10% of renal blood flow 
is directed to the renal medulla despite the increased metabolic activities occurring in the 
medulla (65).  
In the presence of  contrast media, significant vasoconstriction (mediated by adenosine and 
endothelins) occurs in the medulla that further reduces the oxygen partial pressures to as low 
as 10 mmHg (25). Presence of anaemia is a reflection of severity of the comorbidities (142) at 
baseline and therefore a traditional biomarker signifying CIN prognosis.  
We observed significantly low serum albumin levels in the CIN cohort compared to controls 
and the decreased albumin also showed a significant trend for almost 2-fold CIN risk. Serum 
albumin is an important anti-oxidant that decreases formation of ROS through its binding of 
non-ceruloplasmin copper and iron (133). Endothelial dysfunction and inflammation leads to 
production of reactive oxygen species ROS) implicated in CIN (13).   
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Additionally, albumin is a biomarker reflecting underlying inflammation or under nutrition in 
patients.  
6.2.1 Mortality and CIN 
We observed significantly high mortality in the CIN group compared to controls (22.4% vs. 
6.8%, p<0.001). After adjusting for underlying confounders including patient comorbidies, 
(malignancy and cardiac disease), CIN predicted 2 fold mortality risk. Our findings are similar 
to previous observational studies in developed countries that reported increased mortalities in 
patients with CIN(34). Rihal et al.(43) and Sadeghi et al.(42) found mortality of 22.0% 
vs.1.4% and 16.2% vs. 1.2% mortalities in the CIN group compared to controls respectively.  
6.3 Accuracy of biomarkers in the diagnosis of CIN and prognostication 
The novel biomarkers demonstrated diagnostic accuracy (Cystatin C at 24 hours and β2Mat 48 
hours) for CIN and CIN prognosis (baseline β2M, Interleukin18 and TNFα). Additionally, the 
novel biomarkers showed accuracy in excluding patients at risk of developing CIN (baseline 
NGAL). To our knowledge, this is the first prospective case-controlled study to compare a 
panel of novel biomarker (filtration, structural and inflammatory) on the development of CIN 
and patient outcomes.  
Similar to previous findings, Cystatin C at 24 hours demonstrated best accuracy for CIN 
diagnosis compared to serum creatinine (100, 151). In patients undergoing cardiopulmonary 
bypass surgery, Schley et al. showed that the best cystatin discrimination for acute kidney 
injury (AKI) was at 24 hours after an insult. In this study, the area under receiver operating 
curves (AUROC) at 24 hours after surgery was superior compared to the AUROC at baseline, 
2 hours or 4 hours (100). A similar finding was observed by Briguori et al who reported best 
cystatin C AUROC of 0.92 at 24 hours in patients undergoing contrast media administration 
(151). 
 
 
 
95 
 
 
Consistent with two recent finding, NGAL demonstrated best accuracy for excluding patients 
at higher risk for developing CIN. In these studies conducted in Italy and Iran, Quintaville et 
al.(158) and Khatami et al.(159) reported 20% vs. 93% and 9.4% vs. 97.1% positive predictive 
value and negative predictive values respectively.  
Despite limited studies associating β2M and CIN, β2M showed best diagnosis accuracy for 
CIN and CIN mortality in our study. In few studies limited to AKI, β2M showed best 
discrimination of AKI with an AUROC of 0.80 (154).In a study limited to CKD patients, 
increased levels of β2M were positively associated with mortality (155, 156), a similar finding 
to our study. 
Damaging renal injury biomarkers (IL18 and TNFα) at baseline showed prognostic 
significance for CIN mortality. In previous studies, Parikh et al.reported a5-fold mortality risk 
in patients with increased IL18 levels (123). Interleukin l8 and TNFα are pro inflammatory 
cytokines secreted by both injured renal tissue and infiltrating inflammatory cells (67, 68) and 
therefore, the positive association of damaging biomarkers with mortality probably reflects 
severity of the underlying inflammatory in patients at risk.  
6.4 The influence of TNFα and IL10 cytokine gene polymorphisms with CIN and patient 
outcomes 
This is the first study in black South Africans and all black populations to demonstrate 
cytokine gene polymorphisms and susceptibility to CIN and mortality. We observed increased 
frequency of the TNFα-308 high producer A-allele in the CIN group and this was associated 
with an almost 10-fold CIN risk.  Our findings are similar to Chang et al. who found positive 
association of the TNF high producer alleles with CIN among the Han Chinese population 
(14). Similarly, Ivanova et al. found a positive association between the TNFα-308 A-allele 
with autoimmune diseases (167). Few studies have been conducted on the TNFα gene 
polymorphisms and IL10 genes polymorphisms and susceptibility to AKI. Only one study by 
Chang et al. has been conducted that explored genetic susceptibility to CIN in Asian 
populations.  
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We observed an increased frequency increase in the IL10 -1082 A-allele (low producer) in the 
non-surviving CIN+ patients compared to controls despite the low sample size in this nested 
study of black Africans. Our findings are similar to Jaber et al. who reported decreased AKI 
mortality in the IL10-1082 high producer compared to the low producer (A-allele) (76). 
6.5 National and global importance of this study 
This is the first study describing the impact and prognostic implications of CIN in hospitalised 
patients (including Sub-Saharan Africa) and the first to demonstrate the positive genetic 
susceptibility to CIN in blacks carrying polymorphisms in the TNFα and IL10 genes.  
This study has highlighted the increased prevalence of contrast induced nephropathy and 
mortality. Despite being conducted at a tertiary hospital, this study calls for unified and 
standardised guidelines for prevention of contrast induced nephropathy. Additionally, extra 
caution should be taken in patients with underlying anaemia and low albumin who 
demonstrated an increased risk for contrast induced nephropathy. With the increasing rates of 
non-communicable diseases (such as diabetes and cardiac diseases) in Sub-Saharan Africa 
which are known risk factors, the rates of CIN will also increase. 
Our study and the recent study in Asians (Chang et al) have shown the positive influence of 
inflammatory cytokine genes on CIN. In our study, the presence of high producer TNFα-308 
increased susceptibility to CIN among black South Africans. Additionally non-surviving CIN+ 
patients showed increased frequency of the IL10-1082 low producer. TNFα is linked with 
positive acceleration of renal injury while IL10 increases repair. These findings highlight the 
need to replicate these studies in large cohorts and other races. Randomized controlled studies 
should address replacement of IL-10 or anti-TNFα (including other anti-inflammatory 
therapies) in genetically susceptible individuals. 
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The novel biomarkers showed early diagnosis accuracy and prognostic accuracy. Additionally, 
novel biomarkers also demonstrated accuracy for excluding patients at risk for CIN. This is 
important nationally and globally in early identification of patients at risk; however, few 
studies have explored these biomarkers in CIN.  
Therefore optimal cut-off points remain variable in different studies including what is the best 
timing in patients with heterogeneous (CIN group) insults to the kidney.  
6.6 Future research and recommendations 
Future research should address the following; 
1. Multi-institutional studies should be conducted on rates of CIN in South Africa and 
other Sub-Saharan countries. Workable and standardised recommendations on fluid 
pre-hydration should be implemented in patients undergoing contrast administration 
procedures especially in high risk groups. 
2. Studies on genetic susceptibility of TNFα and IL10 genes including other genes 
inflammatory cytokines (IL18, FGF) should be conducted in other races. Additionally, 
these studies should also explore the impact of  IL10 or ant-TNFα replacement therapy 
(including other anti-inflammatory therapies) in genetically susceptible individuals 
3. Our study addressed a panel of biomarkers assessing the diagnostic accuracy and 
prognosis in CIN patients. Future studies should address the best optimal cut-off limits 
and timings for specimen collection in such CIN groups. NGAL showed accuracy in 
excluding patients at risk for CIN and therefore future studies should address the 
impact on decreased CIN risk by measuring NGAL at baseline in patients undergoing 
contrast administration. 
6.7Study limitations  
The positive aspect of this study is that it was a prospective observational study (with a nested 
case-controlled component) investigating novel biomarkers with a large sample size.  
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 Despite this, there are limitations of study; it was a non- interventional study and conducted a 
single tertiary hospital. The study was also limited to few single nucleotide polymorphisms 
(SNPs) that were selected based on previous findings in which they had shown positive 
association with acute kidney injury in other populations. Despite blood and urine 
demonstrating similar findings for novel biomarkers, this study should have compared the 
blood and urine performance for biomarkers. However, timing, storage and contaminants in 
urine remain a challenge. 
6.8 Conclusion 
The objectives of this thesis were to determine the rates and risk factors of CIN in hospitalised 
South Africans, determine the influence of genetic susceptibility (TNFα and IL10 genes) in 
CIN patients and the accuracy of novel biomarkers in early CIN diagnosis and 
prognostication. This thesis has confirmed the relatively high rates of CIN and underlying risk 
factors and patient outcomes. It has also confirmed the positive genetic susceptibility to CIN 
in black South Africans. Lastly, biomarkers for early identification of CIN and prognostication 
have been identified including those for identifying individuals at risk for CIN. 
  
 
 
99 
 
 
References  
 
1. Shema L, Ore L, Geron R, Kristal B. Contrast-induced nephropathy among Israeli 
hospitalized patients: incidence, risk factors, length of stay and mortality. Isr Med 
Assoc J. 2009;11(8):460-4. 
2. Evola S, Lunetta M, Macaione F, Fonte G, Milana G, Corrado E, et al. Risk factors for 
contrast induced nephropathy: a study among Italian patients. Indian Heart J. 
2012;64(5):484-91. 
3. Chao C. Epidemiology, Clinical Features and Diagnosis of Contrast Induced 
Nephropathy: A Brief Review. Gen Med. 2013;1(1):1-5. 
4. Mitchell AM, Jones AE, Tumlin JA, Kline JA. Incidence of contrast-induced 
nephropathy after contrast-enhanced computed tomography in the outpatient setting. 
Clin J Am Soc Nephrol. 2010;5(1):4-9. 
5. Mitchell AM, Jones AE, Tumlin JA, Kline JA. 1-Year Mortality Following Contrast-
Induced Nephropathy. American Journal of Internal Medicine. 2013;1(1):1-6. 
6. Pasternak JJ, Williamson EE. Clinical pharmacology, uses, and adverse reactions of 
iodinated contrast agents: a primer for the non-radiologist. Mayo Clin Proc. 
2012;87(4):390-402. 
7. Solomon R. Contrast Media: Are There Differences in Nephrotoxicity among Contrast 
Media? BioMed Research International. 2014;2014:1-8. Artcile ID934947 
8. Perrin T, Hemett OM, Menth M, Descombes E. Contrast-induced acute kidney injury 
following iodine opacification other than by intravascular injection. Clinical Kidney 
Journal. 2012;5(5):456-8. 
9. Lameire NH. Contrast-induced nephropathy--prevention and risk reduction. Nephrol 
Dial Transplant. 2006;21(6):i11-23. 
10. Finn WF. The clinical and renal consequences of contrast-induced nephropathy. 
Nephrol Dial Transplant. 2006;21(6):i2-10. 
11. Deek H, Newton P, Sheerin N, Noureddine S, Davidson PM. Contrast media induced 
nephropathy: a literature review of the available evidence and recommendations for 
practice. Aust Crit Care. 2014;27(4):166-71. 
12. Bellin MF, Jakobsen JA, Tomassin I, Thomsen HS, Morcos SK, Almen T, et al. 
Contrast medium extravasation injury: guidelines for prevention and management. Eur 
Radiol. 2002;12(11):2807-12. 
13. Pisani A, Riccio E, Andreucci M, Faga T, Ashour M, Di Nuzzi A, et al. Role of 
reactive oxygen species in pathogenesis of radiocontrast-induced nephropathy. Biomed 
Res Int. 2013;2013:1-6. Artcle ID868321 
14. Chang CF, Lu TM, Yang WC, Lin SJ, Lin CC, Chung MY. Gene polymorphisms of 
interleukin-10 and tumor necrosis factor-alpha are associated with contrast-induced 
nephropathy. Am J Nephrol. 2013;37(2):110-7. 
15. Morcos SK, Thomsen HS, Webb JA. Contrast-media-induced nephrotoxicity: a 
consensus report. Contrast Media Safety Committee, European Society of Urogenital 
Radiology (ESUR). Eur Radiol. 1999;9(8):1602-13. 
 
 
100 
 
 
16. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and 
patients at risk. Kidney Int Suppl. 2006;100(5):S11-5. 
17. Marenzi G, Lauri G, Assanelli E, Campodonico J, De Metrio M, Marana I, et al. 
Contrast-induced nephropathy in patients undergoing primary angioplasty for acute 
myocardial infarction. Journal of the American College of Cardiology. 
2004;44(9):1780-5. 
18. Palli E, Makris D, Papanikolaou J, Garoufalis G, Zakynthinos E. Contrast-Induced 
Nephropathy in Aged Critically Ill Patients. Oxidative Medicine and Cellular 
Longevity. 2014;2014:756469. 
19. Diogo LP, Bahlis LF, Carvalhal GF. Computerized tomography contrast induced 
nephropathy (CIN) among adult inpatients. J Bras Nefrol. 2014;36(4):446-50. 
20. Golshahi J, Nasri H, Gharipour M. Contrast-induced nephropathy; A literature review. 
Journal of Nephropathology. 2014;3(2):51-6. 
21. Ivanes F, Isorni MA, Halimi JM, Fauchier L, Saint Etienne C, Babuty D, et al. 
Predictive factors of contrast-induced nephropathy in patients undergoing primary 
coronary angioplasty. Arch Cardiovasc Dis. 2014;107(8-9):424-32. 
22. Ando G, Morabito G, de Gregorio C, Trio O, Saporito F, Oreto G. Age, glomerular 
filtration rate, ejection fraction, and the AGEF score predict contrast-induced 
nephropathy in patients with acute myocardial infarction undergoing primary 
percutaneous coronary intervention. Catheter Cardiovasc Interv. 2013;82(6):878-85. 
23. Bouzas-Mosquera A, Vázquez-Rodríguez JM, Calviño-Santos R, Peteiro-Vázquez J, 
Flores-Ríos X, Marzoa-Rivas R, et al. Contrast-Induced Nephropathy and Acute Renal 
Failure Following Emergent Cardiac Catheterization: Incidence, Risk Factors and 
Prognosis. Review Esp Card. 2007;60(10):1026-34. 
24. Barbieri L, Verdoia M, Schaffer A, Cassetti E, Di Giovine G, Marino P, et al. Pre-
diabetes and the risk of contrast induced nephropathy in patients undergoing coronary 
angiography or percutaneous intervention. Diabetes Res Clin Pract. 2014;106(3):458-
64. 
25. Heyman SN, Rosenberger C, Rosen S, Khamaisi M. Why is diabetes mellitus a risk 
factor for contrast-induced nephropathy? Biomed Res Int. 2013;2013:1-8. Artcle 
ID123589 
26. Rosenstock JL, Gilles E, Geller AB, Panagopoulos G, Mathew S, Malieckal D, et al. 
Impact of heart failure on the incidence of contrast-induced nephropathy in patients 
with chronic kidney disease. Int Urol Nephrol. 2010;42(4):1049-54. 
27. Shoukat S, Gowani SA, Jafferani A, Dhakam SH. Contrast-Induced Nephropathy in 
Patients Undergoing Percutaneous Coronary Intervention. Cardiology Research and 
Practice. 2010;2010. 
28. Li H, Huang S, He Y, Liu Y, Chen J, Zhou Y, et al. Impact of an Early Decrease in 
Systolic Blood Pressure on The Risk of Contrast-Induced Nephropathy after 
Percutaneous Coronary Intervention. Heart Lung Circ. 2016;25(2):118-23. 
29. Li WH, Li DY, Han F, Xu TD, Zhang YB, Zhu H. Impact of anemia on contrast-
induced nephropathy (CIN) in patients undergoing percutaneous coronary 
interventions. Int Urol Nephrol. 2013;45(4):1065-70. 
 
 
101 
 
 
30. Brown JR, Robb JF, Block CA, Schoolwerth AC, Kaplan AV, O'Connor GT, et al. 
Does safe dosing of iodinated contrast prevent contrast-induced acute kidney injury? 
Circ Cardiovasc Interv. 2010;3(4):346-50. 
31. Seeliger E, Sendeski M, Rihal CS, Persson PB. Contrast-induced kidney injury: 
mechanisms, risk factors, and prevention. Eur Heart J. 2012;33(16):2007-15. 
32. Singh J, Daftary A. Iodinated Contrast Media and Their Adverse Reactions. Journal of 
Nuclear Medicine Technology. 2008;36(2):69-74. 
33. Shams-Eddin Taher H, Hassan AKM, Dimitry SR, Mahfouz AK. Predicting contrast 
induced nephropathy post coronary intervention: A prospective cohort study. The 
Egyptian Heart Journal. 2015;67(4):337-43. 
34. Rudnick M, Feldman H. Contrast-induced nephropathy: what are the true clinical 
consequences? Clin J Am Soc Nephrol. 2008;3(1):263-72. 
35. Narula A, Mehran R, Weisz G, Dangas GD, Yu J, Généreux P, et al. Contrast-induced 
acute kidney injury after primary percutaneous coronary intervention: results from the 
HORIZONS-AMI substudy. European Heart Journal. 2014;35(23):1533-40. 
36. Hassoun HT, Grigoryev DN, Lie ML, Liu M, Cheadle C, Tuder RM, et al. Ischemic 
acute kidney injury induces a distant organ functional and genomic response 
distinguishable from bilateral nephrectomy. American Journal of Physiology - Renal 
Physiology. 2007;293(1):F30-F40. 
37. Neyra JA, Shah S, Mooney R, Jacobsen G, Yee J, Novak JE. Contrast-induced acute 
kidney injury following coronary angiography: a cohort study of hospitalized patients 
with or without chronic kidney disease. Nephrol Dial Transplant. 2013;28(6):1463-71. 
38. Wi J, Ko YG, Shin DH, Kim JS, Kim BK, Choi D, et al. Prediction of Contrast-
Induced Nephropathy With Persistent Renal Dysfunction and Adverse Long-term 
Outcomes in Patients With Acute Myocardial Infarction Using the Mehran Risk Score. 
Clin Cardiol. 2013;36(1):46-53. 
39. McCullough PA. Contrast-Induced Acute Kidney Injury. Journal of the American 
College of Cardiology. 2008;51(15):1419-28. 
40. Gruberg L, Mintz GS, Mehran R, Dangas G, Lansky AJ, Kent KM, et al. The 
prognostic implications of further renal function deterioration within 48 h of 
interventional coronary procedures in patients with pre-existent chronic renal 
insufficiency. Journal of the American College of Cardiology. 2000;36(5):1542-8. 
41. McCullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure 
after coronary intervention: incidence, risk factors, and relationship to mortality. Am J 
Med. 1997;103(5):368-75. 
42. Sadeghi HM, Stone GW, Grines CL, Mehran R, Dixon SR, Lansky AJ, et al. Impact of 
renal insufficiency in patients undergoing primary angioplasty for acute myocardial 
infarction. Circulation. 2003;108(22):2769-75. 
43. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and 
prognostic importance of acute renal failure after percutaneous coronary intervention. 
Circulation. 2002;105(19):2259-64. 
 
 
102 
 
 
44. Gruberg L, Mehran R, Dangas G, Mintz GS, Waksman R, Kent KM, et al. Acute renal 
failure requiring dialysis after percutaneous coronary interventions. Catheterization 
and Cardiovascular Interventions. 2001;52(4):409-16. 
45. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. 
Contrast-Induced nephropathy after percutaneous coronary interventions in relation to 
chronic kidney disease and hemodynamic variables. American Journal of 
Cardiology.95(1):13-9. 
46. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: A 
cohort analysis. JAMA. 1996;275(19):1489-94. 
47. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk 
score for prediction of contrast-induced nephropathy after percutaneous coronary 
intervention: Development and initial validation. Journal of the American College of 
Cardiology. 2004;44(7):1393-9. 
48. Sgura FA, Bertelli L, Monopoli D, Leuzzi C, Guerri E, Sparta I, et al. Mehran contrast-
induced nephropathy risk score predicts short- and long-term clinical outcomes in 
patients with ST-elevation-myocardial infarction. Circ Cardiovasc Interv. 
2010;3(5):491-8. 
49. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal 
insufficiency after cardiac catheterization in patients 70 years of age or older. A 
prospective study. Arch Intern Med. 1990;150(6):1237-42. 
50. Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of 
Urogenital Radiology (ESUR) guidelines. Br J Radiol. 2003;76(908):513-8. 
51. Meinel FG, De Cecco CN, Schoepf UJ, Katzberg R. Contrast-induced acute kidney 
injury: definition, epidemiology, and outcome. Biomed Res Int. 2014;2014:1-10. 
Artcle 859328 ID 
52. Nickolas TL, O'Rourke MJ, Yang J, Sise ME, Canetta PA, Barasch N, et al. Sensitivity 
and specificity of a single emergency department measurement of urinary neutrophil 
gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Int Med. 
2008;148. 
53. Chalikias G, Drosos I, Tziakas DN. Contrast-Induced Acute Kidney Injury: An 
Update. Cardiovasc Drugs Ther. 2016;16:16. 
54. Owen RJ, Hiremath S, Myers A, Fraser-Hill M, Barrett BJ. Canadian Association of 
Radiologists consensus guidelines for the prevention of contrast-induced nephropathy: 
update 2012. Can Assoc Radiol J. 2014;65(2):96-105. 
55. Solomon R, Deray G. How to prevent contrast-induced nephropathy and manage risk 
patients: practical recommendations. Kidney Int Suppl. 2006;100(3):S51-3. 
56. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin 
Pract. 2012;120(4):7. 
57. Roy AK, Mc Gorrian C, Treacy C, Kavanaugh E, Brennan A, Mahon NG, et al. A 
Comparison of Traditional and Novel Definitions (RIFLE, AKIN, and KDIGO) of 
Acute Kidney Injury for the Prediction of Outcomes in Acute Decompensated Heart 
Failure. Cardiorenal Medicine. 2013;3(1):26-37. 
 
 
103 
 
 
58. Wong PC, Li Z, Guo J, Zhang A. Pathophysiology of contrast-induced nephropathy. 
Int J Cardiol. 2012;158(2):186-92. 
59. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk 
factors and preventive strategies. Cmaj. 2005;172(11):1461-71. 
60. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced 
nephropathy. Kidney Int. 2005;68(1):14-22. 
61. Azzalini L, Spagnoli V, Ly HQ. Contrast-Induced Nephropathy: From 
Pathophysiology to Preventive Strategies. Can J Cardiol. 2016;32(2):247-55. 
62. Tumlin J, Stacul F, Adam A, Becker CR, Davidson C, Lameire N, et al. 
Pathophysiology of contrast-induced nephropathy. Am J Cardiol. 2006;98(6A):1-17. 
63. Deng J, Wu G, Yang C, Li Y, Jing Q, Han Y. Rosuvastatin attenuates contrast-induced 
nephropathy through modulation of nitric oxide, inflammatory responses, oxidative 
stress and apoptosis in diabetic male rats. J Transl Med. 2015;13(53):1-9. 
64. Basile DP, Anderson MD, Sutton TA. Pathophysiology of Acute Kidney Injury. 
Comprehensive Physiology. 2012;2(2):1303-53. 
65. Geenen RWF, Kingma HJ, van der Molen AJ. Contrast-induced nephropathy: 
pharmacology, pathophysiology and prevention. Insights into Imaging. 2013;4(6):811-
20. 
66. Diez-Silva M, Dao M, Han J, Lim CT, Suresh S. Shape and Biomechanical 
Characteristics of Human Red Blood Cells in Health and Disease. MRS Bull. 
2010;35(5):382-8. 
67. Ortega LM, Fornoni A. Role of cytokines in the pathogenesis of acute and chronic 
kidney disease, glomerulonephritis, and end-stage kidney disease. International Journal 
of Interferon, Cytokine and Mediator Research 2010;(2):49-62. 
68. Akcay A, Nguyen Q, Edelstein CL. Mediators of inflammation in acute kidney injury. 
Mediators Inflamm. 2009;2009:1-12. Artcile ID137072 
69. Sharfuddin AA, Molitoris BA. Pathophysiology of ischemic acute kidney injury. Nat 
Rev Nephrol. 2011;7(4):189-200. 
70. Hudzik B, Szkodzinski J, Danikiewicz A, Romanowski W, Lekston A, Polonski L, et 
al. Serum interleukin-6 concentration predicts contrast-induced nephropathy in patients 
undergoing percutaneous coronary intervention. Eur Cytokine Netw. 2010;21(2):129-
35. 
71. Sutton TA. Alteration of microvascular permeability in acute kidney injury. 
Microvascular research. 2009;77(1):4-7. 
72. Ernandez T, Mayadas TN. Immunoregulatory role of TNFalpha in inflammatory 
kidney diseases. Kidney Int. 2009;76(3):262-76. 
73. Hajeer AH, Hutchinson IV. Influence of TNFalpha gene polymorphisms on TNFalpha 
production and disease. Hum Immunol. 2001;62(11):1191-9. 
74. Bonventre JV, Yang L. Cellular pathophysiology of ischemic acute kidney injury. J 
Clin Invest. 2011;121(11):4210-21. 
75. Elahi MM, Asotra K, Matata BM, Mastana SS. Tumor necrosis factor alpha -308 gene 
locus promoter polymorphism: an analysis of association with health and disease. 
Biochim Biophys Acta. 2009;3:163-72. 
 
 
104 
 
 
76. Jaber BL, Rao M, Guo D, Balakrishnan VS, Perianayagam MC, Freeman RB, et al. 
Cytokine gene promoter polymorphisms and mortality in acute renal failure. Cytokine. 
2004;25(5):212-9. 
77. Sinuani I, Beberashvili I, Averbukh Z, Sandbank J. Role of IL-10 in the progression of 
kidney disease. World J Transplant. 2013;3(4):91-8. 
78. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy--review of a new approach. 
Pharmacol Rev. 2003;55(2):241-69. 
79. Wasung ME, Chawla LS, Madero M. Biomarkers of renal function, which and when? 
Clinica Chimica Acta. 2015;438:350-7. 
80. Fortalesa Melo JI, Chojniak R, Costa Silva DH, Oliveira Junior JC, Vieira Bitencourt 
AG, Holanda Silva D, et al. Use of Cystatin C and Serum Creatinine for the Diagnosis 
of Contrast-Induced Nephropathy in Patients Undergoing Contrast-Enhanced 
Computed Tomography at an Oncology Centre. PLoS ONE. 2015;10(5):e0122877. 
81. Slocum JL, Heung M, Pennathur S. Marking renal injury: can we move beyond serum 
creatinine? Transl Res. 2012;159(4):277-89. 
82. Briguori C, Quintavalle C, Donnarumma E, Condorelli G. Novel biomarkers for 
contrast-induced acute kidney injury. Biomed Res Int. 2014;2014:1-5. Article ID 
568738. 
83. Tong J, Li H, Zhang H, Luo Z, Huang Y, Huang J, et al. Neutrophil Gelatinase-
associated Lipocalin in the Prediction of Contrast-induced Nephropathy: A Systemic 
Review and Meta-analysis. J Cardiovasc Pharmacol. 2015;66(3):239-45. 
84. Siew ED, Ware LB, Bian A, Shintani A, Eden SK, Wickersham N, et al. Distinct 
injury markers for the early detection and prognosis of incident acute kidney injury in 
critically ill adults with preserved kidney function. Kidney Int. 2013;84(4):786-94. 
85. Mårtensson J, Martling CR, Bell M. Novel biomarkers of acute kidney injury and 
failure: clinical applicability. British Journal of Anaesthesia. 2012;109(6):843-50 
86. Yeo C, Khurana R. Neutrophil Gelatinase Associated Lipocalin: An Emerging 
Biomarker for Acute Kidney Injury in Cardiovascular Disease. Proceedings of 
Singapore Healthcare. 2011;20(4):291-300. 
87. Koyner JL, Bennett MR, Worcester EM, Ma Q, Raman J, Jeevanandam V, et al. 
Urinary cystatin C as an early biomarker of acute kidney injury following adult 
cardiothoracic surgery. Kidney Int. 2008;74(8):1059-69. 
88. Mischak H, Delles C, Vlahou A, Vanholder R. Proteomic biomarkers in kidney 
disease: issues in development and implementation. Nat Rev Nephrol. 2015;11(4):221-
32. 
89. Murray PT, Mehta RL, Shaw A, Ronco C, Endre Z, Kellum JA, et al. Current Use of 
Biomarkers in Acute Kidney Injury: Report and Summary of Recommendations from 
the 10(th) Acute Dialysis Quality Initiative Consensus Conference. Kidney 
international. 2014;85(3):513-21. 
90. Charlton JR, Portilla D, Okusa MD. A basic science view of acute kidney injury 
biomarkers. Nephrology Dialysis Transplantation. 2014;29(7):1301-11. 
91. McCullough PA, Shaw AD, Haase M, Bouchard J, Waikar SS, Siew ED, et al. 
Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup 
 
 
105 
 
 
statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. 
Contrib Nephrol. 2013;182:13-29. 
92. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for 
human acute kidney injury. Biomarkers in medicine. 2010;4(2):265-80. 
93. Molitoris BA, Melnikov VY, Okusa MD, Himmelfarb J. Technology Insight: 
biomarker development in acute kidney injury--what can we anticipate? Nat Clin Pract 
Nephrol. 2008;4(3):154-65. 
94. Noto A, Cibecchini F, Fanos V, Mussap M. NGAL and metabolomics: the single 
biomarker to reveal the metabolome alterations in kidney injury. Biomed Res Int. 
2013;612032(10):27. 
95. Ostermann M, Philips BJ, Forni LG. Clinical review: Biomarkers of acute kidney 
injury: where are we now? Crit Care. 2012;16(5). 
96. Varrier M, Fisher R, Ostermann M. ACUTE KIDNEY INJURY-AN UPDATE. EMJ 
Nephrology. 2015;3:77-82. 
97. Vijayasimha M, Padma VV, Mujumdar SK, Satyanarayan PVV. Evaluation of the 
diagnostic performance of new markers for acute kidney injury associated with 
contrast administration. Journal of Mahatma Gandhi Institute of Medical Sciences. 
2013;18(2):116-21. 
98. McIlroy DR, Wagener G, Lee HT. Biomarkers of acute kidney injury: an evolving 
domain. Anesthesiology. 2010;112(4):998-1004. 
99. Bellomo R, Kellum JA, Ronco C. Acute kidney injury. The Lancet.380(9843):756-66. 
100. Schley G, Köberle C, Manuilova E, Rutz S, Forster C, Weyand M, et al. Comparison 
of Plasma and Urine Biomarker Performance in Acute Kidney Injury. PLoS ONE. 
2015;10(12):e0145042. 
101. Zhou F, Luo Q, Wang L, Han L. Diagnostic value of neutrophil gelatinase-associated 
lipocalin for early diagnosis of cardiac surgery-associated acute kidney injury: a meta-
analysis. European Journal of Cardio-Thoracic Surgery. 2016;49(3):746-55. 
102. Schmidt-Ott KM, Mori K, Li JY, Kalandadze A, Cohen DJ, Devarajan P, et al. Dual 
Action of Neutrophil Gelatinase–Associated Lipocalin. Journal of the American 
Society of Nephrology. 2007;18(2):407-13. 
103. Chakraborty S, Kaur S, Guha S, Batra SK. The multifaceted roles of neutrophil 
gelatinase associated lipocalin (NGAL) in inflammation and cancer. Biochim Biophys 
Acta. 2012;1:129-69. 
104. Cruz DN, de Cal M, Garzotto F, Perazella MA, Lentini P, Corradi V, et al. Plasma 
neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury 
in an adult ICU population. Intensive Care Med. 2010;36(3):444-51. 
105. Firu SG, Streba CT, Firu D, Tache DE, Rogoveanu I. Neutrophil Gelatinase 
Associated  (NGAL) - a biomarker of renal dysfunction in patients with liver cirrhosis: 
Do we have enough proof? J Med Life. 2015:15-20. 
106. Filiopoulos V, Biblaki D, Lazarou D, Chrisis D, Fatourou M, Lafoyianni S, et al. 
Plasma neutrophil gelatinase-associated lipocalin (NGAL) as an early predictive 
marker of contrast-induced nephropathy in hospitalized patients undergoing computed 
tomography. Clin Kidney J. 2013;6(6):578-83. 
 
 
106 
 
 
107. Haase M, Bellomo R, Devarajan P, Schlattmann P, Haase-Fielitz A. Accuracy of 
neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute 
kidney injury: a systematic review and meta-analysis. Am J Kidney Dis. 
2009;54(6):1012-24. 
108. Abrahamson M, Olafsson I, Palsdottir A, Ulvsbäck M, Lundwall A, Jensson O, et al. 
Structure and expression of the human cystatin C gene. Biochemical Journal. 
1990;268(2):287-94. 
109. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev 
Clin Lab Sci. 2004;41(5-6):467-550. 
110. Simsek A, Tugcu V, Tasci AI. New Biomarkers for the Quick Detection of Acute 
Kidney Injury. ISRN Nephrology. 2013;2013:9. 
111. Ishibashi Y, Yamauchi M, Musha H, Mikami T, Kawasaki K, Miyake F. Impact of 
contrast-induced nephropathy and cardiovascular events by serum cystatin C in renal 
insufficiency patients undergoing cardiac catheterization. Angiology. 2010;61(8):724-
30. 
112. Nozue T, Michishita I, Mizuguchi I. Predictive value of serum cystatin C, β2-
microglobulin, and urinary liver-type fatty acid-binding protein on the development of 
contrast-induced nephropathy. Cardiovascular Intervention and Therapeutics. 
2010;25(2):85-90. 
113. Krawczeski CD, Vandevoorde RG, Kathman T, Bennett MR, Woo JG, Wang Y, et al. 
Serum cystatin C is an early predictive biomarker of acute kidney injury after pediatric 
cardiopulmonary bypass. Clin J Am Soc Nephrol. 2010;5(9):1552-7. 
114. Alharazy SM, Kong N, Saidin R, Gafor AH, Maskon O, Mohd M, et al. Serum 
neutrophil gelatinase-associated lipocalin and cystatin C are early biomarkers of 
contrast-induced nephropathy after coronary angiography in patients with chronic 
kidney disease. Angiology. 2014;65(5):436-42. 
115. Zhang Z, Lu B, Sheng X, Jin N. Cystatin C in prediction of acute kidney injury: a 
systemic review and meta-analysis. Am J Kidney Dis. 2011;58(3):356-65. 
116. Sedighi O, Abediankenari S, Omranifar B. Association between plasma Beta-2 
microglobulin level and cardiac performance in patients with chronic kidney disease. 
Nephrourol Mon. 2014;7(1). 
117. Xie J, Wang Y, Freeman ME, 3rd, Barlogie B, Yi Q. Beta 2-microglobulin as a 
negative regulator of the immune system: high concentrations of the protein inhibit in 
vitro generation of functional dendritic cells. Blood. 2003;101(10):4005-12. 
118. Coppolino G, Bolignano D, Rivoli L, Mazza G, Presta P, Fuiano G. Tumour Markers 
and Kidney Function: A Systematic Review. BioMed Research International. 
2014;2014:9. 
119. Vaidya VS, Ferguson MA, Bonventre JV. Biomarkers of acute kidney injury. Annu 
Rev Pharmacol Toxicol. 2008;48:463-93. 
120. Wu H, Craft ML, Wang P, Wyburn KR, Chen G, Ma J, et al. IL-18 Contributes to 
Renal Damage after Ischemia-Reperfusion. Journal of the American Society of 
Nephrology : JASN. 2008;19(12):2331-41. 
 
 
107 
 
 
121. Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the 
aging process. Am J Clin Nutr. 2006;83(2):447S-55S. 
122. Sirota JC, Walcher A, Faubel S, Jani A, McFann K, Devarajan P, et al. Urine IL-18, 
NGAL, IL-8 and serum IL-8 are biomarkers of acute kidney injury following liver 
transplantation. BMC Nephrology. 2013;14(1):1-9. 
123. Parikh CR, Abraham E, Ancukiewicz M, Edelstein CL. Urine IL-18 is an early 
diagnostic marker for acute kidney injury and predicts mortality in the intensive care 
unit. J Am Soc Nephrol. 2005;16(10):3046-52. 
124. Lin X, Yuan J, Zhao Y, Zha Y. Urine interleukin-18 in prediction of acute kidney 
injury: a systemic review and meta-analysis. Journal of Nephrology. 2015;28:7-16. 
125. Kostrubiec M, Labyk A, Pedowska-Wloszek J, Dzikowska-Diduch O, Wojciechowski 
A, Garlinska M, et al. Neutrophil gelatinase-associated lipocalin, cystatin C and eGFR 
indicate acute kidney injury and predict prognosis of patients with acute pulmonary 
embolism. Heart. 2012;98(16):1221-8. 
126. Zaya M, Phan A, Schwarz ER. Predictors of re-hospitalization in patients with chronic 
heart failure. World Journal of Cardiology. 2012;4(2):23-30. 
127. Gagneux-Brunon A, Mariat C, Delanaye P. Cystatin C in HIV-infected patients: 
promising but not yet ready for prime time: Nephrol Dial Transplant. 2012 
Apr;27(4):1305-13. doi: 10.1093/ndt/gfs001. Epub 2012 Mar 6. 
128. Odden MC, Scherzer R, Bacchetti P, Szczech LA, Sidney S, Grunfeld C, et al. Cystatin 
C level as a marker of kidney function in human immunodeficiency virus infection: the 
FRAM study. Arch Intern Med. 2007;167(20):2213-9. 
129. Landro L, Damas JK, Flo TH, Heggelund L, Ueland T, Tjonnfjord GE, et al. 
Decreased serum lipocalin-2 levels in human immunodeficiency virus-infected 
patients: increase during highly active anti-retroviral therapy. Clin Exp Immunol. 
2008;152(1):57-63. 
130. Delanghe JR, Speeckaert MM. Creatinine determination according to Jaffe—what does 
it stand for? NDT Plus. 2011;4(2):83-6. 
131. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A 
new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-
12. 
132. Mitchell AM, Jones AE, Tumlin JA, Kline JA. Prospective study of the incidence of 
contrast-induced nephropathy among patients evaluated for pulmonary embolism by 
contrast-enhanced computed tomography. Acad Emerg Med. 2012;19(6):618-25. 
133. Halliwell B. Albumin--an important extracellular antioxidant? Biochem Pharmacol. 
1988;37(4):569-71. 
134. Taverna M, Marie AL, Mira JP, Guidet B. Specific antioxidant properties of human 
serum albumin. Ann Intensive Care. 2013;3(1):2110-5820. 
135. Selistre LdS, Souza VCd, Dubourg L, Wagner MB, Hoefel Filho JR, Saitovitch D. 
Contrast-induced nephropathy after computed tomography. Jornal Brasileiro de 
Nefrologia. 2015;37:27-31. 
 
 
108 
 
 
136. Murat SN, Kurtul A, Yarlioglues M. Impact of Serum Albumin Levels on Contrast-
Induced Acute Kidney Injury in Patients With Acute Coronary Syndromes Treated 
With Percutaneous Coronary Intervention. Angiology. 2015;66(8):732-7. 
137. Song JS, Kim SI, Kim W, Park DW, Kwak HJ, Moon JY, et al. Incidence and risk 
factors of contrast-induced nephropathy after bronchial arteriography or bronchial 
artery embolization. Tuberc Respir Dis. 2013;74(4):163-8. 
138. Zaki T, Samir A, Mohammed Rashid T, Galal H, Samir W. Assessment of estimated 
GFR and clinical predictors of contrast induced nephropathy among diabetic patients 
undergoing cardiac catheterization. The Egyptian Heart Journal. 2015;67(3):249-58. 
139. Wiedermann CJ, Wiedermann W, Joannidis M. Hypoalbuminemia and acute kidney 
injury: a meta-analysis of observational clinical studies. Intensive Care Med. 
2010;36(10):1657-65. 
140. Lee EH, Baek SH, Chin JH, Choi DK, Son HJ, Kim WJ, et al. Preoperative 
hypoalbuminemia is a major risk factor for acute kidney injury following off-pump 
coronary artery bypass surgery. Intensive Care Med. 2012;38(9):1478-86. 
141. Chong E, Poh KK, Liang S, Tan HC. Risk factors and clinical outcomes for contrast-
induced nephropathy after percutaneous coronary intervention in patients with normal 
serum creatinine. Ann Acad Med Singapore. 2010;39(5):374-80. 
142. McKechnie RS, Smith D, Montoye C, Kline-Rogers E, O'Donnell MJ, DeFranco AC, 
et al. Prognostic implication of anemia on in-hospital outcomes after percutaneous 
coronary intervention. Circulation. 2004;110(3):271-7. 
143. Shacham Y, Gal-Oz A, Leshem-Rubinow E, Arbel Y, Flint N, Keren G, et al. 
Association of admission hemoglobin levels and acute kidney injury among 
myocardial infarction patients treated with primary percutaneous intervention. Can J 
Cardiol. 2015;31(1):50-5. 
144. Murakami R, Kumita S, Hayashi H, Sugizaki K, Okazaki E, Kiriyama T, et al. Anemia 
and the risk of contrast-induced nephropathy in patients with renal insufficiency 
undergoing contrast-enhanced MDCT. Eur J Radiol. 2013;82(10):1. 
145. Weisbord SD, Mor MK, Resnick AL, Hartwig KC, Palevsky PM, Fine MJ. Incidence 
and outcomes of contrast-induced AKI following computed tomography. Clin J Am 
Soc Nephrol. 2008;3(5):1274-81. 
146. Schilp J, de Blok C, Langelaan M, Spreeuwenberg P, Wagner C. Guideline adherence 
for identification and hydration of high-risk hospital patients for contrast-induced 
nephropathy. BMC Nephrol. 2014;15(2):1471-2369. 
147. Tsai TT, Patel UD, Chang TI, Kennedy KF, Masoudi FA, Matheny ME, et al. 
Contemporary incidence, predictors, and outcomes of acute kidney injury in patients 
undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI 
registry. JACC Cardiovasc Interv. 2014;7(1):1-9. 
148. Honore PM, Joannes-Boyau O, Boer W. The early biomarker of acute kidney injury: in 
search of the Holy Grail. Intensive Care Med. 2007;33. 
149. Chertow GM, Burdick E, Honour M, Bonventre JV, Bates DW. Acute Kidney Injury, 
Mortality, Length of Stay, and Costs in Hospitalized Patients. Journal of the American 
Society of Nephrology. 2005;16(11):3365-70. 
 
 
109 
 
 
150. Liu Y, Guo W, Zhang J, Xu C, Yu S, Mao Z, et al. Urinary interleukin 18 for detection 
of acute kidney injury: a meta-analysis. Am J Kidney Dis. 2013;62(6):1058-67. 
151. Briguori C, Visconti G, Rivera NV, Focaccio A, Golia B, Giannone R, et al. Cystatin C 
and Contrast-Induced Acute Kidney Injury. Circulation. 2010;121(19):2117-22. 
152. Ribichini F, Gambaro G, Graziani MS, Pighi M, Pesarini G, Pasoli P, et al. 
Comparison of serum creatinine and cystatin C for early diagnosis of contrast-induced 
nephropathy after coronary angiography and interventions. Clin Chem. 
2012;58(2):458-64. 
153. El-Frargy M, El-Refaey A, Eid R, Hussien M. Serum cystatin-C and BETA 2-
microglobulin as accurate markers in the early diagnosis of kidney injury in neonates: 
A single center study2015 July 1, 2015. 712-7 p. 
154. Herrero-Morín JD, Málaga S, Fernández N, Rey C, Diéguez MA, Solís G, et al. 
Cystatin C and beta 2-microglobulin: markers of glomerular filtration in critically ill 
children. Crit Care. 2007;11. 
155. Okuno S, Ishimura E, Kohno K, Fujino-Katoh Y, Maeno Y, Yamakawa T, et al. Serum 
beta2-microglobulin level is a significant predictor of mortality in maintenance 
haemodialysis patients. Nephrol Dial Transplant. 2009;24(2):571-7. 
156. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T, et al. Serum β-2 
Microglobulin Levels Predict Mortality in Dialysis Patients: Results of the HEMO 
Study. Journal of the American Society of Nephrology. 2006;17(2):546-55. 
157. Edelstein CL. Biomarkers of Acute Kidney Injury. Advances in Chronic Kidney 
Disease. 2008;15(3):222-34. 
158. Quintavalle C, Anselmi CV, De Micco F, Roscigno G, Visconti G, Golia B, et al. 
Neutrophil Gelatinase-Associated Lipocalin and Contrast-Induced Acute Kidney 
Injury. Circ Cardiovasc Interv. 2015;8(9):002673. 
159. Khatami MR, Sabbagh MRP, Nikravan N, Khazaeipour Z, Boroumand MA, Sadeghian 
, et al. The role of neutrophil-gelatinase-associated lipocalin in early diagnosis of 
contrast nephropathy. Indian Journal of Nephrology. 2015;25(5):292-6. 
160. Valette X, Savary B, Nowoczyn M, Daubin C, Pottier V, Terzi N, et al. Accuracy of 
plasma neutrophil gelatinase-associated lipocalin in the early diagnosis of contrast-
induced acute kidney injury in critical illness. Intensive Care Med. 2013;39(5):857-65. 
161. Liu Y, Guo W, Zhang J, Xu C, Yu S, Mao Z, et al. Urinary Interleukin 18 for 
Detection of Acute Kidney Injury: A Meta-analysis. American Journal of Kidney 
Diseases.62(6):1058-67. 
162. Washburn KK, Zappitelli M, Arikan AA, Loftis L, Yalavarthy R, Parikh CR, et al. 
Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. 
Nephrology Dialysis Transplantation. 2008;23(2):566-72. 
163. Lin C-Y, Chang C-H, Fan P-C, Tian Y-C, Chang M-Y, Jenq C-C, et al. Serum 
Interleukin-18 at Commencement of Renal Replacement Therapy Predicts Short-Term 
Prognosis in Critically Ill Patients with Acute Kidney Injury. PLoS ONE. 
2013;8(5):e66028. 
164. Vilander LM, Kaunisto MA, Pettila V. Genetic predisposition to acute kidney injury--a 
systematic review. BMC Nephrol. 2015;16(197):015-0190. 
 
 
110 
 
 
165. Cardinal-Fernandez P, Ferruelo A, Martin-Pellicer A, Nin N, Esteban A, Lorente JA. 
Genetic determinants of acute renal damage risk and prognosis: a systematic revie]. 
Med Intensiva. 2012;36(9):626-33. 
166. Lu JC, Coca SG, Patel UD, Cantley L, Parikh CR. Searching for genes that matter in 
acute kidney injury: a systematic review. Clin J Am Soc Nephrol. 2009;4(6):1020-31. 
167. Ivanova M, Vasilev G, Stanilova S, Manolova I. ASSOCIATION OF-308 G/A TNFA 
POLYMORPHISM WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A 
PRELIMINARY STUDY. Trakia Journal of Sciences. 2014;12(1):175-80. 
168. Susantitaphong P, Perianayagam MC, Tighiouart H, Liangos O, Bonventre JV, Jaber 
BL. Tumor necrosis factor alpha promoter polymorphism and severity of acute kidney 
injury. Nephron Clin Pract. 2013;123(1-2):67-73. 
169. Cardinal-Fernández P, Ferruelo A, El-Assar M, Santiago C, Gómez-Gallego F, Martín-
Pellicer A, et al. Genetic predisposition to acute kidney injury induced by severe 
sepsis. Journal of Critical Care. 2013;28(4):365-70. 
170. Dalboni MA, Quinto BM, Grabulosa CC, Narciso R, Monte JC, Durao M, Jr., et al. 
Tumour necrosis factor-alpha plus interleukin-10 low producer phenotype predicts 
acute kidney injury and death in intensive care unit patients. Clin Exp Immunol. 
2013;173(2):242-9. 
171. Lee TS, Chau LY. Heme oxygenase-1 mediates the anti-inflammatory effect of 
interleukin-10 in mice. Nat Med. 2002;8(3):240-6. 
172. Treszl A, Toth-Heyn P, Kocsis I, Nobilis A, Schuler A, Tulassay T, et al. Interleukin 
genetic variants and the risk of renal failure in infants with infection. Pediatr Nephrol. 
2002;17(9):713-7. 
  
 
 
111 
 
 
APPENDIX A 
 
  
 
 
112 
 
 
APPENDIX B 
 
  
 
 
113 
 
 
  
 
 
114 
 
 
 
  
 
 
115 
 
 
  
 
 
116 
 
 
  
 
 
117 
 
 
  
 
 
118 
 
 
  
 
 
119 
 
 
  
 
 
120 
 
 
  
 
 
121 
 
 
 
  
 
 
122 
 
 
  
 
 
123 
 
 
APPENDIX C 
Participants information sheet/ informed consent forms (general and genetics) 
Introduction 
Good day, my name is Justor Banda, a medical doctor in the Division of Nephrology at 
CharlotteMaxekeJohannesburgAcademicHospital. I am doing a PhD research study at the 
University of the Witwatersrand. You are invited to consider participating in this research 
study. Your participation is voluntary and you can withdraw from the study without any 
prejudice and you will continue to receive standard of care treatment. It is important that you 
read and fully understand information on this leaflet as it will help you in making the decision. 
If unable to read or understand English, an interpreter will be provided for you. 
Purpose of the study 
I am conducting a research study to look at reasons why some people exposed to x-rays with 
substance suffer kidney injury and see how we can possibly identify higher risk individuals to 
prevent kidney injury. The human body has two kidneys that perform different functions; for 
example the removal of waste products and forming urine. In order to determine why some 
people suffer kidney injury following exposure to contrast and others do not, I will look for 
inheritable factors called genes that identify those with increased risk to kidney injury after x-
ray procedures. 
Genes are basically a collection of information or instructions that form the makeup of a 
human being and decide how he/she behaves.  
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I will look for the TNFα and IL10 genetic differences or changes which affect the kidney 
when exposed to contrast media. The TNFα is involved in inflammation while the IL10 is 
protective.  
Individuals with some differences or mutations in their genes have increased risks of kidney 
injury compared to those without changes when exposed to x-rays with contrast. Mutations are 
permanent changes in the genes and affect how information is interpreted by the body. From 
this study, I will be able to find out if there are differences in the genes among those who 
develop kidney disease after x-rays studies and those who do not. 
Procedures of the study 
If you agree to participate in the study, your medical records will be reviewed. A medical 
doctor will examine you and collect information assessing risk factors associated with 
development of kidney disease from contrast media studies. Blood and urine samples will be 
collected and an examination of your heart will be done in order to determine renal and heart 
status. An initial total of 10mls (2 teaspoons of blood) will be drawn prior to x-ray exposure 
and half of this sample will be stored for determination of the inheritable factors (genes) 
predisposing to kidney injury following contrast administration (genetic analysis). Subsequent 
blood samples of 5mls (half spoon) will be drawn 4hours after the procedure and at days 1, 2, 
5 and at 3 months in order to look at kidney recovery. 
Benefits of the study 
The benefits of participating in this study are that we will be able to identify earlier those at 
risk of developing kidney injury post exposure to contrast media administration. Participants in 
this study will be screened for kidney dysfunction and those with kidney diseases found during 
screening procedures will be referred to the Division of Nephrology for further management. The 
findings from the study will help in formulating intervention strategies for kidney disease following 
radio contrast administration. 
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Possible risks 
Blood collection may cause pain at site of puncture. Air emboli and infection are very rare 
complications that can occur after vein puncture. Qualified personnel will collect the blood 
samples to prevent such complications. 
Financial arrangements 
You will not be paid for participating in the study. However, there will be no costs to youfor 
any related study visits and procedures, as any costs incurred will be compensated by research 
funds. 
Confidentiality 
All information obtained during the course of this study will be kept strictly confidential. Your 
records will be given unique identification numbers and the initial identification details won’t 
be used. All physical records will be kept in a locked locker with access limited to the research 
team. Electronic data will be password protected. 
Source of information 
If you have any questions, concerns and clarifications, please contact the following; Dr Justor 
Banda will be reachable 24 hours every day on the number, 073-409-3680. 
Additional information can be obtained from the chairperson of Witwatersrand University 
Human Research Ethics Committee, Professor Cleaton Jones on 011-717-2301 
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Informed Consent Form: General 
I confirm that I have been informed about the study by Dr Justor Banda. I understand that my 
personal details will be kept strictly confidential and that I may at any stage withdraw my 
consent and participation in the study and continue to receive the appropriate treatment. I have 
also received, read and understood the study as explained in the participant information sheet 
and consent to taking part in this research study. 
PARTICIPANT (printed 
name)………………………………………………………………………………… 
Signature or thumb print ……………………………… Date……………………. 
Witness (printed name)……………………………………………………………… 
Signature……………………………………………...Date………………………….  
I, Dr Justor Banda confirm that the participant has been fully informed about the nature 
of the above study. 
STUDY INVESTIGATOR  
…………………………………….. Signature……………Date……… 
Printed Name  
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Informed consent form: DNA 
I hereby confirm that I have been informed about the study by Dr. Justor Banda about the 
nature, benefits and risks of the genes study. I understand that my personal details (any 
identifying data) will kept strictly confidential. I have had the opportunity to ask questions and 
I have also received, read and understood the study as explained in the participant information 
sheet and consent to taking part in this research study. 
PARTICIPANT (printed name)…………………………………………………………… 
Signature or thumb print ……………………………… Date …………………………… 
Witness (printed name)……………………………………………………………………. 
Signature……………………………………………...Date……………………………… 
I, Dr Justor Banda confirm that the participant has been fully informed about the nature 
of the above study. 
STUDY INVESTIGATOR  
Name ………………………….. Signature……………Date……………. 
 
 
 
 
 
 
 
